Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW® 2019

AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814

301.654.2055 (National Office) 301.654.3978 (Fax) * Information contained in this report www.gastro.org is current as of April 22, 2019.

AGA Oral Presentations

1. . . . HUMAN INDUCED PLURIPOTENT 21. . . . EFFICACY AND SAFETY OF 41. . . . THE DUTCH AMERICAN RISK STEM CELL-DERIVED MESENCHYMAL… (2*) URSODEOXYCHOLIC ACID… STRATIFICATION TOOL… (5*) (3*)|(Daewoong Pharmaceutical Co., Ltd.) 2. . . . STEM CELL-DERIVED 3D ORGANOIDS 42. . . . THIOPURINE METABOLITE LEVELS RECAPITULATE FEATURES… (2*) 22. . . . CAN CHOLECYSTITIS BE AN IN PREGNANT IBD… (4*)|(6) ADVERSE EVENT… (5*) 3. . . . A NEW FORM OF HUMAN 43. . . . PREGNANCY OUTCOMES IN ROTAVIRUS… (2*) 23. . . . BILIARY DILATION IN PATIENTS INFLAMMATORY BOWEL DISEASE… (5*) WITH NORMAL… (2*)|(4) 4. . . . FIRST LARGE SCALE STUDY DEFINING 44. . . . INFLIXIMAB CLEARANCE IS THE… (4*) 24. . . . TIMING OF CHOLECYSTECTOMY DECREASED DURING 2ND… (1*) AFTER ACUTE BILIARY… (5*) 5. . . . MICROBIOTA-DEPENDENT 45. . . . LONG-TERM OUTCOMES OF IN- BEHAVIORAL ABNORMALITIES IN THE 25. . . . UNDERLYING EATING DISORDER UTERO EXPOSURE TO… (6*) ZONULIN… (2*) PATHOLOGY IN CHRONIC… (5*) 46. . . . SAFETY OF FLEXIBLE 6. . . . INTESTINAL MICROBIAL FUNCTIONAL 26. . . . THE EFFECT OF RECREATIONAL SIGMOIDOSCOPY IN PREGNANT… (5*) CONTENT BETTER DEFINES… (4*)|(2) MARIJUANA USE… (7*)|(2) 85. . . . SIRT2 REGULATES INTESTINAL CELL 7. . . . THE ICON STUDY: INFLAMMATORY 27. . . . TRANSLUMBOSACRAL PROLIFERATION AND… (2*) BOWEL DISEASE… (6*)|(2) NEUROMODULATION THERAPY FOR FECAL INCONTINENCE:… (2*) 86. . . . HEAT SHOCK PROTEIN GP96 IS 8. . . . POPULATION-SCALE MICROBIOME ESSENTIAL… (4*) ANALYSIS DEFINES A NEW… (2*) 28. . . . DEFECATORY FUNCTION TESTING IN FI PATIENTS… (2*) 87. . . . MIR-181A-5P CONTRIBUTES TO 9. . . . PREVALENCE AND PREDICTORS OF INTESTINAL CELL DIFFERENTIATION… (2*) GERD AND… (3*)|(Ironwood 29. . . . RESTORATION OF FECAL Pharmaceuticals) CONTINENCE IN A… (6*) 89. . . . MULTITARGET STOOL DNA TESTING AS ALTERNATIVE… (6*) 10. . . . EFFECT OF RECENTLY DESCRIBED 30. . . . NORMAL VALUES FOR ANORECTAL ADVERSE EVENTS… (5*) PRESSURES MEASURED… 90. . . . POST-COLONOSCOPY MORTALITY (2*)|(3)|(Medspira Inc) IN A FIT-BASED COLORECTAL… (2*) 11. . . . THE EFFECT OF REBAMIPIDE IN PATIENTS… (3*)|(Korea Otsuka 31. . . . ENDOSOMAL SNX17 SETS THE 91. . . . INTERVAL CANCERS AFTER A Pharmaceutical Co., Ltd.) PLASMA MEMBRANE… (2*) NEGATIVE FAECAL… (2*)

12. . . . IMPACT OF IW-3718, A NOVEL 32. . . . UNIQUE REGULATION OF 92. . . . COMPARING THE COST- GASTRIC-RETENTIVE… (3*)|(Ironwood INTESTINAL EPITHELIAL CELL… (2*) EFFECTIVENESS OF NEW COLORECTAL… Pharmaceuticals) (2*) 33. . . . GLP-2 INCREASES ELECTROGENIC 13. . . . ANTIREFLUX SURGERY WITHIN SIX ANION SECRETION AND… (2*)|(3)|(Shire 93. . . . FACTORS ASSOCIATED WITH THE MONTHS AFTER… (5*) Pharmaceuticals) PROGRESSION OF… (7*)|(4)

14. . . . PANCREATIC AND HEMATOPOIETIC 34. . . . E.COLI HEAT STABLE ENTEROTOXIN 94. . . . SYSTEMATIC SCREENING PROTOCOL CALCINEURIN INDEPENDENTLY MEDIATE… (ST) INHIBITION… (2*)|(6) FOR THE STOMACH… (2*) (2*) 35. . . . SHIGELLA GASTROENTERITIS 95. . . . SERUM PROTEOMIC PROFILING IN 15. . . . SOLUTE TRANSPORTER SLC26A9 TARGETS INTESTINAL URATE ULCERATIVE COLITIS… (4*) LOCALIZES TO THE… (2*) TRANSPORTER… (2*) 96. . . . INCREASED INTESTINAL 16. . . . IMMUNE PROFILING OF THE 36. . . . GLUCOCORTICOIDS AND SGK1- PERMEABILITY IS A PREDICTOR… (6*)|(2) HUMAN PANCREAS… (2*) POTENT REGULATORS OF… (2*) 97. . . . INCREASED RISK OF ULCERATIVE 17. . . . DYNAMIC ASSOCIATION OF 37. . . . METHYLATION CHANGES AT THE COLITIS IN… (5*) SYSTEMIC INFLAMMATION, GUT… (2*) GNAS IMPRINTED… (7*) 98. . . . HORMONE THERAPY FOR CANCER 18. . . . ROLE OF SONIC HEDGEHOG 38. . . . ENDOSCOPIC ULTRASOUND- IS A… (6*)|(The Chemotherapy Foundation, PATHWAY IN… (2*)|(5) GUIDED FINE NEEDLE BIOPSY HAS… (5*) philanthropic organization)

19. . . . KRÜPPEL-LIKE FACTOR 5 PLAYS AN 39. . . . AGE, OBESITY, DIABETES AND 99. . . . INFLAMMATORY BOWEL DISEASE IMPORTANT… (4*) INITIAL CYST… (5*) IN UK PRIMARY… (6*)

20. . . . TRANSCRIPTOME ANALYSIS 40. . . . TRIACYLGLYCEROLS AS A MARKER 100. . . . LONGITUDINAL CHANGES IN THE DURING PROGRESSION OF CHRONIC… FOR CHARACTERIZATION… (2*) DIRECT COSTS… (6*)|(Crohn's and Colitis (4*)|(Nil) Cada)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) 101. . . . INCREASED EXPRESSION OF 121. . . . HIGH CONTENT MORPHOLOGICAL 163. . . . METFORMIN AND BET INHIBITORS MELATONIN IN THE… (2*) ANALYSES OF ESOPHAGEAL… (2*)|(4) REDUCE PROLIFERATION… (2*)

102. . . . PHYSIOLOGICAL AND PROTEOMIC 122. . . . CALPONIN-HOMOLOGY AND 164. . . . ESTABLISHMENT OF A CHARACTERIZATION OF MICROTUBULE-ASSOCIATED PROTEIN NOMOGRAM COMPRISING OF… (2*)|(4) CAMPYLOBACTER… (2*)|(NIH K23 INTERACTS WITH… (2*) DK103911) 165. . . . DEVELOPMENT OF THE 144. . . . POSTOPERATIVE ENDOSCOPIC EOSINOPHILIC GASTRITIS MOLECULAR… 103. . . . BENEFICIAL EFFECTS OF A LOCALLY AND CLINICAL RECURRENCE AFTER… (2*)|(CEGIR (U54 AI117804) is part of the ADMINISTERED… (2*)|(4) (6*)|(7) Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases 104. . . . ASSOCIATIONS BETWEEN FECAL 145. . . . INFLAMMATORY POTENTIAL OF Research, NCATS, and is funded through SHORT CHAIN FATTY… (4*) DIET IS NOT… (2*) collaboration between NIAID, NIDDK, and NCATS. CEGIR is also supported by patient 105. . . . SACCHAROMYCES BOULARDII, A 146. . . . GUT MICROBIAL DYSBIOSIS advocacy grou) YEAST PROBIOTIC, REGULATES… (5*) CONTRIBUTES TO FATIGUE… (6*)|(3) 166. . . . L-TYPE CALCIUM CHANNEL 106. . . . ALTERED GENDER DIFFERENCE IN 147. . . . PEPT1 ENHANCED BACTERIAL INHIBITORS (VERAPAMIL AND… (4*) BRAIN HISTAMINE… (2*) PEPTIDE TRANSPORT INTO… (2*) 167. . . . EOE ESOPHAGEAL EPITHELIAL 107. . . . DISCONTINUITY OF CARE AMONG 148. . . . SLC7A5 IS CRUCIAL FOR CELLS INDUCE TH2… (4*)|(2) INFLAMMATORY BOWEL… (5*) MAITENANCE OF… (2*) 168. . . . EPIGENETIC ANALYSIS INDICATES 108. . . . THE PREVALENCE AND USE OF 149. . . . IN-DEPTH CHARACTERIZATION OF ACCELERATED MOLECULAR AGEING… (5*) CANNABIS… (5*) HOST-GENETICS AND GUT… (4*)|(2) 169. . . . INTERLEUKIN-13-MEDIATED 109. . . . ORAL VANCOMYCIN INDUCES AND 150. . . . SINGLE-CELL ANALYSIS OF T CELL RELEASE OF MITOCHONDRIAL DNA MAINTAINS REMISSION… (5*) PATHOGENESIS… (4*) FROM… (2*)|(3)|(Shire)

110. . . . STOPPING 5-AMINOSALICYLATES 151. . . . USING DEEPLEARNING AND 202. . . . THE MICROBIAL METABOLITE IN CROHN'S DISEASE PATIENTS… (6*) GENETIC BIGDATA TO… (2*)|(6) BUTYRATE PROMOTES GOBLET… (2*)

111. . . . INCREASING VACCINATION RATES 152. . . . PENTOXIFYLLINE TREATMENT IN 203. . . . COLONIC MESENCHYMAL WITH A PATIENT… (5*) ACUTE PANCREATITIS: FEASIBILITY… (2*) STROMAL CELL MYD88-MEDIATED SIGNALING… (2*) 112. . . . TELEPHONE STRAIGHT-TO-TEST 153. . . . CORONIN 1 IS NECESSARY FOR M… (TSTT) IMPROVES EARLY DIAGNOSIS… (5*) (2*) 204. . . . SURGERY IN VERY EARLY ONSET INFLAMMATORY… (6*) 113. . . . HIGHER RESILIENCE IS 154. . . . GUT MICROBE-PRODUCED SHORT ASSOCIATED WITH DECREASED… (5*) CHAIN FATTY ACIDS… (2*)|(4) 205. . . . COLLEGE ADJUSTMENT IN IBD STUDENTS: AGE… (3*)|(Abbvie Inc.) 114. . . . TISSUE-ENGINEERED INTESTINES 155. . . . PRIMARY AND PLURIPOTENT CAN NEO-INNERVATE EXPERIMENTALLY STEM CELL DERIVED… (2*)|(4) 206. . . . INCREASED EMERGENCY DENERVATED… (2*) DEPARTMENT VISITS AND 156. . . . H. PYLORI INDUCES GASTRIC HOSPITALIZATIONS… (2*)|(6) 115. . . . TRANSCUTANEOUS AURICULAR EPITHELIAL CELL… (2*) VAGAL NERVE STIMULATION IMPROVES… 207. . . . INCREASED INCIDENCE OF (5*) 157. . . . THE INTESTINAL MALIGNANCY IN PATIENTS… (2*)|(6) MICROENVIRONMENT INDUCES A 116. . . . ELECTROGASTOGRAPHY AT TRANSCRIPTION… (4*) 208. . . . SAFETY AND EFFICACY OF ANTI- BASELINE AND RESPONSE TO… (5*) TNF THERAPY… (5*) 158. . . . LEVERAGING HUMAN INTESTINAL 117. . . . SYNDAPIN 2 IS REQUIRED FOR ORGANOIDS TO ADVANCE… (3*)|(AbbVie) 209. . . . EARLY COMBINED MICROVILLUS… (2*) IMMUNOSUPPRESSION IS EFFECTIVE 159. . . . ALDH1A3 PROMOTES METASTATIC AND… (2*) 118. . . . ACTIVATION OF THE UNFOLDED COLONISATION OF PANCREATIC… (2*) PROTEIN RESPONSE… (2*) 235. . . . EARLY INFLIXIMAB 160. . . . DELETION OF NRF2 IN PHARMACOKINETICS AND WEEK ONE… 119. . . . RNA-BINDING PROTEIN HUR PANCREATIC STELLATE… (5*) (6*)|(2)|(Prometheus Labortories, REGULATES AUTOPHAGY ACTIVITY… (2*) Inc.provided study assay.) 161. . . . PANCREATIC ACINAR CELL 120. . . . MITOCHONDRIAL IMPAIRMENT IN REPROGRAMMING INDUCED BY… (2*) 236. . . . ADOLESCENTS' AND YOUNG CROHN'S DISEASE-LIKE INFLAMMATION… ADULTS' SATISFACTION WITH… (5*) (2*) 162. . . . GLYCEMIC PROFILE OF SUBJECTS WITH FAMILIAL… (5*) 237. . . . GEOGRAPHIC ANALYSIS OF PEDIATRIC INFLAMMATORY BOWEL… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) 270. . . . ESOPHAGEAL HYPERVIGILANCE 302. . . . EARLY CHANGE IN FECAL 238. . . . NUCLEIC ACID AMPLIFICATION AND SYMPTOM ANXIETY ARE… (2*) CALPROTECTIN PREDICTS… (2*)|(4) FOLLOWED BY ENZYME… (2*) 271. . . . MANAGEMENT OF SUPRA- 303. . . . EFFECT OF A PRACTICE-WIDE ANTI- 251. . . . ENDOSCOPIST-RELATED FACTORS GASTRIC BELCHING WITH COGNITIVE… (1*) TNF THERAPEUTIC… (2*)|(4) INFLUENCING POLYP DETECTION RATE… (5*)|(The first author completed this 272. . . . AVOIDANT/RESTRICTIVE FOOD 304. . . . NEW KEY PLAYERS IN IMPAIRED research during a Newman Fellowship INTAKE DISORDER AMONG ADULT… (5*) ANGIOGENESIS… (2*) programme, sponsored by Boston Scientific) 273. . . . A MULTIDISCIPLINARY 305. . . . GENERATION OF STRATIFIED 252. . . . A PROSPECTIVE RANDOMIZED INTEGRATED TREATMENT APPROACH IS… ESOPHAGEAL EPITHELIUM FROM… (6*) TANDEM COLONOSCOPY STUDY… (2*) (4*)|(Nil) 306. . . . CELLS LINEAGE TRACED FROM 274. . . . VARIATION IN ADENOMA LGR5+ CELLS… (2*) 253. . . . THE POLYP-BASED RESECT-AND- DETECTION RATE AND… (2*) DISCARD STRATEGY: A PROSPECTIVE… (5*) 307. . . . PROTEOMIC ANALYSIS OF 275. . . . DETERMINATION OF INTESTINAL BRUSH BORDER… (2*) 254. . . . VALIDATION OF BLUE LIGHT BENCHMARKS FOR SERRATED POLYP… (5*) IMAGING (BLI)… (5*) 308. . . . TEDUGLUTIDE IN A REAL WORLD 276. . . . EFFICACY AND SAFETY OF HOT SETTING… (5*) 255. . . . ARTIFICAL INTELLIGENCE IMAGE AND… (5*) CLASSIFIER BASED ON… (4*) 309. . . . A NOVEL R-SPONDIN 1/POMC 277. . . . RAPID DEVELOPMENT OF NEUROCIRCUIT IN… (2*) 256. . . . ARTIFICIAL INTELLIGENCE FOR FELLOWS' COGNITIVE AND… (5*) REAL-TIME MULTIPLE POLYP… (5*) 322. . . . PREVENTION OF RECURRENT 278. . . . SIMULATION BASED TRAINING IDIOPATHIC GASTRODUODENAL ULCER… 257. . . . HIGHER ABUNDANCE OF BILE IMPROVES CONFIDENCE LEVELS… (5*) (2*) ACID-METABOLIZING MICROBIOTA… (5*) 279. . . . VALIDATION OF A NATURAL 323. . . . RISK OF GASTROINTESTINAL 258. . . . INTEGRATED METABOLOMIC AND LANGUAGE PROCESSING… (2*) BLEEDING AFTER TREATMENT… (5*) MICROBIOME APPROACH REVEALED… (6*) 280. . . . INHIBITORY SMAD6 REDUCES 324. . . . OPTIMAL TIMING OF WARFARIN 259. . . . INCREASED BACTERIOPHAGE SOX9 EXPRESSION IN… (2*) RESUMPTION AFTER… (5*) ABUNDANCE AND LOSS OF… (2*)|(4) 281. . . . ROLE OF ENDOGENOUS AND 325. . . . DEVELOPMENT AND VALIDATION 260. . . . IDENTIFICATION OF PATHOGENIC EXOGENOUS CARBON… (4*)|(Jagiellonian OF MACHINE LEARNING… (2*) BACTERIA IN SEVERE… (2*) University Medical College, Faculty of Medicine, statutory grant No. 007716) 326. . . . RIVAROXABAN IS ASSOCIATED 261. . . . PROTEUS IS A KEY CANDIDATE IN… WITH HIGHER RATES… (1*) (6*) 282. . . . EXPOSURE OF BARRETT’S AND ESOPHAGEAL ADENOCARCINOMA… 327. . . . FAK ACTIVATORS PROMOTE 262. . . . DIETARY SERINE REGULATE THE (2*)|(4) INTESTINAL MUCOSAL HEALING… (5*) INTEGRITY OF… (2*) 283. . . . THE ROLE OF ST6GAL-I, A 328. . . . PRECLINICAL DRUG EVALUATION 263. . . . GUT MICROBIOTA PROFILING IN A GLYCOSYLTRANSFERASE… (4*)|(2) REVEALS INHIBITION OF… (2*) PROSPECTIVE… (4*) 284. . . . TRANSGENIC MOUSE MODEL 329. . . . TNFAIP8 IS A CRITICAL 264. . . . DIETARY EMULSIFIERS REDUCE BASED ON VSIG10L,… (2*) REGULATOR OF… (2*) THERMOGENESIS IN BROWN… (2*) 297. . . . DEEP LEARNING ALGORITHM FOR 330. . . . PHARMACOLOGICAL INHIBITION 265. . . . NEUROTENSIN (NT)-α-DEFENSINS CHARACTERIZATION OF… (5*) OF THE APICAL SODIUM-DEPENDENT… (2*) AXIS MEDIATES THE INFLUENCE… (2*) 298. . . . ARTIFICIAL INTELLIGENCE FOR 331. . . . THE LONG NON-CODING RNA, 266. . . . DIETARY INTERVENTIONS DETECTING GASTRIC CANCER… (5*) IFNG-AS1/NEST, IS… (6*)|(4) AMELIORATE INFECTIOUS COLITIS THROUGH… (2*) 299. . . . VIDEO VALIDATION OF SMALL 332. . . . TUMOR NECROSIS FACTOR BOWEL CONVOLUTIONAL… (5*) RECEPTOR 2 REGULATES… (2*)|(6) 267. . . . EXCLUSIVE ENTERAL NUTRITION (EEN) AND CROHN'S… (2*)|(3) 300. . . . DIFFERENTIATION BETWEEN 333. . . . TREM1, THE FIRST ANTI-TNF PANCREATIC CANCER AND NORMAL… (2*) SPECIFIC BIOMARKER… (4*) 268. . . . GUT MICROBIOTA MATURATION DURING EARLY LIFE… (2*)|(4) 301. . . . CROHN'S DISEASE EXCLUSION DIET 334. . . . DEVELOPMENT AND VALIDATION IS EQUALLY… (2*)|(3)|(Nestlé Health OF A CLINICAL… (3*)|(Takeda 269. . . . COLONIC EOSINOPHILIA IS Sciences) Pharmaceuticals U.S.A., Inc.) ASSOCIATED WITH CURRENT… (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) 335. . . . VEDOLIZUMAB TARGETS 426. . . . MARKED ALTERATIONS IN THE LYMPHOID AGGREGATES IN THE… 371. . . . USING A MACHINE LEARNING FECAL VIROME… (4*) (2*)|(3)|(Takeda Pharmaceuticals) PROGRAM -… (2*) 427. . . . FECAL MICROBIOTA 336. . . . USING DEEP LEARNING FOR 372. . . . ELMO1, A MICROBIAL SENSOR, TRANSPLANTATION REGULATES AUTOMATED GRADING… (2*) REGULATES BACTERIAL… (2*) CIRCULATING MICRORNA… (4*)

337. . . . COMPLETE HISTOLOGIC 373. . . . ROLE OF SURFACE 428. . . . SOLUTE CARRIER FAMILY 26 NORMALIZATION IS ASSOCIATED WITH… POLYSACCHARIDES OF ADHERENT- MEMBER 3… (3*)|(2)|(Funding: Merck & (5*) INVASIVE… (6*) Company sponsored this study. HWK was supported by NIH R03 DK103964 grant. CP 338. . . . LIVER TRANSPLANTATION FOR 374. . . . MICRORNA-125A PROTECTS was supported by NIH U01 DK110003-01 PRIMARY SCLEROSING CHOLANGITIS… (5*) INTESTINAL MUCOSAL INFLAMMATION and P30 DK 41301-26.) THROUGH… (2*)|(the tiol tural Science 347. . . . IS SUCROSE THE SIXTH FODMAP Foundation of Chi (81630017)) 429. . . . AUTOIMMUNE ANTIBODIES AND IN… (4*) SYMPTOMS OF AUTOIMMUNE… (2*) 375. . . . HELMINTH EXPOSURE ALTERS 348. . . . BMI RATHER THAN SYMPTOMS IS TH17 SUBPOPULATION PLASTICITY… (2*) 430. . . . A MULTICENTER, RANDOMIZED, ASSOCIATED… (5*) DOUBLE-BLIND STUDY OF… (3*)|(Lyric 377. . . . PROTECTIVE AND POTENTIALLY Pharmaceuticals, South San Francisco, CA, 349. . . . BASELINE GLP-1 LEVEL AGGRESSIVE BACTERIAL SPECIES… (2*) USA) CORRELATES WITH DEGREE… (5*) 401. . . . EFFICACY AND SAFETY OF 431. . . . ACTIVATION OF NRF2 350. . . . GWAS-IDENTIFIED METABOLIC COMBINED CPP-1X/SULINDAC… ATTENUATES DELAYED GASTRIC… (2*) SYNDROME GENES ARE TIGHTLY… (3*)|(Cancer Prevention Pharmaceuticals, (2*)|(3)|(Pathway Genomics) Inc.) 432. . . . PROTEOMICS IN GASTROPARESIS: UNIQUE AND OVERLAPPING… (2*)|(Study 357. . . . PROSPECTIVE EVALUATION OF A 414. . . . A ROLE FOR THE STOMACH IN… funded by NIDDK grants: U01DK112193, NOVEL, ENDOSCOPIC… (2*)|(6) (4*) U01DK112194, U01DK073983, U01DK073975, U01DK074035, 358. . . . CLOSE FOLLOW-UP IS ASSOCIATED 415. . . . COMBINED BLOCKADE OF α4β7 U01DK074007, U01DK073974, WITH FEWER… (2*) AND αEβ7… (3*)|(Genentech Inc., South U24DK074008) San Francisco, CA) 359. . . . EOSINOPHILIC ESOPHAGITIS-LIKE 433. . . . LOSS OF CX3CR1-POSITIVE DISEASE WITH LACK OF… (2*) 416. . . . THE ORAL α4β7 INTEGRIN GASTRIC MUSCULARIS MACROPHAGES… SPECIFIC ANTAGONIST… (3*)|(Protagonist (2*) 360. . . . ORAL VISCOUS BUDESONIDE Therapeutics, Inc.) VERSUS SWALLOWED FLUTICASONE… (2*) 434. . . . CHARACTERIZATION OF PYLORIC 417. . . . FUNCTIONAL CHARACTERIZATION TONIC AND PHASIC… (5*) 361. . . . FUNCTIONAL LUMINAL IMAGING OF ENTEROCHROMAFFIN CELLS USING… PROBE PROVIDES AN… (6*)|(2) (2*) 435. . . . DUAL THERAPY WITH ESOMEPRAZOLE AND AMOXICILLIN… 362. . . . IBD EPIDEMIOLOGY: WHAT IS 418. . . . DEFECTIVE CFTR FUNCTION IN (2*)|(3)|(This study was funded by ‘12th GOING ON… (5*) PANCREATIC DUCTAL… (4*)|(2) Five-Year’ tiol Science and Technology Support Plan project (2012BAI06B02) and 363. . . . DOES RIFAXIMIN OFFER ANY 419. . . . LACTOBACILLUS REUTERI AstraZeneca Investment (Chi) Co., Ltd.) PROMISE IN… (5*) SECRETES γ-GLUTAMYLCYSTEINE TO SUPPRESS… (2*) 436. . . . THE EFFICACY OF FOURTEEN-DAYS 364. . . . EARLY USE OF AZATHIOPRINE ESOMEPRAZOLE AND… (4*) ASSOCIATED WITH… (5*) 421. . . . PATHOLOGICAL ACTIVATION OF PIEZO1 IS THE… (2*) 437. . . . AN OPEN-LABEL, MULTI-CENTER, 365. . . . EFFICACY AND SAFETY OF RANDOMIZED, SUPERIORITY TRIAL… (5*) INFLIXIMAB RETREATMENT… (5*) 422. . . . EPITHELIAL IDO1 MODULATES AHR AND NOTCH… (2*)|(6) 438. . . . HISTOLOGICAL GASTRITIS IN A 366. . . . SURVEILLANCE COLONOSCOPIES COMMUNITY POPULATION… (3*)|(The IN ULCERATIVE COLITIS: DOES… (4*) 423. . . . IDENTIFYING THE MOST COST- study was supported by Olympus Sverige EFFECTIVE TREATMENT ALGORITHM… (5*) AB (Box 1816, 171 23 Sol, Sweden), who 367. . . . VAGUS NERVE STIMULATION supplied study equipment.) REDUCES DISEASE ACTIVITY… 424. . . . A PROSPECTIVE, LONGITUDINAL (3*)|(SetPoint Medical) STUDY OF METABOLOMIC… (2*) 439. . . . RESIDUAL RISK OF GASTRIC CANCER FOLLOWING… (5*) 369. . . . TARGETED DELETION OF THE ATP- 425. . . . DURABLE TRANSFER OF BINDING CASSETTE… (2*) CANDIDATE PROCARCINOGENIC 440. . . . ROBUSTNESS OF ELUXADOLINE BACTERIA… (2*) FOR THE TREATMENT… (3*)|(This study 370. . . . PREVALENCE OF NON-ALCOHOLIC was supported by Allergan plc, Dublin, FATTY LIVER DISEASE… (5*) Ireland. Writing assistance by Complete

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) HealthVizion, Inc., Chicago, IL, USA with funding by Allergan plc, Dublin, Ireland.) 459. . . . TRENDS IN PRESCRIBING OF ACID- 522. . . . SEROTONIN MODULATES ARYL REDUCING THERAPIES… (1*) HYDROCARBON RECEPTOR (AHR)… (2*)|(6) 441. . . . PSYCHOLOGICAL FACTORS HAVE A VARYING EFFECT… (6*) 460. . . . EFFECTS OF PROTON-PUMP 523. . . . KSR1 AND EXO70 INTERACT WITH INHIBITORS IN PATIENTS… (5*) ERK1/2… (2*) 442. . . . SAFETY PROFILE OF ELUXADOLINE IN PATIENTS… (3*)|(This study was 461. . . . ANOTHER FALSE ALARM: NO 524. . . . EPIDERMAL GROWTH FACTOR supported by Allergan plc, Dublin, Ireland. GOOD EVIDENCE… (5*) IMPROVES GLUCAGON-LIKE PEPTIDE-2- Writing assistance by Complete MEDIATED… (2*) HealthVizion, Inc., Chicago, IL, USA with 462. . . . CIRCULATING EXTRACELLULAR funding by Allergan plc, Dublin, Ireland.) VESICLES AND SPHINGOLIPIDS CARGO… 525. . . . ENDOCRINE PROGENITOR CELLS (2*) ORCHESTRATE THE INTESTINAL… (2*) 443. . . . INTESTINAL BIOFILMS ARE AN ENDOSCOPIC FEATURE… (2*) 463. . . . SIGNIFICANTLY WORSE 527. . . . LYSOPHOSPHATIDIC ACID FUNCTIONAL STATUS AT TIME… (5*) TREATMENT AMELIORATES THE 444. . . . RIFAXIMIN FOR IMPROVING FUNCTION… (7*) ABDOMINAL PAIN AND… (3*)|(Funded by 464. . . . SIGNIFICANT INCREASES IN Salix Pharmaceuticals.) ALCOHOL CIRRHOSIS RELATED… (5*) 528. . . . IN BARRET’S EPITHELIAL CELLS, NUCLEOPHOSMIN 1… (2*) 445. . . . NT-NTR1 SIGNALING POSITIVELY 490. . . . INFLAMMATION-INDUCED LOSS REGULATES INTESTINAL FATTY… (2*) OF SPROUTY2 IN THE… (2*)|(6)|(NIH 529. . . . 3D ORGANOIDS REVEAL THE R01DK095004 (MRF) Crohn's & Colitis EXPANSION OF… (2*) 446. . . . MODULATION OF BILE ACIDS Foundation Career Development Award PATHWAY IN… (2*)|(3)|(Funds and product (MAS)) 530. . . . ESOPHAGEAL SQUAMOUS CANCER provided by Satiogen Pharmaceuticals) CELLS CONDITION LYMPHATIC… (2*) 509. . . . WOMEN GASTROENTEROLOGISTS 447. . . . DIFFERENCES IN PREVALENCE OF ARE UNDERREPRESENTED IN 531. . . . TARGETING NERVE-CANCER METABOLIC CONDITIONS… (5*) RECOGNITION… (5*) METABOLISM IMPROVED OVERALL SURVIVAL… (2*)|(4) 448. . . . CHOLECYSTECTOMY ALTERS 510. . . . STRATEGIES TO ACCOUNT FOR GASTROINTESTINAL HEALTH INDICES COLONOSCOPY VOLUME… (6*) 532. . . . RSPO3 FUNCTIONS AS TUMOUR- AND… (4*) SUPPRESSOR AND INHIBITS… (2*)|(( The 511. . . . ENDOSCOPIC HISTORY project was supported by 449. . . . HIGH FAT KETOGENIC DIET POTENTIALLY EXPLAINS SURVIVAL NSFC81472727,NSFC81272403,NSFC817732 DECREASES SERUM… (4*) DIFFERENCES… (4*) 59; Science and Technology Commission of Shanghai Municipality (15JC1403100)).) 450. . . . EFFECT OF FARNESOID X 512. . . . DONOR HEALTH SCREENING FOR RECEPTOR ACTIVATION… (2*) FECAL MICROBIOTA… (5*) 533. . . . GENERATION OF NOVEL PIK3CA- INDUCED GASTRIC CANCER… (2*) 451. . . . FUNCTIONAL GENOMIC 513. . . . MORTALITY IN MICROSCOPIC SCREENING USING CRISPR/CAS9 COLITIS - RESULTS… (5*) 534. . . . MRI IS HIGHLY PREDICTIVE OF IDENTIFIES… (4*) THE… (5*) 514. . . . BEVERAGE INTAKE AND THE 452. . . . TRIM67 PREVENTS INCIDENCE OF… (2*) 535. . . . ILEAL BIOPSY EPITHELIAL CELL COLORECTALTUMORIGENESIS IN MICE BY… PYROPTOSIS PREDICTS… (3*)|(Takeda (2*) 515. . . . COLONOSCOPY AFTER HOLIDAYS Pharma: grant support) IS AN INDEPENDENT… (5*) 453. . . . THERAPEUTIC DOSE OF PELVIC 536. . . . PREDICTING VEDOLIZUMAB RADIATION SLOWS… (2*) 516. . . . RACIAL DISPARITIES IN THE CARE INDUCED ENDOSCOPIC REMISSION IN… OF… (4*) (4*)|(2) 454. . . . PD-L1 EXPRESSION REGULATES TUMOR CELL APOPTOSIS… (2*)|(4) 517. . . . RACIAL AND ETHNIC TRENDS IN 537. . . . FECAL CALPROTECTIN IS AN EARLY ESOPHAGEAL… (5*) PREDICTOR… (3*)|(Truvion Healthcare 455. . . . DIFFERENTIAL POST- (Preventis)) TRANSLATIONAL MODIFICATION OF 518. . . . RACIAL DISPARITIES IN RATES OF POLYMORPHIC MSH3… (2*)|(4) SURGERY… (5*) 538. . . . A BLOOD BASED PRE-SURGICAL TRANSCRIPTOMIC SIGNATURE… (6*)|(4) 456. . . . DCLK1 MONOCLONAL ANTIBODY- 519. . . . THE AGE TO STOP ENDOSCOPIC BASED CAR-T CELLS AS… (2*) SURVEILLANCE… (2*) 539. . . . WEARABLE DEVICES CAN PREDICT DISEASE ACTIVITY… (3*)|(Takeda 457. . . . ON DEMAND VS CONTINUOUS 520. . . . OVERUSE OF SURVEILLANCE Pharmaceuticals) USE OF… (4*) ENDOSCOPY FOR BARRETT’S… (2*) 567. . . . ADEQUATE INFLIXIMAB EXPOSURE 458. . . . SUCCESSFUL REDUCTION OF 521. . . . NUMBER OF SESSIONS TO DURING THE INDUCTION… (5*) OVERALL AND INAPPROPRIATE… (5*) ACHIEVE COMPLETE… (7*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) 568. . . . HIGHER INFLIXIMAB AND 598. . . . IDENTIFICATION OF 617. . . . SIMULTANEOUS LOSS OF BOTH ADALIMUMAB TROUGH LEVELS… (5*) IMMUNOTOXIC PEPTIDES FROM DIETARY… ATYPICAL PROTEIN… (2*)|(7) (2*)|(4) 569. . . . ADALIMUMAB FOR PATIENTS 618. . . . ROLE OF LGR5 IN DCLK1+ CELL- WITH CROHN'S DISEASE… (3*)|(Abbvie) 599. . . . EFFECT OF BIFIDOBACTERIUM DERIVED… (7*)|(4) INFANTIS NSL SUPER… (5*) 570. . . . EARLY ENDOSCOPIC RETROGRADE 619. . . . MYELOID CALCINEURIN IN THE CHOLANGIOGRAPHY WITH BILIARY… 600. . . . CONCORDANCE OF BULB AND CONTROL OF… (4*) (2*)|(4) DISTAL DUODENAL… (5*) 620. . . . NEUTROPHILS RESTRICT TUMOR- 571. . . . THE PREDICTIVE EFFECT OF A 601. . . . THE EFFECT OF ESOMEPRAZOLE ASSOCIATED MICROBIOTA TO DAMPEN… HIGH-QUALITY… (5*) ON THE… (2*)|(tural Science Fund of Chi (2*) (U1702281 and 81670551)) 584. . . . EFFICACY AND SAFETY OF 621. . . . FECAL MICROBIOTA RIFAXIMIN TREATMENT… (3*)|(Funded by 602. . . . THROMBOEMBOLIC EVENTS IN TRANSPLANTATION FOR THE Salix Pharmaceuticals.) ACUTE PANCREATITIS… (5*) TREATMENT… (3*)|(4)|(This study was an Investigator Initiated Study funded by Finch 585. . . . EFFECT OF THROMBOPOIETIN 603. . . . NATURAL HISTORY OF LOW Therapeutics.) RECEPTOR AGONIST IS… (5*) OUTPUT EXTERNAL… (5*) 622. . . . DOUBLE-BLIND RANDOMIZED 586. . . . BALLOON-OCCLUDED 604. . . . IMPACT OF STATIN USE ON PLACEBO-CONTROLLED TRIAL OF WEEKLY… RETROGRADE TRANSVENOUS CLINICAL… (5*) (3*)|(2)|(SERES THERAPEUTICS NIH Grant OBLITERATION (BRTO) VERSUS… (5*) P30 DK40561 Massachusetts General 605. . . . THE CLINICAL COURSE AND Hospital Claflin Distinguished Scholar 587. . . . PENTADECAPEPTIDE BPC 157 DIAGNOSTIC WORK-UP… (5*) Award) THERAPY IN BILE… (4*) 606. . . . CLINICAL FEATURES OF 623. . . . SER-287, AN INVESTIGATIONAL 588. . . . COMPLICATIONS ASSOCIATED HYPERTRIGLYCERIDEMIA-INDUCED ACUTE MICROBIOME THERAPEUTIC, INDUCES… WITH ANESTHESIA SERVICES IN… (2*) PANCREATITIS… (5*) (3*)|(Seres Therapeutics)

589. . . . QUALITATIVE DERIVATION AND 607. . . . DYNAMIC ANALYSIS OF PATIENTS 624. . . . COMPARISON OF TWO OPEN- QUANTITATIVE PREDICTION OF… (7*) WITH ACUTE… (3*)|(This was not a funded LABEL TRIALS DEMONSTRATES… (3*)|(This study but it was performed in part by Ariel alysis was funded by Rebiotix Inc., Roseville, 590. . . . HIGH DIAGNOSTIC YIELD USING Precision Medicine, a commercial entity. MN, USA.) ADVANCED ARTIFICIAL… (5*) We performed a cohort alysis that was agreed upon a priori by the investigators as 625. . . . DONOR FUNGI AND BACTERIA 591. . . . DERIVATION AND VALIDATION OF a collaboration.) ENGRAFTMENT AFTER… (4*) QUANTITATIVE PARAMETERS… (7*) 608. . . . PAIN MODULATORY PHENOTYPES 626. . . . GUT MICROBIOTA FROM 592. . . . SEQUENTIAL DIAGNOSIS OF LIVER DIFFERENTIATE CHRONIC PANCREATITIS… COLORECTAL CANCER PATIENTS… (2*) METASTASIS FROM… (5*) (7*) 627. . . . DYSREGULATION OF EPITHELIAL 593. . . . DEVELOPMENT, VALIDATION OF A 609. . . . RESULTS FROM A MULTICENTER, TLR4 SELECTS FOR… (2*)|(6) POST-ERCP PANCREATITIS… (5*) PHASE II,… (3*) 628. . . . IDENTIFICATION OF CROSSTALK 594. . . . ENDOSCOPIC ULTRASOUND- 610. . . . CHRONIC PANCREATITIS IS BETWEEN GUT MICROBIOTA,… (2*) GUIDED TREATMENT OF GASTRIC ASSOCIATED WITH INCREASED… (5*) VARICES… (5*) 629. . . . COLORECTAL CANCER- 611. . . . A NOVEL METHOD FOR ASSOCIATED BACTERIA INDUCE TH1 AND… 595. . . . UTILITY OF SYMPTOM SEVERITY, ASSESSMENT AND… (7*) (6*) FREQUENCY, AND… (3*)|(The origil study was funded by Alvine Pharmaceuticals. The 612. . . . PANCREATIC ATROPHY DOES NOT 630. . . . GUT MICROBIOTA MODULATES data was then acquired by ImmunogenX. CORRELATE WITH… (5*) THE CHEMOPREVENTIVE EFFICACY… (2*) This is a post hoc alysis of the lead in data from that trial and shared with us from 613. . . . PANCREATIC CANCER INCIDENCE 631. . . . DIETARY INTAKE, H2S-PRODUCING ImmunogenX. No funding for this current IN A LARGE… (7*) MICROBES, AND RISK… (2*)|(6) post hoc alysis was used from t) 614. . . . PAIN “BURN-OUT” DURING THE 632. . . . DEVELOPMENT OF A NOVEL 596. . . . REAL LIFE PATTERNS OF GLUTEN- NATURAL COURSE… (2*) MIRNA-BASED SIGNATURE… (5*) FREE DIET… (5*) 615. . . . ACCELERATED ONSET OF 633. . . . GA-68 DOTATATE PET IN GASTRO- 597. . . . A THEORY-BASED, BEHAVIORALLY SPONTANEOUS PROXIMAL COLONIC… (2*) ENTERO-PANCREATIC NEUROENDOCRINE… FOCUSED COOKING INTERVENTION… (4*) (5*) 616. . . . LOSS OF GLUTATHIONE PEROXIDASE 1 PROTECTS… (2*) 635. . . . THE UTILITY OF COMPUTED TOMOGRAPHY (CT)… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) QUESTION… (POSTER PRESENTATION)… 686. . . . RISK OF METACHRONOUS 636. . . . DUODENAL NEUROENDOCRINE (5*) COLORECTAL CANCER AMONG… (4*) TUMORS EXHIBIT DISTINCT SOMATIC… (2*) 664. . . . HEPATOCELLULAR CARCINOMA 687. . . . LONG-TERM RISK OF COLORECTAL 637. . . . DELINEATION OF THE SCREENING RATES IN A… (POSTER CANCER AFTER… (2*) PATHOGENESIS OF MESENTERIC… (4*) PRESENTATION)… (5*) 688. . . . BASELINE FINDINGS ON 649. . . . ECONOMIC BURDEN OF CELIAC 665. . . . EVALUATING THE IMPACT OF A SCREENING COLONOSCOPY IN… (2*) DISEASE IN… (3*)|(Takeda Pharmaceuticals NOVEL,… (POSTER PRESENTATION)… (5*) Intertiol Co.) 689. . . . RISK OF COLORECTAL CANCER 666. . . . THE IMPACT OF DELAY BETWEEN AND RELATED-MORTALITY… (2*)|(7) 650. . . . PREVALENCE OF CELIAC DISEASE BIOLOGIC… (POSTER PRESENTATION)… (5*) AUTOIMMUNITY AND… (5*) 690. . . . COMPLICATIONS OF SCREENING 667. . . . OPTIMIZING OUTPATIENT COLONOSCOPY IN A… (2*) 651. . . . INTERNATIONAL STUDY GROUP OF COLORECTAL CANCER SCREENING PEDIATRIC PANCREATITIS:… (2*) AND…(POSTER PRESENTATION)… (5*) 691. . . . INCREASING PHYSICIAN ADENOMA DETECTION RATE IS… (2*) 652. . . . CLINICAL OUTCOMES IN 668. . . . RATE OF INAPPROPRIATE FIT AUSTRALIAN CHILDREN WITH… (5*) TESTING AT… (POSTER PRESENTATION)… 692. . . . ESCHERICHIA COLI HEAT-STABLE (5*) TOXIN IMPAIRS COLONIC… (2*) 653. . . . EXTENSIVE GENE TESTING AND GENETIC INVOLVEMENT… (2*)|(Conflicts of 669. . . . PROACTIVE MANAGEMENT OF 693. . . . ATYPICAL PKCζ ACTIVITY AND Interests: Dr. C. Alexander Valencia worked IRON DEFICIENCY AND… (POSTER RECRUITMENT TO… (2*) at Cincinti Children’s when the study was PRESENTATION)… (5*) conducted, he currently works at 694. . . . THE IBD CANDIDATE GENE, PTPN2, PerkinElmer genomics, Pittsburgh, PA, and 670. . . . UTILIZING A TIME SERIES STUDY REGULATES… (2*)|(6) this company has not provided any fincial TO… (POSTER PRESENTATION)…(5*) support for the study. Dr. Abu-El-Hai) 695. . . . TTC7A-DEFICIENCT HUMAN 671. . . . IMPLEMENTATION OF AN ACUTE COLONIC ENTEROIDS EXHIBIT ALTERED… 654. . . . THE STOOL MICROBIOME MAY CARE CLINICAL… (POSTER PRESENTATION)… (4*) PREDICT OUTCOMES… (6*)|(4) (5*) 696. . . . TEDUGLUTIDE INCREASES 655. . . . STANDARDIZING THE CARE OF 672. . . . HEMATOCHEZIA DECREASES USE ADAPTATION IN A MURINE… ACUTE SEVERE… (POSTER PRESENTATION)… OF VENOUS THROMBOEMBOLISM… (3*)|(4)|(Shire, Lexington, USA - (5*) (POSTER PRESENTATION)… (5*) Investigator Initiated Research Grant)

656. . . . MULTI-SYSTEM APPROACH TO 673. . . . STANDARDIZING INPATIENT 697. . . . INTESTINAL PERMEABILITY IS AN DECREASING PROTON PUMP… (POSTER BOWEL PREPARATION ORDERS IMPORTANT FACTOR… (2*) PRESENTATION)… (5*) IMPROVES… (POSTER PRESENTATION)… (5*) 698. . . . DISTINCTIVE SUBPOPULATION OF 657. . . . FENTANYL WASTE WAS REDUCED INNATE LYMPHOID CELLS… (5*) BY CONSERVATION… (POSTER 674. . . . PATIENTS' SELF-IDENTIFIED STOOL PRESENTATION)… (5*) COLOR IS COMPARABLE… (POSTER 699. . . . HUMAN MONOCYTES ENHANCE PRESENTATION)… (5*) INTESTINAL STEM CELL… (2*) 658. . . . IMPROVING FIRST-CASE START DELAYS IN A… (POSTER PRESENTATION)… 675. . . . REDUCING INAPPROPRIATE FECAL 700. . . . SEMAPHORIN-3E REGULATES (5*) IMMUNOHISTOCHEMICAL TEST (FIT)… APOPTOSIS DURING THE DEVELOPMENT… (POSTER PRESENTATION)… (5*) (7*) 659. . . . NEW PATIENT ACCESS IN A GASTROENTEROLOGY… (POSTER 676. . . . ENDOSCOPIC MANAGEMENT OF 701. . . . DIETARY INTAKE OF WALNUT TO PRESENTATION)… (5*) ACHALASIA: TIME FOR… (POSTER MITIGATE… (4*) PRESENTATION)… (5*) 660. . . . IMPROVING VACCINATION 702. . . . MOLECULAR CHARACTERIZATION ADHERENCE IN INFLAMMATORY BOWEL… 677. . . . ESOPHAGEAL MANOMETRY OF MOUSE MODELS OF… (5*) (POSTER PRESENTATION)… (2*)|(7) STANDARDIZATION - A COMMUNITY… (POSTER PRESENTATION)… (5*) 703. . . . TYPE 2 CYTOKINES PROMOTE 661. . . . USE OF A SIMPLE 6-ITEM HYPERPLASIA AND… (2*) QUESTIONNAIRE… (POSTER 678. . . . IMPACT OF GUIDED RELAXATION PRESENTATION)… (5*) AND MUSIC… (POSTER PRESENTATION)… 704. . . . PREOPERATIVE SERUM (5*) VEDOLIZUMAB LEVELS DO NOT… (5*) 662. . . . QUALITY GAPS IN PREVENTATIVE CARE PROVIDED… (POSTER 679. . . . DISCREPANCY BETWEEN SELF- 705. . . . PRE-OPERATIVE BIOLOGICS PRESENTATION)… (5*) REPORTED PREFERENCES ON SIGNIFICANTLY REDUCE POST-OPERATIVE POLYPECTOMY… (POSTER LEAKS… (5*) 663. . . . LET'S MAKE YOUR CLINIC VISIT A PRESENTATION)… (5*) LITTLE SIMPLER - DEVELOPMENT OF A

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) 706. . . . A PROMINENT ROLE FOR (3*)|(Theravance Biopharma R&D, Inc. 814. . . . HELICOBACTER PYLORI INDUCES CHEMOKINES, IN… (2*) Alfasigma S.p.A.) ABERRANT LRIG1 STEM… (2*)

707. . . . RISK OF VENOUS 785. . . . SEXUAL DIMORPHIC EPIGENETIC 815. . . . LONG-TERM CHANGES OF GUT THROMBOEMBOLISM ACCORDING TO… REGULATION OF CHRONIC… (2*) MICROBIOTA, ANTIBIOTIC… (2*)|(4) (5*) 786. . . . HOME BIOFEEDBACK THERAPY 816. . . . EFFECTS OF ANTI-HELICOBACTER 708. . . . A SIGNIFICANT DECREASE IN THE WITH NOVEL DEVICE… (7*)|(3)|(InControl PYLORI THERAPY ON… (2*)|(4) RATE… (6*) Medical.) 817. . . . EFFICACY OF 1-FOOD AND 4-FOOD 709. . . . COLECTOMY RATES ARE 787. . . . GUT DYSBIOSIS CONTRIBUTES TO ELIMINATION… (2*)|(4) SIGNIFICANTLY HIGHER AMONG… (4*) VISCERAL HYPERSENSITIVITY… (2*) 818. . . . CYTOKINE EXPRESSION 756. . . . FUNCTIONAL LUMINAL IMAGING 788. . . . MICRORNA LET-7F IS ILLUSTRATES HETEROGENEITY OF ACTIVE… PROBE (FLIP) ASSESSMENT… (2*) OVEREXPRESSED IN COLONIC… (2*) (2*)|(6)

757. . . . FUNCTIONAL GASTROINTESTINAL 789. . . . FEAR OF PAIN AND 819. . . . METABOLISM OF WHEAT DISORDERS AND BEHAVIORAL SEROTONERGIC GENE… (4*) AMYLASE TRYPSIN INHIBITORS… (2*) PROBLEMS… (5*) 790. . . . IMPACT OF PERSONALIZED 820. . . . PROSPECTIVE LONGITUDINAL GUT 758. . . . LONG-TERM OUTCOMES OF COUNSELING ON DEPRESSION… (4*)|(5) METAGENOMIC ANALYSIS SUGGESTS… (2*) GASTRIC ELECTRICAL STIMULATION… (5*) 791. . . . A NOVEL HUMANIZED ANIMAL 821. . . . A RANDOMIZED, PLACEBO- 759. . . . SIGNIFICANT VARIANTS IN MODEL OF… (2*) CONTROLLED EVALUATION OF THE… MONOGENIC INFLAMMATORY BOWEL… (3*)|(ImmusanT, Inc.) (6*) 792. . . . EXOME SEQUENCING TO IDENTIFY RISK FACTORS… (2*) 822. . . . FURTHER DEVELOPMENT OF A 760. . . . MUTATIONS IN X-LINKED NOVEL IN… (4*) INHIBITOR OF APOPTOSIS… (2*)|(4) 793. . . . PATHWAYS OF PROGRESSION FROM INTRADUCTAL PAPILLARY… (2*) 823. . . . BENEFITS AND BARRIERS OF A 773. . . . CYSTINE/GLUTAMATE HANDHELD… (2*)|(Nima Labs supplied 30 ANTIPORTER (XCT) IS REQUIRED FOR… (2*) 794. . . . MUTATIONS IN REGULATORY Nima devices (the capsules were purchased ELEMENTS OF THE… (2*) separately by the above-acknowledged 774. . . . ROLE OF CELL CYCLE INHIBITOR grant support). Nima labs was not privy to P21WAF1/CIP1,… (2*) 795. . . . VALIDATION OF PANCREATITIS the study design, results, or composition of ACTIVITY SCORING SYSTEM… (5*) the abstract.) 775. . . . EXOGENOUS STIFFNESS RESULTS IN NUCLEAR TRANSLOCATION… (4*)|(7) 796. . . . REAL-WORLD EFFECTIVENESS OF 824. . . . ACUTE GLUTEN-INDUCED TOFACITINIB IN ULCERATIVE… (5*) SYMPTOMS IN CELIAC DISEASE… 777. . . . LOSS OF TGF-β SIGNALING (3*)|(ImmusanT, Inc.) PROMOTES PROLIFERATION… (2*)|(4) 797. . . . REAL-WORLD SAFETY OF TOFACITINIB IN INFLAMMATORY… (4*) 825. . . . AN ACUTE RISE IN SERUM IL-2… 778. . . . NCX1/CA SIGNAL PATHWAY (6*)|(4)|(Nestle Research Center/Society CONTRIBUTES TO THE… (2*) 798. . . . EFFICACY AND SAFETY OF OPEN- for the Study of Celiac Disease) LABEL TREATMENT… (3*)|(Pfizer Inc) 779. . . . USE OF NON-ASPIRIN NON- 826. . . . POLYGENIC RISK SCORE, FAMILY STEROIDAL ANTI-INFLAMMATORY 799. . . . EFFICACY OF UPADACITINIB AS AN HISTORY, AND… (2*) DRUGS… (5*) INDUCTION… (3*)|(AbbVie-sponsored) 827. . . . OPTIMAL TIMING OF TOTAL 780. . . . INNOVATIVE SYSTEM FOR 800. . . . IMPROVED ENDOSCOPIC GASTRECTOMY TO… (5*) SELECTIVE ERADICATION OF… (5*) OUTCOMES AND MUCOSAL HEALING… (3*)|(The authors and AbbVie scientists 828. . . . WHAT`S MY RISK OF CANCER 781. . . . QUANTIFYING EVOLUTION OF designed the study, and alysed and DOCTOR?… (5*) EARLY DYSPLASTIC LESIONS… (2*)|(6) interpreted the data. AbbVie funded the research and provided writing support. All 829. . . . THE IDENTIFICATION OF DNA 782. . . . PATIENT-MATCHED STEM CELLS authors contributed to the development of MISMATCH REPAIR… (2*)|(4) OF THE BARRETT'S-DYSPLASIA- the content. The authors and AbbVie ADENOCARCINOMA… (2*) reviewed and approved the) 830. . . . SCREENING UPPER ENDOSCOPY IS USEFUL FOR… (5*) 783. . . . LONG-TERM PROTON PUMP 801. . . . CLINICAL, ENDOSCOPIC, INHIBITOR USE AND… (3*)|(Investigator HISTOLOGIC AND BIOMARKER ACTIVITY… 831. . . . AN EVALUATION OF THE RISKS initiated research grant from Pfizer) (3*)|(Theravance Biopharma US, Inc) AND… (5*)

784. . . . VELUSETRAG IMPROVES 813. . . . CURCUMA LONGA LINN VERSUS 832. . . . DASHBOARD DRIVEN DOSING OF GASTOPARESIS BOTH IN SYMPTOMS… OMEPRAZOLE IN… (7*) INFLIXIMAB IS… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) 833. . . . EFFICACY AND SAFETY OF 853. . . . CHOLANGIOCARCINOMA (CCA) 872. . . . YOGURT CONSUMPTION AND RISK USTEKINUMAB AS… (3*)|(This study was DERIVED EXTRACELLULAR VESICLES OF CONVENTIONAL… (2*) funded by Janssen Research & REPROGRAM… (7*)|(4) Development, LLC) 873. . . . COGNITIVE BEHAVIORAL 855. . . . SLC25A22 DRIVES THERAPY-INDUCED CHANGES IN RESTING… 834. . . . WITHDRAWAL OF THIOPURINES IN ONCOMETABOLITE SUCCINATE TO (2*) CROHN'S DISEASE… (2*)|(Grant from the PROMOTE… (2*) Ministry of Health, Labour and Welfare of 874. . . . GUT DYSBIOSIS CHARACTERIZED Japan (“Investigation and research for 856. . . . ASSESSMENT OF THE IMPACT OF BY OVERABUNDANCE OF… (2*) intractable inflammatory bowel disease”).) INTRODUCING… (5*) 875. . . . FECAL MICROBIOTA FROM IBS 835. . . . LONG-TERM SAFETY OF 857. . . . MEDICATION UTILIZATION AND PATIENT INDUCES… (4*) VEDOLIZUMAB IN ULCERATIVE… SATISFACTION IN IRRITABLE… (5*) (3*)|(Takeda) 876. . . . STRESS-INDUCED DISRUPTION OF 858. . . . THERAPEUTIC RESPONSE TO INTESTINAL BARRIER AND… (7*)|(This 836. . . . IMMUNOLOGIC PREDICTORS OF SMALL INTESTINAL BACTERIAL… (5*) study proposal received AGA Student RESPONSE TO VEDOLIZUMAB… (3*)|(The Research Fellowship award.) study was supported by Takeda (IISR-2014- 859. . . . IDENTIFICATION OF BILE ACID 100922)) DIARRHEA IN… (4*) 877. . . . MICROBIOTA PLAYS A KEY ROLE IN… (4*) 837. . . . PILOT STUDY OF EARLY 860. . . . LOW FODMAP DIET IN THE LONG… SCREENING IN… (4*) (5*) 878. . . . GUT MICROBIOME BIOMARKERS BEFORE AND DURING… (2*) 838. . . . IS 45 THE NEW 50? ADENOMA… 861. . . . EFFECT OF KETOTIFEN ON (5*) ABDOMINAL SYMPTOMS,… (2*) 879. . . . SWITCHING FROM INFLIXIMAB ORIGINATOR TO A… (5*) 839. . . . DISPARITIES IN COLORECTAL 862. . . . INTESTINAL ACIDIFICATION CANCER SCREENING: THE… (5*) SENSED BY PH-SENSING RECEPTOR… (4*) 880. . . . DELINEATING THE PHENOTYPE OF PEDIATRIC PSC-IBD… (5*) 840. . . . COLORECTAL CANCER SCREENING 863. . . . INDUCTION OF AUTOPHAGY IN AMONG HISPANICS IN… (4*) CX3CR1+ MONONUCLEAR… (2*)|(4) 881. . . . PILOT STUDY OF EOSINOPHILIC BIOMARKER MEASURED… (5*) 841. . . . PATIENT-DIRECTED MESSAGING 864. . . . PLATELETS AND THEIR TO INCREASE COLORECTAL CANCER… (5*) INTERACTION WITH PRIMARY… (4*) 882. . . . NORMALIZATION OF FECAL CALPROTECTIN REQUIRES HIGHER… (5*) 842. . . . SEQUENTIAL OR ACTIVE CHOICE 865. . . . CIRCULATING FIBROCYTES ARE FOR COLORECTAL… (2*) INCREASED IN PATIENTS… (2*) 883. . . . INTEGRATION OF CLINICAL, IMMUNOLOGIC AND GENOMIC… (2*) 843. . . . IMPACT OF MAILED OUTREACH 866. . . . ORALLY ACTIVE ELAFIN-EUDRAGIT AND INREACH… (2*) INHIBITS COLITIS-ASSOCIATED 884. . . . PROSPECTIVE COMPARISON OF INTESTINAL… (2*)|(6) SACRAL NERVE STIMULATION… (5*) 844. . . . IDENTIFICATION OF PUTATIVE CANCER STEM CELLS… (5*) 867. . . . THE BCL-2 INHIBITOR ABT-263 945. . . . GLUTEN AVOIDANCE AND SELF- ATTENUATES INTESTINAL… (3*)|(Abbvie) REPORTED NON-CELIAC WHEAT… 845. . . . GENOMEWIDE TRANSCRIPTOMIC (3*)|(This study was supported by a grant PROFILING IDENTIFIES A NOVEL… (4*) 868. . . . THE ROLE OF NUCLEAR FACTOR from Prometheus laboratories.) NFIB-MEDIATED… (5*) 847. . . . MIR130B EXPRESSED BY SLFN4+- 946. . . . A HIGH RATE OF IGE-NEGATIVE MDSCS STIMULATES EPITHELIAL… (2*) 869. . . . SOX12 PROMOTES COLORECTAL FOOD… (6*)|(2) CANCER PROLIFERATION AND… (2*)|(This 848. . . . LOSS OF HUMAN EPIDIDYMIS study was supported by combined grants 947. . . . PRIMING AND MATURATION OF PROTEIN (HE4)… (2*)|(3) from the tiol tural Science Foundation of Chi THE HUMAN… (4*) (No.81522031, No. 81772623, No. 849. . . . LOSS OF SLC26A9 RESULTS IN 81627807, No.81430072 and No. 948. . . . NUCLEAR RECEPTOR LIVER THE… (2*) 81421003), tiol Key Research and RECEPTOR HOMOLOG-1 PROMOTES… Development Program of Chi (2*)|(6) 850. . . . INDUCEMENT OF DOUBLE STRAND (2018YFC1312103) and tiol Center for BREAKS (DSB)… (2*)|(4) Clinic) 949. . . . DEVELOPMENT OF COORDINATED ELECTRICAL ACTIVITY IN… (6*) 851. . . . ZINC FINGER PROTEIN 545 870. . . . PLASMA BIOMARKERS OF INSULIN SUPPRESSES COLORECTAL… (2*) AND THE… (2*) 950. . . . MATERNAL MILK ENHANCES INTESTINAL MUCOSAL BARRIER… (2*)|(6) 852. . . . OVEREXPRESSION OF RAGE AND 871. . . . TRANSCRIPTIONAL SIGNATURES ITS LIGANDS… (2*)|(4) OF WESTERN-STYLE AND PRUDENT… (4*) 969. . . . PRIMARY CILIA TRANSDUCE INFLAMMATORY AND HEDGEHOG… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) 970. . . . REGULATION OF ONCOGENIC 990. . . . LONG NONCODING RNA H19 1010. . . . CASPASE-11 IS CRITICAL FOR STRESS RESPONSE PATHWAY… (2*) REGULATES AUTOPHAGY… (2*) ENTERIC NITRERGIC… (2*)

971. . . . THE INNATE IMMUNE MOLECULE 991. . . . MATRIX METALLOPROTEINASE 7 1011. . . . THE VOLTAGE-GATED SODIUM NLRC5 PROTECTS… (2*)|(4) CONTRIBUTES TO INTESTINAL… (2*)|(4) CHANNEL NAV1.7 CONTRIBUTES… (2*)

972. . . . NLRP3 INFLAMMASOME-DERIVED 992. . . . HYPOXIA-INDUCIBLE FACTOR 1 1012. . . . GENOME-WIDE ASSOCIATION INTERLEUKIN-1β ATTENUATES STRESS- ALPHA (HIF1A) COOPERATES… (2*)|(4) ANALYSIS OF DIVERTICULAR DISEASE… INDUCED GASTRIC… (5*) (2*)|(4) 993. . . . MYELOID TRANSLOCATION GENE 973. . . . FEASIBILITY OF ADIPOSE ON CHROMOSOME 16… (2*) 1013. . . . EXPLORING THE ROLES OF MESENCHYMAL STEM CELL… VOLTAGE-GATED CALCIUM… (2*)|(7) (4*)|(81770561 CXTDA2017033 994. . . . MIR-148A REGULATES CHIEF CELL BRA2014332 BE2015716) PLASTICITY IN… (2*) 1014. . . . SEEKING DIETARY FIBERS TO AMELIORATE INFLAMMATORY… (2*) 974. . . . AURORA KINASE A ACTIVATES 995. . . . TRANSGENIC EXPRESSION OF MIR- UNFOLDED PROTEIN… (2*) 195 DISRUPTS INTESTINAL… (2*) 1015. . . . PROBIOTICS DIFFERENTIALLY AFFECT THE GUT MICROBIAL… (2*) 975. . . . PROTON-PUMP INHIBITORS MAY 996. . . . THE EPIGENETIC PROTEIN SP140 ENHANCE INTESTINAL PERMEABILITY… DIRECTS INFLAMMATORY… (2*)|(3)|(Marie 1016. . . . PROBIOTICS FOR THE (3*)|(DAIICHI SANKYO COMPANY, LIMITED Skłodowska-Curie Actions and PREVENTION OF PEDIATRIC… (5*) EA Pharma Co., Ltd) GlaxoSmithKline (Stevege, UK)) 1017. . . . EFFECTS OF A FLATULOGENIC 976. . . . A DOUBLE-BLIND, RANDOMIZED, 997. . . . DIETARY AND PHENOTYPIC DIET COMBINED… (3*)|(Da Nutricia PLACEBO-CONTROLLED, CROSSOVER, INSIGHTS INTO THE… (2*) Research) MULTIPLE-DOSE… (3*)|(Novartis was the Sponsor of this study) 998. . . . VITAMIN, MINERAL, AND PROTEIN 1018. . . . TRANSLATIONAL STUDIES OF DEFICIENCES IN… (5*) LACTOBACILLUS GASSERI EFFECTS… 977. . . . INTESTINE MICROBIOME (3*)|(4)|(Funded by Biogaia Probiotics, ASPIRATION (IMBA) CAPSULE: A… (4*) 999. . . . IMPAIRED DUODENAL EPITHELIAL Stockholm, and ALF funding, Uppsala, BARRIER AND SECRETORY… (2*) Sweden.) 978. . . . IMPACT OF GASTROINTESTINAL PATHOGEN PANEL IMPLEMENTATION… 1000. . . . SYMPTOMATIC CONTROL OF 1019. . . . DISRUPTED CIRCADIAN (5*) CYCLIC VOMITING SYNDROME… (4*) OSCILLATION OF GUT-DERIVED SHORT… (2*)|(4) 979. . . . A LARGE SCALE EVALUATION OF 1001. . . . IMPACT OF RECREATIONAL THE… (4*) CANNABIS LEGALIZATION ON… (5*) 1067. . . . A MACHINE LEARNING-BASED MODEL TO PREDICT… (6*)|(7) 980. . . . CHARACTERISTICS OF GASTRIC 1002. . . . CYCLIC VOMITING SYNDROME MUCOSA AND FECAL… (2*) PRACTICE GUIDELINES COMMITTEE… 1068. . . . INDEPENDENT VALIDATION OF A (6*)|(This article received exterl funding TISSUE SYSTEMS… (2*)|(3)|(This study was 982. . . . RISK FACTORS FOR EARLY-ONSET support from the Cyclic Vomiting Syndrome funded in part by Cernostics, Inc.) COLORECTAL CANCER… (2*) Association (CVSA).) 1069. . . . A MULTICENTER STUDY OF THE 983. . . . COMPREHENSIVE ASSESSMENT OF 1004. . . . MAINTENENCE TREATMENT ADEQUACY… (3*)|(Study was funded by DIET QUALITY AND… (2*) WITH MIRIKIZUMAB, A P19-DIRECTED… Covidien/Medtronic.) (3*)|(Eli Lilly and Company) 984. . . . U.S. SEER COLORECTAL CANCER 1070. . . . WHEN SHOULD WE LOOK FOR INCIDENCE RATE… (5*) 1005. . . . A CONTROLLED TRIAL OF RECURRENCE… (7*) AMISELIMOD, A… (3*)|(MITSUBISHI TABE 985. . . . COST-EFFECTIVENESS AND PHARMA) 1071. . . . MUCOSAL INTEGRITY TESTING NATIONAL IMPACT OF INITIATING… (4*) CAN DETECT CHANGES… (4*) 1006. . . . HISTOLOGIC REMISSION AND 986. . . . ALPHA-TOCOPHERYLQUINONE MUCOSAL HEALING IN… (3*)|(Are 1072. . . . DIAGNOSTIC UTILITY OF ENHANCES INTESTINAL EPITHELIAL TIGHT Pharmaceuticals, Inc.) CONTRACTILE SEGMENT IMPEDANCE… (5*) JUNCTION… (5*) 1007. . . . ABX464 IS SAFE AND 1073. . . . THE AVERAGE RECOVERY TIME 987. . . . VITAMIN D RECEPTOR REGULATES EFFICACIOUS IN… (3*)|(ABIVAX) OF THE… (5*) EPITHELIAL TIGHT… (2*) 1008. . . . ESTROGENS MODULATE THE 1074. . . . PROLONGED WIRELESS PH 988. . . . TCPTP REGULATES INTESTINAL EFFECT OF STRESS… (2*) MONITORING OFF PPI… (2*) EPITHELIAL AND MACROPHAGE… (2*) 1009. . . . SENSORY NEUROPLASTICITY IN 1075. . . . RUMINATION SYNDROME AND 989. . . . LOSS OF CLAUDIN-3 EXPRESSION THE DORSAL ROOT… (2*)|(NIH/NIDDK) SUPRA-GASTRIC BELCHING CAN… (5*) INDUCES GUT… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) 1076. . . . FORKHEAD BOX K2 (FOXK2) 1094. . . . ROLE OF HISTONE ACETYLATION PROMOTES HUMAN… (2*)|(This study was IN UPREGULATION… (2*) 1131. . . . SPERMINE OXIDASE DELETION supported by combined grants from the tiol CONFERS PROTECTION FROM… (2*)|(4) tural Science Foundation of Chi 1095. . . . TRANSMEMBRANE PROTEIN 237 (No.81522031, No. 81772623, No. (TMEM237) INTERACTS WITH… (2*) 1132. . . . THE MACROPHAGE REVERSE 81627807, No.81430072 and No. TRANSSULFURATION PATHWAY 81421003), tiol Key Research and 1096. . . . REGULATION OF NA-GLUTAMINE MEDIATES… (2*)|(4) Development Program of Chi CO-TRANSPORT B0AT1 IN… (2*) (2018YFC1312103) and tiol Center for 1133. . . . ααINDUCTION OF GASTRIC Clinic) 1097. . . . LINACLOTIDE STIMULATES DYSBIOSIS BY CARCINOGENIC… (2*) DUODENAL BICARBONATE SECRETION 1077. . . . A NOVEL GENE EXPRESSION VIA… (4*) 1134. . . . POSTTRANSCRIPTIONAL SIGNATURE FOR… (4*) CONTROL OF VDR EXPRESSION BY… (2*) 1098. . . . INCREASED DIVALENT METAL 1078. . . . METHYLATED DNA MARKERS TRANSPORTER 1 (DMT1)… (2*) 1135. . . . 5-HT3 RECEPTOR ACTIVATION DETECT ESOPHAGEAL SQUAMOUS… INCREASES ANION SECRETION… (2*) (3*)|(2)|(Exact Sciences, Madison, WI.) 1099. . . . THE MICROBIOME IN IRRITABLE BOWEL SYNDROME:… (2*) 1136. . . . FUSOBACTERIUM NUCLEATUM 1079. . . . A NOVEL GENE EXPRESSION INITIATES COLORECTAL CANCER BY… (2*) SIGNATURE FOR… (5*) 1100. . . . REDUCED BACTERIA-DERIVED BILE SALT HYDROLASE ENZYMATIC… 1137. . . . FORWARD GENETICS IDENTIFIES 1080. . . . CHARACTERIZATION OF SONIC (3*)|(The study was sponsored by Nestle HOST LOCUS RESPONSIBLE… (2*) HEDGEHOG IN ESOPHAGEAL… (2*) Institute of Health (NIHS).) 1138. . . . SHORT-CHAIN FATTY ACIDS 1081. . . . GENOME-WIDE 1101. . . . FMT WITH OR WITHOUT POSTPONE THE PROGRESSION… (2*) TRANSCRIPTOMIC PROFILING FOR THE ANTIBIOTIC PRETREATMENT… (3*)|(FMT IDENTIFICATION… (4*) capsules provided by OpenBiome) 1139. . . . THE INTESTINAL VIROME IN CHILDREN WITH… (7*)|(2) 1082. . . . ‘TURNING-OFF’ STRESS-INDUCED 1102. . . . EFFICACY OF HUMAN MILK VISCERAL PAIN VIA OPTOGENTIC… (2*)|(6) OLIGOSACCHARIDES ON… (3*) 1140. . . . SYN-007, AN ORAL BETA- LACTAMASE PREVENTS GUT… 1083. . . . GUT SENSING OF NUTRIENT 1103. . . . DAILY INTAKE OF (3*)|(Synthetic Biologics, Inc.) CALORIC CONTENT… (2*)|(4) SULFORAPHANE-RICH BROCCOLI SPROUTS… (3*)|(Murakami Nohen Co. Ltd.) 1141. . . . TOWARDS HEALTH: RECURRENT 1084. . . . ENTERIC ALPHA-SYNUCLEIN CLOSTRIDIUM DIFFICILE INFECTION… INCLUSIONS, COLONIC INFLAMMATION, 1104. . . . INTEGRATED MULTI-OMICS (3*)|(This alysis was funded by Rebiotix INCREASED… (5*) ANALYSIS OF THE FAECAL… (2*) Inc., Roseville, MN, USA.)

1085. . . . NEURONAL SEROTONIN AS A 1105. . . . IMPACT OF CONCURRENT 1142. . . . THE EFFECTS OF HUMAN MILK LINK BETWEEN… (2*)|(6) PHARMACOTHERAPY WITH OLIGOSACCHARIDES… (4*)|(3)|(Supported INTRAGASTRIC… (5*) by an unrestricted grant from Glycom A/S) 1086. . . . BILATERAL BRAIN-GUT INTERACTIONS AND ANORECTAL 1106. . . . AN ANALYSIS OF LEPTIN AND 1143. . . . FUNCTIONAL LUMEN IMAGING SENSATION… (7*) INSULIN-GLUCOSE… (5*) PROBE DEMONSTRATES REDUCED… (5*)

1087. . . . ENTERIC INFLAMMATION AND 1107. . . . OBESITY IS AN INDEPENDENT 1144. . . . ABNORMALITIES OF ALTERED COLONIC CHOLINERGIC… (4*) RISK FACTOR… (5*) ESOPHAGEAL DISTENSION-CONTRACTION PROFILE DURING… (2*) 1088. . . . META-ANALYSIS: THE RISK OF 1108. . . . TRANSPYLORIC SHUTTLE DEVELOPING NEW… (5*) TREATMENT IMPROVES 1145. . . . DISTENSION-INDUCED CARDIOMETABOLIC RISK… (3*)|(BaroNova) CONTRACTILITY IS FREQUENTLY PRESENT, 1090. . . . GASTROINESTINAL SYMPTOMS BUT… (2*) OBSERVED AFTER CHIMERIC ANTIGEN… 1109. . . . ENDOSCOPIC MANAGEMENT OF (5*) LATE DUMPING SYNDROME:… (5*) 1146. . . . ESOPHAGEAL HYPERCONTRACTILITY IS ABOLISHED BY 1091. . . . EARLY INTRODUCTION OF NON- 1110. . . . OUTCOMES OF A NOVEL CHOLINERGIC… (4*) STEROIDAL IMMUNOSUPPRESSIVE BARIATRIC STENT… (5*) THERAPY… (5*) 1147. . . . PROSPECTIVE EVALUATION OF 1129. . . . LONG-TERM MULTIDONOR FECAL RISK FACTORS FOR… (5*) 1092. . . . IMPORTANCE OF ENDOSCOPIC MICROBIOTA TRANSFER (FMT)… (5*) AND HISTOLOGICAL EVALUATION… (5*) 1148. . . . CHARACTERIZATION AND 1130. . . . TRANSFERABLE IGA-REACTIVE MECHANISM OF THE ESOPHAGO- 1093. . . . A NOVEL ROLE OF S-ACYLATION MICROBIOTA STRATIFY CLINICAL ESOPHAGEAL… (2*) IN… (2*) RESPONSE… (3*)|(2)|(Boehringer Ingelheim Pharmaceuticals provided the 1149. . . . MICROBIAL SEQUENCING OF THE fincial support to conduct the study) APPENDICEAL MICROBIOME… (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) 0. . . . DELETION OF CLAUDIN-7 LEADS TO 1150. . . . INTRA-PERSONAL GUT THE… (2*) MICROBIAL VARIATIONS IN PATIENTS… (6*)

1151. . . . CD8+ T CELL-SPECIFIC TUMOR NECROSIS FACTOR… (2*)|(6)

1152. . . . A HEALTHY HUMAN FECAL SPECIMEN INCLUDES… (3*)|(6)|(Janssen Research Development)

1153. . . . CRITICAL ROLE OF TOLL-LIKE RECEPTOR 2… (2*)

1154. . . . LACK OF VITAMIN D RECEPTOR IN… (2*)

1155. . . . COMPARATIVE IN-VIVO DIAGNOSTIC PERFORMANCE OF CURRENT… (5*)

1156. . . . INTELLIGENT REAL-TIME IMAGE SEGMENTATION (IRIS) IMPROVES… (3*)|(NinePoint Medical, Inc.)

1157. . . . GOBLET CELL METAPLASIA VARIATIONS IN TARGETED… (3*)

1158. . . . RISK STRATIFICATION OF BARRETT'S ESOPHAGUS WITH… (5*)

1159. . . . RELIABILITY OF VIDEOCONFERENCING PATHOLOGY IN THE… (5*)

0. . . . INTERLEUKIN-33 PROMOTES REG3G EXPRESSION IN INTESTINAL… (2*)

0. . . . CATHARTOCYTOSIS, A NOVEL CELLULAR PROCESS ESSENTIAL… (4*)|(2)

0. . . . THE ROLE OF TUFT CELL SPECIFICATION… (2*)

0. . . . GENOME ANALYSIS OF DUODENAL GASTRINOMAS AND… (2*)

0. . . . EFFICACY IN BIOLOGIC-FAILURE AND NONBIOLOGIC-FAILURE POPULATIONS… (3*)|(This study was funded by Janssen Research & Development, LLC)

0. . . . INTERLEUKIN-27-PRODUCING IMMUNE CELLS IN THE GASTRIC… (2*)

0. . . . RNA BINDING PROTEIN IMP1 PROMOTES EXOSOME… (2*)|(7)

0. . . . A NOVEL ROLE FOR γδ INTRAEPITHELIAL… (2*)|(4)

0. . . . TRENDS IN YOUNG-ONSET COLORECTAL CANCER INCIDENCE… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

AGA Poster Presentations

BSQS12|Sa1117. . . . TNKS2 PROMOTES Sa1037. . . . TRENDS AND HEALTHCARE WNT/β-CATENIN SIGNALING THROUGH Sa1018. . . . WOMEN WITH HEPATITIS C DISPARITIES IN CIRRHOTICS… (5*) DEGREDATION… (2*) VIRUS (HCV)… (3*)|(Abbvie - investigator initiated research grant support) Sa1082. . . . DEVELOPMENT AND BSQS17|Su1879. . . . NOVEL ROLE FOR VALIDATION OF A MACHINE-LEARNING… DEATH RECEPTOR 3… (2*) Sa1019. . . . IS ETHNICITY ASSOCIATED (2*) WITH RATES OF… (5*) BSQS9|Su1033. . . . CONTRASTING EFFECTS Sa1083. . . . AUTOMATED TIME-RELEASED OF GLOBAL VERSUS TISSUE-SPECIFIC… (2*) Sa1020. . . . RACIAL DISPARITIES IN TIME REMINDERS IMPROVES PATIENT ACCESS… FROM ADMISSION… (5*) (4*) Sa1000. . . . A NATIONAL SURVEY OF INTERNISTS' PERCEPTIONS… (4*) Sa1021. . . . HISPANICS UNDER-UTILIZE Sa1084. . . . MOBILE APPLICATION USE BARIATRIC SURGERY… (5*) IMPROVES NO-SHOW RATES… Sa1001. . . . STRONG RECOMMENDATIONS (5*)|(Mobile app (MageMySurgery) is a BASED ON LOWER QUALITY… (5*) Sa1022. . . . RACIAL DISPARITIES IN product of Higgs Boson Health and use of COLORECTAL CANCER MORTALITY:… (2*) app was doted. No direct study funding was Sa1002. . . . UNDERUTILIZATION OF provided.) ASPIRIN IN PATIENTS WITH… (1*)|(5) Sa1023. . . . PATIENT AND PROVIDER REPORTED BARRIERS TO… (4*) Sa1085. . . . COLONOSCOPY VOLUME OF Sa1003. . . . POOR KNOWLEDGE OF COLONIC IRRIGATION (VOCI)… (5*) PERSONAL AND FAMILIAL… (5*) Sa1024. . . . RACIAL DISPARITIES IN THE EVALUATION AND… (5*) Sa1086. . . . DIGITAL RECTAL EXAMS ARE Sa1004. . . . UNDISCLOSED PAYMENTS BY RARELY PERFORMED… (5*) PHARMACEUTICAL AND MEDICAL… (5*) Sa1025. . . . A QUESTIONNAIRE STUDY TO ASSESS THE… (3*)|(Takeda (Chi) Intertiol Sa1087. . . . A NOVEL ELECTRONIC Sa1005. . . . UTILITY OF AND COMPLIANCE Trade Co., Ltd.) MEDICAL RECORD-BASED WORKFLOW… WITH RECOMMENDED… (5*) (5*) Sa1026. . . . DEVELOPING A STUDY OF Sa1006. . . . ADHERENCE TO GUIDELINES COLORECTAL CANCER… (2*) Sa1088. . . . CORRELATION BETWEEN AND BEST PRACTICES… (4*) SURROGATE QUALITY INDICATORS FOR… Sa1027. . . . BEYOND AVAILABILITY: (5*) Sa1007. . . . INTERNATIONAL GUIDELINES EVALUATING ACCEPTABILITY OF HIGH… ON THE MANAGEMENT OF… (5*) (2*)| Sa1089. . . . A RETROSPECTIVE REVIEW OF INTRAVENOUS IRON… (5*) Sa1008. . . . INTERNATIONAL GUIDELINES Sa1028. . . . COST SAVINGS FROM GENERIC ON THE MANAGEMENT OF… (5*) PROTON PUMP… (5*) Sa1090. . . . ANEMIA IN PEDIATRIC INFLAMMATORY BOWEL DISEASE:… (5*) Sa1009. . . . IS COLONOSCOPY NECESSARY Sa1029. . . . COST-EFFECTIVENESS OF FIRST- AFTER AN ACUTE… (5*) LINE BIOLOGICS FOR THE… (4*) Sa1091. . . . APPLICATION OF BAYESIAN MODELING WITH INFLIXIMAB… (5*)|(1) Sa1010. . . . LACK OF RECOMMENDED Sa1030. . . . PATIENT OUTCOMES BASED PNEUMOCOCCAL CONJUGATE VACCINE… ON REFERRAL PATTERNS… (5*) Sa1092. . . . LUMINAL NITRIC OXIDE AND (3*)|(This study was sponsored by Pfizer PLASMA NITRITE/NITRATE… (1*) Inc. All authors are employees of Pfizer Inc.) Sa1031. . . . WHAT IS THE NATURAL HISTORY OF… (3*)|(Janssen Cada) Sa1093. . . . HEALTH CARE COSTS OF Sa1011. . . . A COMPARISON OF ENDOSCOPY AND… (5*) CHARACTERISTICS IN LEFT… (5*) Sa1032. . . . SUBSTANTIAL INCREASE IN ANESTHESIA ASSISTANCE FOR… (5*) Sa1094. . . . FACTORS INFLUENCING Sa1012. . . . TARGETED SCREENING FOR TIMING OF PARACENTESIS AFTER… (5*) HEPATITIS C AND… (5*) Sa1033. . . . HEALTHCARE RESOURCE USE AND DIRECT MEDICAL… (3*)|(The funding Sa1095. . . . UNDERSTANDING THE ROLE OF Sa1013. . . . A MULTICENTER STUDY ON for this study was provided by Allergan plc. PHYSICIAN ATTIRE… (5*) GUIDELINE ADHERENCE… (4*) Writing assistance by Complete HealthVizion, funded by Allergan plc.) Sa1096. . . . A PERSONALIZED MODEL TO Sa1014. . . . PREVALENCE AND RELEVANCE ASSESS INTESTINAL… (4*) OF FINANCIAL CONFLICTS… (5*) Sa1034. . . . CAN ALBUMIN-BILIRUBIN GRADE (ALBI) PREDICT PRESENCE… Sa1097. . . . HUMAN COLON ORGANOID Sa1015. . . . HIGH SMOKING CESSATION (5*)|(Non) MODEL OF SESSILE… (4*) RATES IN A… (5*) Sa1035. . . . IN-HOSPITAL MORTALITY OF Sa1098. . . . MOLECULAR RESPONSE OF Sa1016. . . . CHARACTERIZING TOXIC MEGACOLON HAS… (5*) CANINE INTESTINAL ORGANOIDS… (4*) INAPPROPRIATE PROPHYLACTIC TRANSFUSION OF BLOOD… (5*) Sa1036. . . . VEDOLIZUMAB CLINICAL Sa1099. . . . ESTABLISHMENT OF LONG- DECISION SUPPORT TOOL PREDICTS… TERM NORMAL HUMAN INTESTINAL… (2*) Sa1017. . . . COLONIC BIOPSY PRACTICE IN (3*)|(Takeda Pharmaceuticals U.S.A., Inc.) PATIENTS WITH… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa1100. . . . KRÜPPEL-LIKE FACTOR 4 Sa1121. . . . A BUTYRATE-TARGETING Sa1140. . . . HISTOPATHOLOGIST FEATURES REGULATES BMI1+ INTESTINAL… (2*) SYNBIOTIC ATTENUATES CHRONIC-BINGE PREDICTIVE OF DIAGNOSTIC ETHANOL… (2*) CONCORDANCE… (6*) Sa1101. . . . KRÜPPEL-LIKE FACTOR 5 IS CRITICAL FOR… (2*) Sa1122. . . . THE ELECTROGENIC Sa1141. . . . VALIDATION AND NA+/HCO3- CO-TRANSPORTER COMPARISON OF TOOLS FOR… (2*) Sa1102. . . . PROTEIN KINASE D PROMOTES (NBCE1/SLC4A4) IS… (2*) INTESTINAL STEM… (2*) Sa1142. . . . HISTOLOGIC CHANGES IN THE Sa1123. . . . ACTIVATION OF KV7 NEOSQUAMOUS EPITHELIUM… (6*) Sa1103. . . . STEM CELL EXPANSION AND CHANNELS IN ENTERIC… (2*) INCREASED MESENCHYMAL… (2*) Sa1143. . . . SURFACE KI-67 EXPRESSION Sa1124. . . . CHRONIC RETARDATION OF ON HISTOPATHOLOGY PREDICTS… (5*) Sa1104. . . . DEFICIENCY OF NT-NTR1 GASTROINTESTINAL TRANSIT TIME… SIGNALING PREVENTS THE… (2*) (3*)|(YUYANG Dnu Co., Ltd) Sa1144. . . . WIDE AREA TRANSEPITHELIAL SAMPLING IMPROVES DETECTION… Sa1105. . . . CONDITIONAL KNOCKOUT OF Sa1125. . . . INDUCIBLE GENETIC LINEAGE (3*)|(CDx Diagnostics) CDC42/RAC NUCLEOTIDE EXCHANGE… (2*) TRACING REVEALS UNEXPECTED… (2*) Sa1145. . . . NEOSQUAMOUS EPITHELIUM Sa1106. . . . INTERACTION BETWEEN Sa1126. . . . PROBENICID IS EFFICIENT IN FOLLOWING ENDOSCOPIC ABLATION OF… PANCREATIC CANCER CELLS AND… (2*)|(5) THE RECOVERY… (4*) (2*)

Sa1107. . . . ADENYLATE CYCLASE 6 AND Sa1127. . . . INTESTINAL GUANYLATE Sa1146. . . . ESOPHAGEAL EXTRACELLULAR CYSTIC FIBROSIS… (2*) CYCLASE C MRNA EXPRESSION… (3*)|(This MATRIX HYDROGEL MITIGATES study was sponsored by Allergan plc and METAPLASTIC… (4*)|(C.R. BARD (B.D.)) Sa1108. . . . ANALYSING INTESTINAL Ironwood Pharmaceuticals.) ORGANOIDS IN A MULTI-OMICS,… (2*) Sa1147. . . . ANALYSIS OF SOCIO- Sa1128. . . . ALTERED GASTROINTESTINAL ECONOMIC FACTORS AFFECTING THE… (4*) Sa1109. . . . ROTAVIRUS-MEDIATED IMMUNOGLOBULINS, MICROBIAL DEGRADATION OF DGAT1: A PREVIOUSLY… COMMUNITIES AND… (2*)| Sa1148. . . . THE MAJORITY OF PATIENTS (2*) WITH CONFIRMED… (5*) Sa1129. . . . EFFECTS OF BUTYRATE Sa1110. . . . CROSS PRESENTATION OF SUPPLEMENTATION ON NHE8KO… (2*) Sa1149. . . . INCIDENCE OF HIGH GRADE MICROBIAL TRANSGLUTAMINASE BY… (1*) DYSPLASIA (HGD)… (5*) Sa1130. . . . LOSS OF NHE8 IMPAIRS Sa1111. . . . REGULATION OF THE BMP GOBLET CELL… (2*) Sa1150. . . . BACK TO THE FUTURE - SIGNALING INHIBITOR… (2*) MULTIMODAL… (5*) Sa1131. . . . LACTOBACILLUS RHAMNOSUS Sa1112. . . . THE ROLE OF NADPH OXIDASE GG COLONIZATION IN EARLY… (2*) Sa1151. . . . MUTATIONAL LOAD PREDICTS 2… (2*)|(Brain Korea 21 PLUS Project for RISK OF PROGRESSION… (5*) medical science) Sa1132. . . . EARLY LIFE LACTOBACILLUS RHAMNOSUS GG COLONIZATION… Sa1152. . . . AGE OF DIAGNOSIS IN Sa1113. . . . GUT DYSBIOSIS WITH (2*)|(tiol tural Science Foundation of Chi FAMILIAL ESOPHAGEAL… (2*) DECREASED AKKERMANSIA (NO.81741075)) MUCINIPHILA.AND… (2*) Sa1153. . . . NON-INVASIVE SCREENING Sa1133. . . . LACTOBACILLUS REUTERI DSM FOR BARRETT’S ESOPHAGUS USING… Sa1114. . . . RUBICON INHIBITS 17938 FEEDING OF… (2*) (5*)|(The eNose Company, Zutphen, NL, AUTOPHAGY AND ACCELERATES THE… (5*) provided Aeonose device for study but no Sa1135. . . . GENOMIC BIOMARKERS FOR funding.) Sa1115. . . . THE POTENTIAL FUNCTION OF CANCER RISK IN… (7*) CIRCULAR RNA… (2*) Sa1154. . . . CLINICAL CONSEQUENCES OF Sa1136. . . . DETECTION OF BARRETT’S NON-ADHERENCE IN SURVEILLANCE… (5*) Sa1116. . . . MYPT1 LEVEL MAY BE ESOPHAGUS THROUGH EXHALED… REGULATED THROUGH… (2*) (3*)|(The AeonoseTM was provided by the Sa1155. . . . INCIDENCE OF DYSPLASIA IN eNose company for free.) OBESE VERSUS… (5*) Sa1118. . . . DEVELOPMENT OF A NOVEL GALLBLADDER CANCER… (2*) Sa1137. . . . LIQUID NITROGEN SPRAY Sa1156. . . . PARTICIPATION IN NON- CRYOTHERAPY ERADICATES DYSPLASIA… ENDOSCOPIC SCREENING TECHNIQUES Sa1119. . . . DEOXYCHOLIC ACID ENHANCES (3*)|(CSA Medical) FOR… (2*) LYMPHOCYTE MIGRATION TO… (4*) Sa1138. . . . ASSESSING THE AMERICAN Sa1157. . . . ULTRA-SHORT SEGMENT Sa1120. . . . SUPPRESSION OF COLLEGE OF GASTROENTEROLOGY… (2*) BARRETT`S OESOPHAGUS: IS IT… (5*) PLASMACYTOID DENDRITIC CELL MIGRATING… (5*) Sa1139. . . . RISK OF DYSPLASTIC Sa1158. . . . LINKED COLOR IMAGING (LCI), PROGRESSION IN PATIENTS… (5*) A NOVEL… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa1159. . . . THE IMPACTS OF ON-DEMAND Sa1199. . . . PREVALENCE AND PROFILE OF VERSUS CONTINUOUS… (4*) Sa1179. . . . PROTON PUMP INHIBITOR PATIENTS WITH… (3*) THERAPY REDUCES RISK… (5*) Sa1160. . . . THE NATURAL HISTORY OF Sa1200. . . . HYPERGASTRINEMIA LOW GRADE… (5*) Sa1180. . . . COMPARISON OF ESOPHAGEAL SECONDARY TO LONG-TERM PROTON FUNCTION TESTING PROFILES… (5*) PUMP… (2*) Sa1161. . . . LATE RECURRENCE OF DYSPLASTIC BARRETT’S ESOPHAGUS… (5*) Sa1181. . . . IDENTIFYING Sa1201. . . . SIGNIFICANT DIFFERENCE IN GASTROESOPHAGEAL REFLUX DISEASE THE PROPORTION OF… (1*) Sa1162. . . . UTILITY AND YIELD OF POST-LUNG TRANSPLANT… (5*) POSITRON EMISSION… (5*) Sa1202. . . . CONCOMITANT Sa1182. . . . AN EXPLORATORY LATENT AZITHROMYCIN AND HIGH DOSE Sa1163. . . . THE RISK OF PREVALENT AND CLASS ANALYSIS OF… (7*) PROTON… (5*) INCIDENT… (5*) Sa1183. . . . STRAIN DIFFERENCES IN ACID Sa1203. . . . ACUTE EFFECT OF Sa1164. . . . MEN WITH ESOPHAGEAL MEDIATED ESOPHAGO- CURCUMINOID ON REFLUX… (2*) ADENOCARCINOMA RISK FACTORS… (5*) CARDIOVASCULAR… (2*) Sa1204. . . . A COMPARISON OF DIFFERENT Sa1165. . . . GASTROESOPHAGEAL REFLUX Sa1184. . . . INCREASED SENSITIVITY OF TREATMENTS FOR… (1*) INDUCES ISOLG-P53 ADDUCTS IN… (2*) COUGH REFLEX IS… (2*)|(.) Sa1205. . . . PREDICTING FACTORS OF Sa1166. . . . ESOPHAGEAL INFUSION OF Sa1185. . . . BARIUM SWALLOW FINDINGS RECURRENCE IN PATIENTS… (4*) MENTHOL DOES NOT… (2*)|(.) DO NOT CORRELATE… (5*) Sa1206. . . . LONG TERM PROTON PUMP Sa1167. . . . HUMAN ESOPHAGEAL Sa1186. . . . EFFICACY OF PNEUMATIC INHIBITOR USE… (5*) MYOFIBROBLASTS EXPOSED TO GASTRO- DILATATION FOR SEVERE… (5*) ESOPHAGEAL… (2*) Sa1207. . . . THE EFFECT OF A MEDICAL Sa1187. . . . ON ORDINARY DOSE OF PPI, DEVICE… (3*)|(SOFAR S.p.A) Sa1168. . . . REDUCED ESOPHAGEAL RESIDUAL… (5*) CONTRACTILITY IS A RISK… (5*) Sa1208. . . . SERUM CONCENTRATION AND Sa1188. . . . ABNORMAL BOLUS REFLUX ON PHARMACOKINETICS OF SINGLE… (4*) Sa1169. . . . GERD SYMPTOMS IMPEDANCE-PH MONITORING… (5*) EXACERBATION AFTER PPI Sa1293. . . . TRANSPYLORIC FEED IN DISCONTINUATION… (4*) Sa1189. . . . GASTROESOPHAGEAL REFLUX GASTROESOPHAGEAL REFLUX DISEASE IS AN INDEPENDENT… (5*) ASSOCCIATED… (5*) Sa1170. . . . ASSESSMENT OF GASTROESOPHAGEAL REFLUX DISEASE Sa1190. . . . PREVALENCE OF DYSBIOSIS IN Sa1294. . . . PHARYNGEAL AND UPPER BY… (5*) PATIENTS ON… (5*) ESOPHAGEAL SPHINCTER MOTOR… (5*)

Sa1171. . . . ASSOCIATION BETWEEN Sa1191. . . . MEASURING HEARTBURN Sa1295. . . . SERPINB12 AS A POSSIBLE SKELETAL MUSCLE ATTENUATION AND… SEVERITY AND REGURGITATION MARKER OF… (5*) (5*) FREQUENCY… (3*)|(Ironwood Pharmaceuticals, Inc.) Sa1296. . . . MIR-597-5P IS ASSOCIATED Sa1172. . . . WEIGHT REGAIN FOLLOWING WITH TUMOR INVASION… (2*) ROUX-EN-Y GASTRIC BYPASS:… (5*) Sa1192. . . . AMELIORATING EFFECTS AND AUTONOMIC MECHANISMS OF… (5*) Sa1297. . . . THERAPEUTIC EFFECT OF Sa1173. . . . SALIVA SECRETION IN NIVOLUMAB THERAPY ON… (5*) PATIENTS WITH PPI-RESISTANT… (4*) Sa1193. . . . PATIENT AND PHYSICIAN PERSPECTIVES AND PRACTICE… (5*) Sa1298. . . . GASTRIC XANTHOMA IS A Sa1174. . . . ESOPHAGEAL MUCOSAL USEFUL PREDICTOR… (5*) INNERVATION IN FUNCTIONAL Sa1194. . . . 1-YEAR INTERIM ANALYSIS HEARTBURN… (4*) RESULTS OF VISION… (3*)|(Takeda Sa1299. . . . WOMEN WITH GASTRIC Pharmaceutical Company Limited) CANCER ARE SIGNIFICANTLY… (5*) Sa1175. . . . EARLY ADULTHOOD CHRONIC ANTIBIOTIC USE AND… (2*)|(UM1 Sa1195. . . . TREATMENT OUTCOMES IN Sa1300. . . . HER2 REGULATES THE CANCER CA186107, K24 DK098311, R01DK088782) PATIENTS WITH GLOBUS:… (4*) STEM CELL… (5*)

Sa1176. . . . IMPACT OF PRE-TRANSPLANT Sa1196. . . . A SLEEP POSITIONING DEVICE Sa1301. . . . SEVERE ATROPHIC GASTRITIS REFLUX TESTING ON… (5*) REDUCES ESOPHAGEAL… (5*) IS A RISK… (5*)

Sa1177. . . . GASTROESOPHAGEAL REFLUX Sa1197. . . . PROTON PUMP INHIBITORS Sa1302. . . . THE ANTITUMOR EFFECT OF IS ASSOCIATED WITH CHRONIC… (5*) THERAPY AND THE… (5*) TALAPORFIN PHOTO… (5*)

Sa1178. . . . ABNORMAL REFLUX ON Sa1198. . . . MANAGEMENT PATTERNS FOR Sa1303. . . . THE EFFECT OF TALAPORFIN- COMBINED HYPOPHARYNGEAL- NONACID REFLUX PATIENTS… (5*) MEDIATED PHOTODYNAMIC THERAPY… ESOPHAGEAL IMPEDANCE-PH… (5*) (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa1324. . . . PATIENT-REPORTED SYMPTOM Sa1356. . . . DEPRESSION AS A SYMPTOM Sa1304. . . . CLINICOPATHOLOGIC BURDEN IN PANCREATIC CANCER… (5*) OF PANCREATIC… (5*) FEATURES OF SUBMUCOSAL PAPILLARY GASTRIC… (5*) Sa1325. . . . GEOGRAPHICAL COST Sa1357. . . . PANCREATIC CANCER IN LIVER VARIATION OF ACUTE PANCREATITIS… (5*) TRANSPLANT RECIPIENTS… (5*) Sa1305. . . . GENETIC POLYMORPHISMS AS RISK FACTORS FOR… (2*) Sa1337. . . . EXERCISE-INDUCED MYOKINES Sa1358. . . . EPIDEMIOLOGY, AS A MECHANISM FOR… (5*) ENVIRONMENTAL AND METABOLIC RISK Sa1306. . . . BIOMARKERS IN FACTORS… (5*) MULTIVISCERAL AND INTESTINAL Sa1338. . . . DEVELOPMENT OF A NOVEL TRANSPLANTATION… (5*) CIRCULATING TUMOR… (2*) Sa1359. . . . CHOLECYSTITIS IN PANCREATIC CARCINOMA: A POORLY… (5*) Sa1307. . . . CHRONIC MORPHINE Sa1339. . . . ANALYSIS OF 1200 CANCER- TREATMENT IMPAIRS THE RELATED GENES FOR… (2*) Sa1360. . . . HEAT SHOCK PROTEIN 27 ANTINOCICEPTIVE… (6*) (HSP27) EXPRESSION… (5*) Sa1340. . . . TUMOR SUPPRESSOR ROLE OF Sa1308. . . . ABDOMINAL PAIN IN MIR-107 AND… (2*) Sa1361. . . . UTILITY OF LIQUID BIOPSY QUIESCENT INFLAMMATORY BOWEL… (4*) USING URINE… (4*) Sa1341. . . . PANCREATIC ACINAR Sa1309. . . . ANTIBIOTICS TREATMENT CARCINOMA HAS DISTINCT MUTATION… Sa1362. . . . PROTON PUMP INHIBITOR AFFECTS BODY METABOLISM AND… (5*) (4*) (PPI) AND HISTAMINE-2… (5*)

Sa1310. . . . ALTERATION OF COLONIC Sa1342. . . . BROWN ADIPOSE TISSUE Sa1363. . . . PREDICTIVE FACTORS FOR THE MUCOSAL PERMEABILITY UNDER… (5*) ACTIVATION DETECTED BY… (5*) DEVELOPMENT OF… (5*)

Sa1311. . . . ANTI-INFLAMMATORY AND Sa1343. . . . RATES OF PANCREATIC Sa1364. . . . A NEW INVESTIGATION OF VISCERAL PAIN RELIEVING EFFECTS… (4*) NEOPLASIA IN A… (4*) DRUG REPURPOSING… (5*)

Sa1312. . . . AMELIORATING EFFECTS OF Sa1344. . . . DEVELOPMENT OF A Sa1365. . . . PATIENT-REPORTED BURDEN SACRAL NERVE STIMULATION… (5*) PREOPERATIVE PREDICTIVE RISK… (5*) OF INTENSIFIED SURVEILLANCE AND… (4*)

Sa1313. . . . DEVELOPMENT AND Sa1345. . . . PROGNOSTIC FACTORS FOR Sa1366. . . . INCREASED MEDIUM-TERM VALIDATION OF A TEST-SPECIFIC… (5*) PATIENTS WITH BORDERLINE… (5*) RISK OF PANCREATIC CANCER… (5*)

Sa1314. . . . DELETION OF SCAVENGER Sa1346. . . . ASSOCIATION BETWEEN Sa1367. . . . HALF OF SPORADIC RECEPTOR PROTECTS AGAINST… (4*) HELICOBACTER PYLORI INFECTION AND… PANCREATIC DUCTAL (5*) ADENOCARCINOMA… (5*) Sa1315. . . . REDUCED ABDOMINAL PAIN PERCEPTION IN INFLAMMATORY… (4*) Sa1347. . . . COMPARISON OF EFFICACY Sa1368. . . . GENOMIC PROFILING OF BETWEEN ADJUVANT CHEMOTHERAPY… PANCREATIC DUCTAL Sa1316. . . . ETHNIC DISPARITIES IN (5*) ADENOCARCINOMA… (5*) MORTALITY RATES FOLLOWING… (5*) Sa1348. . . . EUS DETECTION OF TRACE Sa1369. . . . DEPRESSION PRECEDING Sa1317. . . . GLOBAL INCIDENCE OF ACUTE ASCITES IN… (5*) PANCREATIC CANCER: A LONGITUDINAL… PANCREATITIS THROUGH… (5*)|(Nil) (5*) Sa1349. . . . HIGH FAT, HIGH CALORIE DIET Sa1318. . . . DIFFERENCES IN OUTCOMES EFFECTS… (2*)| Sa1370. . . . EARLY DETECTION OF AND ETIOLOGIES OF… (5*) PANCREATIC CANCER LEADS… (5*) Sa1350. . . . UPDATED INTERNATIONAL Sa1319. . . . OUTCOMES OF ACUTE CANCER OF THE PANCREAS… (4*) Sa1371. . . . EUS AND CT SCAN DIAGNOSTIC PANCREATITIS IN JULY:… (5*) YIELD… (5*) Sa1351. . . . ELEVATED HEMOGLOBIN A1C Sa1320. . . . THE CURRENT STATE OF ACUTE IS ASSOCIATED WITH… (4*) Sa1372. . . . PANCREATIC DUCTAL PANCREATITIS… (5*) ADENOCARCINOMA DETECTED AFTER Sa1352. . . . RISING INCIDENCE OF ACUTE… (5*) Sa1321. . . . SEVERE ACUTE PANCREATITIS PANCREATIC CANCER IN… (5*) INCIDENCE AND OUTCOMES… (5*) Sa1374. . . . IMPACT OF ABO BLOOD TYPE Sa1353. . . . FACTORS AFFECTING EUS-FNA IN… (5*) Sa1322. . . . EFFECT OF THE AMERICAN DIAGNOSTIC YIELD FOR… (5*) GASTROENTEROLOGICAL ASSOCIATION… Sa1375. . . . THE UTILITY OF CA 19-9 IN… (5*) Sa1354. . . . SEX AND AGE DISPARITIES IN (5*) PANCREATIC… (2*) Sa1323. . . . THE QUALITY OF EARLY ACUTE Sa1376. . . . EXPRESSION OF NOTCH PANCREATITIS… (5*) Sa1355. . . . OUTCOMES OF NEOADJUVANT RECEPTORS AND THEIR… (2*) CHEMORADIATION WITH AND… (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa1377. . . . REDUCTION IN Sa1398. . . . NOVEL BIO-DEGRADABLE Sa1547. . . . RAPID CHOLESTEROL (CH) AMYLASE/LIPASE SUPERFLUOUS TESTING: STENT IN PATIENTS WITH… (5*) CRYSTALLIZATION VIA THE… (2*) A… (5*) Sa1399. . . . PANCREATIC FUNCTIONAL Sa1548. . . . INVESTIGATIONS INTO VIRAL Sa1378. . . . RIFAXIMIN IN SELECTIVE AND STRUCTURAL EVALUATION WITH… ETIOLOGY OF PRIMARY… (6*) DIGESTIVE DECONTAMINATION IN… (5*) (5*) Sa1549. . . . CAUSATIVE PATHOGENS Sa1379. . . . ACUTE PANCREATITIS IN Sa1523. . . . UTILITY OF SHEAR WAVE PATTERN IN ENDOSCOPIC ULTRASOUND- SARCOIDOSIS: IS THERE… (5*) ELASTOGRAPHY TO… (4*) GUIDED… (5*)

Sa1380. . . . ACUTE PANCREATITIS Sa1524. . . . VALIDATION AND Sa1550. . . . THE EFFECT OF STATIN WITH NATIONAL OUTCOMES IN THE… (5*) OPTIMIZATION OF AN EARLY… (4*) EZETIMIBE… (5*)

Sa1381. . . . SYSTEMIC ANTICOAGULATION Sa1532. . . . NON-CALCULOUS BENIGN Sa1551. . . . SULFASALAZINE COMPARED IS ASSOCIATED WITH DECREASED… (5*) CHOLANGITIS IS MORE LIKELY… (5*) TO MESALAMINE IN PRIMARY… (5*)

Sa1382. . . . THE EPIDEMIOLOGY OF ACUTE Sa1533. . . . ASSOCIATION BETWEEN Sa1552. . . . FIBROSCAN ASSESSMENT OF PANCREATITIS IN… (5*) BACTEREMIA AND 30-DAY MORTALITY… PATIENTS UNDERGOING ENDOSCOPY… (4*) (3*)|(1)|(Echosens) Sa1383. . . . THE IMPACT OF OPIOID AND NON-OPIOID… (5*) Sa1534. . . . PRIMARY BILIARY Sa1553. . . . RELIABILITY AND VALIDITY CHOLANGITIS PATIENTS WHO ARE… (5*) ASSESSMENT IF THE… (3*)|(1)|(Intercept Sa1384. . . . EARLY FEEDING IN ACUTE Pharmaceuticals) PANCREATITIS IN… (5*) Sa1535. . . . PREDICTORS OF 30-DAY READMISSION AFTER INPATIENT… (5*) Sa1554. . . . FIBROSCAN RISK ASSESSMENT Sa1385. . . . PANCREATITIS IN TYPE 2 OF NON-ALCOHOLIC FATTY… DIABETES: A… (5*) Sa1536. . . . ENDOSCOPIC (3*)|(Echosens) SPHINCTEROTOMY ON THIENOPYRIDINE Sa1386. . . . CONTINUOUS REGIONAL THERAPY HAS… (5*) Sa1555. . . . LIVER DISEASE AMONG OLDER ARTERIAL INFUSION OF PROTEASE… (5*) MEXICAN AMERICANS… (2*) Sa1537. . . . ROLE OF PROPHYLACTIC Sa1387. . . . HOMA-ESTIMATED INSULIN CHOLECYSTECTOMY AFTER ENDOSCOPIC… Sa1556. . . . PERCEPTIONS AND RESISTANCE AS AN INDEPENDENT… (5*) (5*) KNOWLEDGE ABOUT ADVANCE CARE… (5*)

Sa1388. . . . IS AGGRESSIVE FLUID Sa1538. . . . THE EPIDEMIOLOGY OF Sa1645. . . . A NEW PEDIATRIC INTESTINAL RESUSCITATION THE BEST… (5*) ULCERATIVE COLITIS-PRIMARY BILIARY… PSEUDO-OBSTRUCTION SYNDROM… (5*) (5*) Sa1389. . . . INTENSIVE-FLUSHING Sa1646. . . . GASTROINTESTINAL (GI) TREATMENT IN ABDOMINAL CAVITY Sa1539. . . . POTENTIAL REPURPOSING OF FEATURES OF 22Q11.2 DELETION… (5*) DURING… (5*) ANGIOTENSIN INHIBITORS OR… (6*) Sa1647. . . . FEASABILITY OF A SPIRULINA Sa1391. . . . SEVERITY IN ACUTE Sa1540. . . . INCREASED ODDS OF ACUTE BREATH TEST… (4*)|(tionwide Children's PANCREATITIS: EFFECT OF… (4*) CHOLANGITIS IN… (5*) Hospital 4 provided a total of $1250 for patient incentives. (Each healthy volunteer Sa1392. . . . DOES ANTI-INTERLEUKIN Sa1541. . . . METABOLOMIC ANALYSIS OF who underwent the breath test received an MEDICATIONS IMPACT ACUTE PRIMARY SCLEROSING CHOLANGITIS… incentive of $50.) Cairn Diagnostics PANCREATITIS… (5*) (6*)|(Pfizer Inc.) provided the GEBT kits (with the meal components and test tubes for) Sa1393. . . . RELATION BETWEEN Sa1542. . . . DETECTION OF LOW PREGNANCY AND ACUTE PANCREATITIS:… PHOSPHOLIPID ASSOCIATED Sa1648. . . . SACRAL NERVE STIMULATION (4*) CHOLELITHIASIS… (5*) FOR CHILDREN WITH… (5*)

Sa1394. . . . INCIDENCE OF ACUTE Sa1543. . . . DECREASED ODDS OF Sa1649. . . . OXYTOCIN PLASMA PANCREATITIS IS NOT… (5*) MORTALITY IN PATIENTS… (5*) CONCENTRATIONS IN ADOLESCENTS WITH… (2*) Sa1395. . . . ACUTE PANCREATITIS IN Sa1544. . . . EVALUATION OF ADVANCED CHRONIC KIDNEY… (5*) HYPERBILIRUBINEMIA IN PATIENTS WHO… Sa1650. . . . ENDORECTAL BALLOON (ERB) (5*) DURING IMAGE GUIDED… (2*) Sa1396. . . . EVALUATION OF REAL-TIME PANCREATIC PARENCHYMAL AND… (5*) Sa1545. . . . LONG TERM TREATMENT OF Sa1651. . . . DOES COACHING IMPROVE A PRIMARY BILIARY… (5*) TRAINEES' ABILITY… (5*) Sa1397. . . . CHRONIC ASYMPTOMATIC PANCREATIC HYPERENZYMEMIA (CAPH): Sa1546. . . . PREDICTING LATE CBD STONE Sa1652. . . . TOWARDS AN OPTIMAL TOOL META-ANALYSIS… (5*) AFTER LAPAROSCOPIC… (5*) FOR ASSESSMENT… (2*)|(Intone MV.)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa1653. . . . CLINICAL UTILITY OF Sa1673. . . . EVALUATION OF COMPLIANCE Sa1690. . . . EFFECT OF CONSUMPTION OF TRANSLUMBOSACRAL ANORECTAL AND RECTAL SENSITIVITY… (5*) NOPAL FIBER… (2*) MAGNETIC… (2*) Sa1674. . . . OBESITY IS INDEPENDENTLY Sa1691. . . . PROSPECTIVE EVALUATION OF Sa1654. . . . VALIDATION OF A ASSOCIATED WITH INCREASED… (5*) THE CLINICAL IMPACT… (4*) PROSPECTIVE STOOL DIARY… (5*) Sa1675. . . . THE IMMEDIATE AND DELAYED Sa1692. . . . CLINICAL POTENTIAL OF Sa1655. . . . CAN THE RESULTS OF EFFECTS OF… (5*) CIRCULATING TUMOR CELLS… (2*) ANORECTAL INVESTIGATIONS… (6*) Sa1676. . . . IDENTIFICATION AND Sa1693. . . . COHESIN SA1 REGULATES Sa1656. . . . REPETITIVE TRANSPELVIC CHARACTERIZATION OF RVM NEURONS… FATTY ACID METABOLISM,… (2*) MAGNETIC STIMULATION (TPMS) (2*) ATTENUATES… (4*) Sa1694. . . . CONVENIENT METHOD TO Sa1677. . . . CHRONIC COLONIC CAPTURE CIRCULATING TUMOR… (5*) Sa1657. . . . ANAL TAPE A GENUINE ADMINISTRATION OF THE GUANYLATE… EXTERNAL DEVICE FOR… (5*) (3*)|(Ironwood Pharmaceuticals) Sa1695. . . . EVALUATING THE THERAPEUTIC ROLE OF METFORMIN… (4*) Sa1658. . . . INFLUENCE OF A DEFECATION Sa1678. . . . FOLIC ACID ATTENUATES POSTURE MODIFICATION… (5*) CHRONIC VISCERAL HYPERSENSITIVITY… Sa1696. . . . STAT3-MEDIATED GENE AND (2*)|(The present work was supported in MIRNA EXPRESSION PROFILING… (4*) Sa1659. . . . COMPARISON OF CHANGES IN part by grants from the tiol tural Science RECTAL AREA… (2*) Foundation of Chi (81471137 and Sa1697. . . . IS COMPUTED TOMOGRAPHY 31730040).) AN ACCURATE DIAGNOSTIC… (4*) Sa1660. . . . COEXISTENCE OF FECAL INCONTINENCE AND CONSTIPATION… (5*) Sa1679. . . . MULTIPLE RATHER THAN Sa1698. . . . INITIAL EXPERIENCE WITH SPECIFIC ANTIBODIES WERE… (2*) PEPTIDE RECEPTOR RADIONUCLIDE… (5*) Sa1661. . . . IDENTIFYING SUBTYPES IN PATIENTS WITH FUNCTIONAL… (2*) Sa1680. . . . SECOND GENERATION ANTI- Sa1699. . . . ENDOSCOPIC SUBMUCOSAL CDTB AND ANTI-VINCULIN TESTING… (5*) RESECTION WITH AN ENDOSCOPIC… (5*) Sa1662. . . . CHARACTERISTICS OF PATIENTS WHO ‘FAIL’ BIOFEEDBACK… (5*) Sa1681. . . . GC-C AGONISM WITH Sa1700. . . . CHANGE IN INCIDENCE, LINACLOTIDE ATTENUATES CHRONIC… CHARACTERISTICS AND MANAGEMENT… Sa1663. . . . FECOBIONICS DEFECATORY (3*)|(Ironwood Pharmaceuticals, Inc.) (4*) FUNCTION TESTING IN HEALTHY… (2*) Sa1682. . . . METABOLIC ALTERATIONS TO Sa1701. . . . RECURRENCE RATES AFTER Sa1664. . . . ARE DYSSYNERGIC FECAL GUT MICROBIOTA… (2*)|(This study ENDOSCOPIC RESECTION OF… (5*) DEFECATION AND ALTERED RECTAL… (5*) was supported by Grant-in-Aids for Scientific Research from the Ministry of Sa1702. . . . OPERATIVE RESECTION OF Sa1665. . . . SPONTANEOUS INTERNAL Education, Culture, Sports, Science and DUODENAL CARCINOID TUMORS:… ANAL SPHINCTER RELAXATION ON… (5*) Technology, Japan and by Research Grant (5*)|(Shria Kumar is supported by a tiol from Miyarisan Pharmaceutical Co., Ltd., Institutes of Health T32 grant (5 T32 DK Sa1666. . . . INTEGRATION OF SMOOTH Tokyo, Japan.) 7740-22). dim Mahmud is supported by a MUSCLE AND NEURAL… (2*) tiol Institutes of Health T32 grant (2-T32- Sa1683. . . . POTENTIAL CLINICAL VALUE OF DK007740-21A1).) Sa1667. . . . USE OF [LYS5,MELEU9,NLE10]- LACTOBACILLUS RHAMNOSUS… (2*) NKA(4–10) (LMN-NKA) AS A… (2*)|(Dignify Sa1703. . . . IS SURVEILLANCE WITH Therapeutics, LLC) Sa1684. . . . ALTERATION OF MICROBIOTA GASTRIC ACID MEASUREMENT… (2*) BY MATERNAL SEPARATION… (2*) Sa1668. . . . ON-DEMAND, DRUG-INDUCED Sa1704. . . . ENDOSCOPIC MANAGEMENT DEFECATION FOLLOWING INTRAVENOUS Sa1685. . . . PROTEOMIC OF DUODENAL NEUROENDOCRINE (IV),… (2*)|(Dignify Therapeutics, LLC) CHARACTERIZATION OF IBS VS CONTROL… TUMORS… (5*) (3*)|(Nestlé Institute of Health Sciences) Sa1669. . . . FLATUS INCONTINENCE IN Sa1705. . . . CHARACTERISTICS AND WOMEN: COMPARISON WITH… (5*) Sa1686. . . . ASSESSMENT OF THE FECAL ENDOSCOPIC MANAGEMENT OF GASTRIC… MICROBIOME AND… (4*) (5*) Sa1670. . . . LONG TERM CLINICAL AND PHYSIOLOGICAL CONSEQUENCES… Sa1687. . . . EXPOSURE TO PETS IS Sa1706. . . . MAP9 DEFICIENCY (5*)|(no funding) ASSOCIATED WITH… (5*) SPONTANEOUSLY DRIVES COLON TUMORIGENESIS… (2*) Sa1671. . . . ANATOMICAL DEFECTS OF THE Sa1688. . . . INDUCTION OF BRAIN- ANAL SPHINCTER… (2*) DERIVED NEUROTROPHIC FACTOR IN… (4*) Sa1707. . . . USING ENDOSCOPIC FINE NEEDLE BIOPSIES OF… (2*) Sa1672. . . . EVALUATION OF DIFFERENCES Sa1689. . . . PILOT STUDY OF TERMINAL IN SYMPTOM AND… (4*) ILEUM MUCOSA… (5*) Sa1708. . . . SELENOPROTEIN P MODIFIES WNT-DRIVEN SPORADIC COLORECTAL… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa1725. . . . LEOPARD STUDY - ITALIAN Sa1709. . . . TARGETING DR5 IN BOTH MULTICENTER PROSPECTIVE… (1*) Sa1746. . . . ORAL CALCIUM MDSCS AND… (2*)|(( The project was NANOPARTICLE THERAPY AIDS IN… (4*) supported by Sa1726. . . . IN VIVO AND EX VIVO NSFC81472727,NSFC81272403,NSFC817732 MICROSTRUCTURE… (5*) Sa1747. . . . FXR AGONISTS WITH 59; Science and Technology Commission of SUSTAINED ACTIVITY EXHIBIT… Shanghai Municipality (15JC1403100)).) Sa1727. . . . OUTCOMES OF GI POLYPS (3*)|(Metacrine) RESECTED USING… (5*) Sa1710. . . . TRPV1 INHIBITS GASTRIC Sa1748. . . . THE BOWEL CLEANSING CANCER DEVELOPMENT VIA… (2*)|(tiol Key Sa1728. . . . THE PROGNOSTIC VALUE OF A NATIONAL INITIATIVE (BCLEAN):… Research and Development Program of Chi NEW… (1*) (3*)|(received arm-length funding from (No. 2016YFC1302200) and tiol tural Pendopharm Inc.) Science Foundation of Chi (No. 81570477)) Sa1729. . . . RISK FACTORS FOR COLONIC DIVERTICULOSIS: A… (1*) Sa1749. . . . GASTROENTEROLOGY- Sa1711. . . . BONE MARROW-DERIVED RELATED HASHTAG UTILIZATION ON MYOFIBROBLASTS PROMOTES GASTRIC Sa1730. . . . THE HISTOLOGICAL HEALING IN INSTAGRAM AND… (5*) CANCER… (2*)|(( The project was ULCERATIVE COLITIS… (5*) supported by Sa1750. . . . PREVALENCE AND OUTCOMES NSFC81472727,NSFC81272403,NSFC817732 Sa1731. . . . A TRANS-NASAL, IMAGE- OF PORTOMESENTERIC VEIN… (5*) 59; Science and Technology Commission of GUIDED APPROACH FOR BRUSH… (6*) Shanghai Municipality (15JC1403100)).) Sa1751. . . . OUTCOME, COMPLICATION Sa1732. . . . PREDICTORS OF 30 DAYS AND LONG-TERM FOLLOW UP… (5*) Sa1712. . . . THE EXPRESSION OF CIRCULAR READMISSIONS AFTER… (5*) RNA, CDR1-AS,… (2*) Sa1752. . . . VALIDATION OF A FECAL Sa1733. . . . ETIOLOGIES AND TRENDS OF INCONTINENCE BOWEL… (2*)|(Medspira Sa1713. . . . MIR-143 SUPPRESSES 30 DAYS… (5*) Scientific provided software and TUMORIGENESIS AND PROGRESSION OF… physiological recorders at discounted (2*) Sa1734. . . . EVALUATING THE EFFICACY OF prices.) HEMOSTATIC NANOPOWDER… (5*) Sa1714. . . . OXALIPLATIN INHIBITS Sa1753. . . . IBD NURSE INTERVENTION FOR DIFFERENTIATION OF M-MDSCS INTO… Sa1735. . . . BASELINE BOWEL STIFFNESS PATIENTS ASSIGNED… (3*)|(This work was (2*) ON REAL-TIME SHEAR… (5*) supported by the Pfizer independent grants for learning & change) Sa1715. . . . DECREASED P62 PROTEIN Sa1736. . . . THE ROLE OF “ROSE” FOR EXPRESSION IS ASSOCIATED… (5*) ERCP-GUIDED… (5*) Sa1754. . . . SLEEP DISTURBANCE AND TRAVEL INTERRUPTION WITH… Sa1716. . . . STAT6 SIGNALING IN COLON Sa1737. . . . FXR AGONIST M480, EXHIBITS (3*)|(Pendopharm) CANCER CELLS… (4*) EFFICACY IN… (3*)|(Metacrine) Sa1755. . . . PRESENTING SYMPTOM Sa1717. . . . DEVELOPMENT OF A Sa1738. . . . OLORINAB (FORMERLY SEVERITY AND HEALTH-RELATED SWALLOWABLE DIGANOSTIC CAPSULE… APD371), A PERIPHERALLY RESTRICTED,… QUALITY… (5*) (3*)|(Progenity Inc.) (3*)|(Are Pharmaceuticals Inc. and NHMRC Australia.) Sa1756. . . . EFFECTS OF PHARMACEUTICAL Sa1718. . . . A NEAR-INFRARED PROBE FOR DIRECT-TO-CONSUMER ADVERTISING IN VIVO… (6*) Sa1739. . . . USING THE ZONULIN (DTCA)… (5*) TRANSGENIC MOUSE MODEL… (2*) Sa1719. . . . COMPARISON OF TWO CUT- Sa1757. . . . IMPROVEMENT IN DISEASE OFF VALUES OF… (2*) Sa1740. . . . SPONTANEOUS MOUSE ACTIVITY IS ASSOCIATED… (5*) COLITIS PRODUCED BY DELETION… (2*)| Sa1720. . . . EFFECT OF COLONOSCOPY Sa1758. . . . THE RELATIONSHIP BETWEEN ASSISTED DEVICES ON… (5*) Sa1741. . . . IDENTIFICATION AND SERUM BILIRUBIN AND… (2*) CHARACTERIZATION OF THE FIRST… (2*)| Sa1721. . . . MORE LESIONS PER PATIENT Sa1759. . . . TRENDS IN TNF-ALPHA DETECTED WITH… (3*)|(Norgine) Sa1742. . . . INTERLEUKIN-10 KNOCKOUT INHIBITOR UTILIZATION IN… (5*) MICE DO NOT EXHIBIT… (6*) Sa1722. . . . ASSESSMENT OF Sa1760. . . . RISK FACTORS FOR POST- COLONOSCOPY QUALITY IN NON- Sa1743. . . . INVESTIGATION OF THE OPERATIVE CROHN'S DISEASE… (5*) ACADEMIC… (5*) RELATIONSHIP BETWEEN ASPIRIN- INDUCED… (1*) Sa1761. . . . CHITINASE 3-LIKE-1 PROTEIN: A Sa1723. . . . MUCOSAL HEALING DEFINED NOVEL BIOMARKER… (6*) BY ADVANCED ELECTRONIC… (5*) Sa1744. . . . A NOVEL PORCINE MODEL OF CROHN’S… (2*) Sa1762. . . . LARGE-SCALE PROTEOMICS Sa1724. . . . MOXIFLOXACIN PROMOTES IDENTIFIES ANTI-TNF RESPONSE MULTIPHOTON MICROSCOPIC IMAGING Sa1745. . . . GLACIAL ACETIC ACID- SIGNATURE… (2*) FOR… (5*) INDUCED ULCERATIVE COLITIS LESIONS… (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa1763. . . . A MULTI-PROTEIN SERUM TEST PREDICTS MUCOSAL… (3*)|(Prometheus Sa1782. . . . EFFECT OF VACCINATION AND Sa1800. . . . EPIDEMIOLOGY, NATIONAL Laboratories performed a blood assay and IMMUNOSUPPRESSIVE MEDICATIONS… TRENDS AND OUTCOMES OF… (5*) covered the cost for that assay.) (5*) Sa1801. . . . EMERGING IBD Sa1764. . . . PERIPHERAL BLOOD Sa1783. . . . INCIDENCE OF DEMOGRAPHICS IN SOUTH ASIA… (5*) EOSINOPHILIA IS A BIOMARKER… (2*) INDETERMINATE COLITIS IN THE… (5*) Sa1802. . . . DOES CLOSTRIDIUM DIFFICILE Sa1766. . . . INVESTIGATIONS OF THE Sa1784. . . . INFLAMMATORY BOWEL INCREASE THE RISK… (5*) CHARACTERISTICS AND ANTI-TNFα… (5*) DISEASE IN UK PRIMARY… (6*) Sa1803. . . . TOTAL ABDOMINAL Sa1767. . . . SOMASCAN AS A DISCOVERY Sa1785. . . . THE PREVALENCE AND COLECTOMY AMONGST HOSPITALIZED PLATFORM TO… (6*) EPIDEMIOLOGY OF POUCHITIS… (5*) PATIENTS… (5*)

Sa1768. . . . THE INTESTINAL MICROBIOME Sa1786. . . . ASSESSMENT OF METAL Sa1804. . . . INCIDENCE OF OBSTRUCTIVE IN INFLAMMATORY BOWEL… (2*)|(This EXPOSURES IN DECIDUOUS… (4*) COMPLICATIONS AFTER INTRA- Tobacco Formula grant is under the ABDOMINAL… (5*) Pennsylvania Commonwealth Universal Sa1787. . . . THE PROGRESSION OF Research Enhancement (C.U.R.E) program INFLAMMATORY BOWEL DISEASE… (5*) Sa1805. . . . MEDICATION PRESCRIPTION with the grant number SAP # 4100068710.) PATTERNS IN ULCERATIVE COLITIS… Sa1788. . . . NATURAL HISTORY OF (2*)|(Funds for statistical support provided Sa1769. . . . WORLDWIDE INCIDENCE OF DIABETES MELLITUS AND… (2*) by Pfizer) OLDER-ONSET INFLAMMATORY BOWEL… (2*) Sa1789. . . . DOSE–RESPONSE Sa1806. . . . INFLAMMATORY BOWEL RELATIONSHIP BETWEEN CIGARETTE DISEASE AND MEDICATION USE… (5*) Sa1770. . . . DE-NOVO INFLAMMATORY SMOKING AND… (5*) BOWEL DISEASE AFTER BARIATRIC… (5*) Sa1807. . . . RATES OF COLECTOMY IN Sa1790. . . . MULTI-PARAMETER DATA-SETS PATIENTS WITH… (5*) Sa1771. . . . THE GLOBAL BURDEN OF ARE REQUIRED TO IDENTIFY… (1*) INFLAMMATORY BOWEL… (5*) Sa1808. . . . TRENDS OF 5-ASA Sa1791. . . . ASSOCIATION BETWEEN MEDICATION USE IN… (5*) Sa1772. . . . PREVALENCE OF CERVICAL ALBUMIN GLOBULIN RATIO AND… (5*) DYSPLASIA IN WOMEN… (5*) Sa1809. . . . ADMISSION TRENDS AND Sa1792. . . . THE INCIDENCE OF ECONOMIC BURDEN OF… (5*) Sa1773. . . . NONALCOHOLIC LIVER DISEASE INFLAMMATORY BOWEL DISEASE:… (4*) SIGNIFICANTLY MORE PREVALENT… (5*) Sa1810. . . . SURGERY AND Sa1793. . . . EVALUATION OF THE 10-YEAR HOSPITALIZATIONS RATES IN Sa1774. . . . INCREASED PREVALENCE OF CARDIOVASCULAR DISEASE… (4*) INFLAMMATORY… (1*)|(5)(The study was NONALCOHOLIC LIVER DISEASE… (5*) supported by the McGill CAS Research Sa1794. . . . EXTRA INTESTINAL Support Program.) Sa1775. . . . CROHN'S DISEASE AND MANIFESTATIONS AND OTHER ULCERATIVE COLITIS WAS… (5*) COMORBIDITIES… (3*)|(Janssen Sa1811. . . . GENOTYPE AND POST- Immunology sponsored) OPERATIVE IMMUNOSUPPRESSION Sa1776. . . . THE 30-YEAR TREND ANALYSIS IMPACT SURGICAL… (2*) IN THE… (2*)|(This work was supported by Sa1795. . . . SEXUAL FUNCTION IN a Korean Health Technology R&D Project PATIENTS WITH INFLAMMATORY… (5*) Sa1812. . . . ENDOSCOPIC AND DEEP grant from the Korea Health Industry REMISSION AT 1… (5*) Development Institute (A120176) and by a Sa1796. . . . ASSOCIATION BETWEEN USE research grant from Janssen Korea Ltd.) OF ANTIHYPERTENSIVE AGENTS… (5*) Sa1813. . . . CUFFITIS IS ASSOCIATED WITH A SIGNIFICANT… (5*) Sa1777. . . . OVARIAN CANCER AND Sa1797. . . . FERTILITY, CONCEPTION AND UTERINE CANCER ARE… (5*) DELIVERY IN PATIENTS… (5*) Sa1814. . . . EARLY COMBINED IMMUNOSUPPRESSION IS MORE Sa1778. . . . INCREASED RISK OF Sa1798. . . . THE PREVALENCE OF EFFECTIVE… (3*)|(Robarts clinical trials) MENINGITIS IN PATIENTS… (6*)|(Crohn's INFLAMMATORY BOWEL DISEASE… and Colitis Foundation (Grant Number (2*)|(Funding for Oria M. Damas: This work Sa1815. . . . THE IMPACT OF OPIOID 568735 to BK)) was supported by NIH N3U54MD010722- ABUSE/DEPENDENCE DISORDER… (5*) 03S1. Funding for Maria T. Abreu: This Sa1779. . . . HOSPITALIZATIONS FOR IBD work was supported by The Micky & Sa1816. . . . ELEVATED FECAL THROUGHOUT THE WORLD:… (2*) Madeleine Arison Family Foundation CALPROTECTIN IN HEALTHY FIRST… (6*) Crohn's & Colitis Discovery Laboratory and Sa1780. . . . REVISITING THE ASSOCIATION Martin Kalser Chair.) Sa1817. . . . FIBROSIS CONSTITUTES LESS BETWEEN INFLAMMATORY BOWEL… (5*) THAN 0.5 OF… (4*) Sa1799. . . . CHARACTERIZATION OF Sa1781. . . . THE RISK OF INFLAMMATORY WOMEN WITH INFLAMMATORY BOWEL… Sa1818. . . . INNATE IMMUNE BOWEL DISEASE… (5*) (2*) DYSREGULATION, DETECTABLE UP TO…

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) (3*)|(Support for this study was provided Sa1837. . . . EVALUATION AND Sa1857. . . . UPPER GASTROINTESTINAL by Janssen Pharmaceuticals and MANAGEMENT OF POUCHITIS IN… (5*) TRACT PHENOTYPE OF CROHN’S… (5*) Prometheus Laboratories under a Cooperative Research and Development Sa1838. . . . NONALCOHOLIC FATTY LIVER Sa1858. . . . RATE AND RISK FACTORS Agreement entitled ‘Antimicrobial DISEASE WITH ADVANCED… (5*) ASSOCIATED WITH… (2*) antibodies as predictors of inflammatory bowel diseases’ NCRADA number NMR-11- Sa1839. . . . THE DILEMMA IN Sa1859. . . . THE IMPACT OF TOBACCO 3920.) COMPLICATED ILEAL POUCH… (5*) SMOKING ON… (5*)

Sa1819. . . . RETROSPECTIVE STUDY ON Sa1841. . . . PREDICTIVE FACTORS OF A Sa1860. . . . RISK FACTORS FOR REPEATED INCIDENCE RATES OF… (5*) SUBSEQUENT ANO-PERINEAL… (5*) VISITS TO… (5*)

Sa1820. . . . NON-ADHERENCE TO SELF- Sa1842. . . . DELAYED DIAGNOSIS OF Sa1861. . . . IMPACT OF BIOLOGIC THERAPY INJECTABLE BIOLOGIC MEDICATION IN… CROHN’S DISEASE IS… (7*) ON RESOLUTION… (2*) (5*) Sa1843. . . . PREGNANCY COUNSELING Sa1862. . . . REAL WORLD USE OF THE IBD… Sa1821. . . . DOES INFLAMMATION IN IBD BENEFICIAL IN PATIENTS WITH… (3*)|(UCB (5*) BURNOUT OVER… (2*) sponsored) Sa1863. . . . PATIENT EMPOWERMENT Sa1822. . . . ELDERLY-ONSET VS ADULT- Sa1844. . . . CLINICAL SIGNIFICANCE OF THROUGH AN EDUCATIONAL ONSET ULCERATIVE COLITIS: A… (5*) GRANULOMAS IN CROHN’S… (5*) INTERVENTION… (3*)|(Funding provided through an unrestricted educatiol grant Sa1823. . . . FEMALE ADOLESCENTS WITH Sa1845. . . . FOLLOW-UP OF ULCERATIVE from Abbvie.) ULCERATIVE COLITIS MAY… (2*) COLITIS PATIENTS WITH… (5*) Sa1864. . . . GUT-BRAIN-AXIS REVISITED: Sa1824. . . . OBESITY IS FREQUENT IN Sa1846. . . . FAMILIAL VERSUS SPORADIC SHEDDING LIGHT ON THE… (2*) INFLAMMATORY DISEASE… (2*) INFLAMMATORY BOWEL DISEASE… (2*)|(This work was supported by NIH Sa1865. . . . THERE IS MORE THAN Sa1825. . . . SOUTH ASIAN IMMIGRANTS IN N3U54MD010722-03S1, The Micky & PHARMACOLOGY: COMPREHENSIVE… (6*) THE UNITED… (5*) Madeleine Arison Family Foundation Crohn's & Colitis Discovery Laboratory, and Sa1866. . . . ASSOCIATION OF PSYCHIATRIC Sa1826. . . . CLINICAL CHARACTERISTICS OF Martin Kalser Chair.) COMORBIDITIES WITH OPIOID… (5*) NASH/NAFLD PATIENTS IN… (5*) Sa1847. . . . ADVERSE ANTEPARTUM Sa1867. . . . SEXUAL QUALITY OF LIFE IN Sa1827. . . . THE NATURAL COURSE OF OUTCOMES IN PREGNANT WOMEN… (5*) INFLAMMATORY… (4*) INFLAMMATORY BOWEL… (5*) Sa1848. . . . TEMPORAL TREND IN DISEASE Sa1868. . . . FERTILITY IMPACT OF INITIAL Sa1828. . . . CONSUMPTION OF DIETARY CHARACTERISTIC, TREATMENT… (5*) SURGICAL MODALITY… (5*) TRIGGER FOODS AMONG… (2*) Sa1849. . . . ASSOCIATION OF SEROLOGIC Sa1869. . . . PSYCHOLOGICAL FACTORS Sa1829. . . . DIET STABILITY IN PERSONS MARKERS AND SURGERY… (5*) ASSOCIATED WITH ADHERENCE TO… (4*) WITH IBD:… (2*) Sa1850. . . . FAMILIAL MEDITERRANEAN Sa1870. . . . THE USE OF AN EMR PATIENT… Sa1830. . . . INSTABILITY IN SATURATED FEVER IN THE UNITED… (5*) (5*) FAT AND SUGAR… (2*) Sa1851. . . . WESTERN VERSUS Sa1871. . . . HIGH INFLIXIMAB TROUGH Sa1831. . . . ELEVATED SERUM MEDITERRANEAN DIETARY MARKERS LEVELS HAVE NO… (3*)| IMMUNOGLOBULIN G4 FAILS TO… (5*) DIFFER… (4*) Sa1872. . . . MEASURING THE MEDIATING Sa1832. . . . CROHN’S LIKE DISEASE OF THE Sa1852. . . . HOW DO DIETARY PATTERNS EFFECTS OF TOFACITINIB… (3*)|(Pfizer Inc) ILEAL… (5*) FOR INFLAMMATORY… (4*) Sa1873. . . . MEASURING THE MEDIATING Sa1833. . . . MUCOSAL EOSINOPHILIA IS AN Sa1853. . . . PSEUDOPOLYPS IN EFFECTS OF MAYO… (3*)|(Pfizer Inc) INDEPENDENT PREDICTOR… (2*) INFLAMMATORY BOWEL DISEASE: HISTOLOGIC… (2*) Sa1874. . . . THE VISCERAL SENSITIVITY Sa1834. . . . OUTCOME AFTER INDEX: A NOVEL… (4*) DISCONTINUATION OF Sa1854. . . . IMPACT OF BARIATRIC IMMUNOSUPPRESSANT OR… (5*) SURGERY ON THE… (5*) Sa1875. . . . DISEASE-RELATED WORRIES AND CONCERNS IN PATIENTS… Sa1835. . . . CHARACTERISTICS AND Sa1855. . . . ANALYSIS OF THE CLINICAL, (3*)|(AbbVie funded the study, contributed OUTCOMES OF PATIENTS WITH… (5*) GASTROSCOPIC, AND… (5*) to its design, and was involved in the collection, alysis, and interpretation of the Sa1836. . . . NUTRITIONAL STATUS EFFECT Sa1856. . . . RISK FACTORS ASSOCIATED data, and in the writing, review, and ON HEALTH CARE… (5*) WITH PROXIMAL DISEASE… (5*) approval of the publication. Medical writing support was provided by Catherine DeBrosse, PhD, a)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa1893. . . . A SINGLE CELL SURVEY OF Sa1876. . . . BODY IMAGE LARGE… (3*) Sa1913. . . . IDENTIFYING REGULATORS OF DISSATISFACTION IS INCREASED IN… (5*) MICROBIOME-ENCODED BILE ACID… (2*) Sa1894. . . . ENTERIC GLIAL MHC II Sa1877. . . . INDIVIDUALISED, CONTRIBUTES TO… (2*) Sa1914. . . . THE PREDICTION MODEL FOR UNSUPERVISED EXERCISE PROGRAM GASTRIC MICROBIOME… (2*) ACHIEVES HIGH… (4*) Sa1895. . . . CHARACTERIZATION AND MODELING OF THE CREEPING… (3*) Sa1915. . . . ALTERED CIRCADIAN RHYTHM Sa1878. . . . EFFECTS OF SUBCUTANEOUS CYCLING OF MICROBES… (2*) VEDOLIZUMAB ON HEALTH-RELATED… Sa1896. . . . SERUM BIOMARKERS OF (3*)|(Takeda) DEGRADATION AND FORMATION… (5*) Sa1916. . . . DIFFERENT EFFECTS OF HISTAMINE 2 RECEPTOR… (4*)|(Chung Sa1879. . . . DISABILITY IN PATIENTS WITH Sa1897. . . . HDAC INHIBITORS DRIVE TGF- Shan Medical University Hospital, Taichung, ILEAL POUCH… (5*) β1-MEDIATED STRENGTHENING AND… (2*) Taiwan (CSH-2014-D-004-Y2))

Sa1880. . . . LONGITUDINAL Sa1898. . . . LIPIDOMIC PROFILING REVEALS Sa1917. . . . A MICROBIAL SIGNATURE PSYCHOLOGICAL HEALTH IN VETERANS ALTERED LIPID COMPOSITION… (5*) PREDICTS ADVANCED FIBROSIS… (4*) WITH… (5*) Sa1899. . . . FIBROSIS IN PEDIATRIC Sa1918. . . . JEJUNAL BUT NOT COLONIC Sa1881. . . . EFFECTS OF INTRAVENOUS PATIENTS WITH ULCERATIVE… (2*) HYDROGEN SULFIDE… (2*) VEDOLIZUMAB ON HEALTH-RELATED… (3*)|(Takeda) Sa1900. . . . INTEROBSERVER AGREEMENT Sa1919. . . . INTESTINAL MICROBIOME AMONG ENDOSCOPISTS IN EVALUATING… CHANGES AFTER AN ANTIBIOTIC… Sa1882. . . . PSYCHIATRIC OUTCOMES ARE (6*)|(Kenneth-Rainin Foundation) (4*)|(Monica Lester Charitable Trust) SIGNIFICANTLY IMPACTED WITH… (4*) Sa1901. . . . EXPRESSION OF INTEGRIN Sa1920. . . . ORAL HEALTH AND THE Sa1883. . . . ALTERATIONS IN FUNCTIONAL A4B7 AND MADCAM1… (3*)|(Takeda COLONIC MUCOSA-ASSOCIATED… (2*)| AND MICROSTRUCTURAL DEFAULT… (2*) Pharmaceuticals) Sa1921. . . . ALTERING NITROGEN-SENSING Sa1884. . . . UNMET NEED OF Sa1902. . . . A COMPARISON OF IN E. COLI CAUSES… (7*)| INFLAMMATORY BOWEL DISEASE… DIVERTICULITIS IN CROHN’S… (5*) (3*)|(Janssen Inc. provided an educatiol Sa1922. . . . DISTINCT SHIFTS IN GUT grant to the Gastrointestil Society. The Sa1903. . . . THE ROLE OF SUB-MUCOSAL MICROBIOTA COMPOSITION… (2*) doctors were not paid for their COLLAGEN DEPOSITION… (5*) participation.) Sa1923. . . . THE IMPACT OF INTESTINAL Sa1904. . . . LONG-TERM SAFETY AND DYSBIOSIS IN… (4*) Sa1885. . . . PERCEIVED DISEASE SEVERITY OUTCOMES OF COLONOSCOPIC… (5*) AND TREATMENT SATISFACTION… Sa1924. . . . EFFECT OF SHORT CHAIN (3*)|(Pfizer Inc) Sa1905. . . . A PHASE I RANDOMIZED, FATTY ACIDS… (4*) DOUBLE-BLIND, PLACEBO-CONTROLLED… Sa1886. . . . SEXUAL DYSFUNCTION IN (3*)|(Study funded by 4D Pharma. RH and Sa1925. . . . ALTERATION IN GUT PATIENTS WITH INFLAMMATORY… (5*) RKR supported by Career Researcher MICROBIOTA IS ASSOCIATED… (2*) Fellowships from NHS Research Scotland.) Sa1887. . . . GENERAL HEALTH STATUS IN Sa1926. . . . SELECTIVE MICROBIOTA PATIENTS WITH… (3*)|(This study was Sa1906. . . . DOSE ESCALATION WITH TRANSPLANTATION IS EFFECTIVE FOR… funded by Janssen Research & ORIGINATOR INFLIXIMAB IS… (3*)|(Janssen (1*)| Development, LLC) Scientific Affairs, LLC supported this study) Sa1927. . . . ASSOCIATIONS OF EARLY LIFE Sa1888. . . . USTEKINUMAB THERAPY Sa1907. . . . ANTIBIOTICS WORSEN ADVERSITY AND… (2*) INDUCED CLINICALLY MEANINGFUL VISCERAL BUT NOT SOMATIC… (6*) IMPROVEMENT… (3*)|(This study was Sa1928. . . . HUMAN BREAST MILK funded by Janssen Research & Sa1908. . . . ABERRANT ENTERIC PROMOTES THE SECRETION… (3*)|(BioGaia Development, LLC) NEUROMUSCULAR SYSTEM AND AB) DYSBIOSIS… (2*)| Sa1889. . . . DOES PREGNANCY ADVERSELY Sa1929. . . . DISTINGUISHING DISEASE AND IMPACT THE HEALTH… (4*) Sa1909. . . . DEEP SEQUENCING OF THE ANTIBIOTIC EFFECTS IN… (2*)|(This work ENTIRE HUMAN… (4*) was supported by a Tobacco Formula grant, Sa1890. . . . THE ASSESSMENT OF under the Commonwealth Universal INDIVIDUAL PATIENT PREFERENCES… (6*) Sa1910. . . . LIFE COURSE ANTIBIOTIC USE Research Enhancement (C.U.R.E) program AND ALTERATIONS… (2*) with the grant number SAP # 4100068710.) Sa1891. . . . A SURVEY OF DISCLOSURE PREFERENCES IN… (5*) Sa1911. . . . ANALYSIS OF THE SMALL Sa1930. . . . FECAL MICROBIOTA INTESTINAL MICROBIOME… (4*) TRANSPLANTATION: PERCEPTIONS AND Sa1892. . . . NUTRITIONAL STATUS EXPERIENCES… (4*) CORRELATES WITH QUALITY OF… (5*) Sa1912. . . . REVEALING THE ENTIRE INTESTINAL MICROBIOTA AND… (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa1931. . . . PHYSICO-CHEMISTRY, Sa2012. . . . REGULATION OF COLON PROTEOMICS AND IN VIVO Sa1949. . . . POSTMENOPAUSAL WOMEN CARCINOGENESIS BY THE… (5*) COMPARATIVE… (5*) WITH IRRITABLE BOWEL SYNDROME… (5*) Sa2013. . . . ASPIRIN IS PROTECTIVE Sa1932. . . . EFFECT OF SACCHAROMYCES Sa1950. . . . EFFECT OF SYMPTOM AGAINST GASTRIC CANCER… (2*) BOULARDII CNCM I-745… (3*)|(The current SEVERITY AND GENDER… (5*) project was partially funded by a Biocodex Sa2014. . . . ASPIRIN USE AND THE grant, however they were not involved Sa1951. . . . VALIDITY AND SAFETY OF INCIDENCE OF… (2*) neither in the study design, patients SYMPTOM IMPROVEMENT… (2*) recruitment nor data alysis. USFQ, UTE and Sa2015. . . . 5-AMINOSALICYLIC ACID UDLA (Private Universities in Ecuador) also Sa1952. . . . ROLE OF LOW-GRADE INHIBITS XENOBIOTIC METABOLISM IN… funded partially the current research) INFLAMMATION IN THE… (5*) (4*)

Sa1933. . . . GUT MICROBIOME CROSS- Sa1953. . . . PICTOGRAMS ARE HIGHLY Sa2016. . . . TRANSCRIPTIONAL AND POST- TALK: PLAUSIBLE OR JUST… (5*) EFFECTIVE FOR DIAGNOSING… (4*) TRANSLATIONAL IMPLICATIONS OF COHESIN… (2*) Sa1934. . . . THE FECAL-ANTI CANDIDA Sa1954. . . . POST INFECTION IBS (PI-IBS) IS ACTIVITY CAN BE… (5*) VERY… (4*) Sa2017. . . . PREEMPTIVE ADALIMUMAB AMELIORATED CACHEXIA THROUGH Sa1935. . . . COMPARING FAECAL VOLATILE Sa1955. . . . IS ROME IV CRITERIA FOR IBS… CONCERTED… (4*) ORGANIC COMPOUNDS FOLLOWING… (5*) (5*) Sa2018. . . . COLORECTAL NEOPLASMS IN Sa1936. . . . EFFICACY AND SAFETY OF Sa1956. . . . ANXIETY, DEPRESSION AND NEW USERS OF… (4*) SACCHAROMYCES BOULARDII… (4*) STRUCTURAL FACTORS IMPACT… (2*) Sa2019. . . . CHEMOPREVENTION OF Sa1937. . . . FIVE CASES OF BACILLUS Sa1957. . . . INCIDENCE, PREVALENCE AND COLORECTAL CANCER IN THE… (5*) LICHENIFORMIS BACTEREMIA… (1*) RISK FACTORS ASSOCIATED… (3*)|(This project was supported by a grant from Sa2020. . . . TARGETING CYCLOOXYGENASE Sa1938. . . . ENTEROBACTERIACEAE ARE Prometheus laboratories.) 2 (COX-2) WITH EXERCISE-INDUCED… (2*) ESSENTIAL FOR THE MODULATION… (3*) Sa1958. . . . MEASURING DIET INTAKE AND Sa2021. . . . A MULTICENTER STUDY OF THE Sa1939. . . . THE GUT MICROBIOME AS A GASTROINTESTINAL SYMPTOMS… (2*) SAFETY… (3*)|(Covidien/Medtronic) NOVEL… (7*) Sa1959. . . . EVALUATION OF THE Sa2022. . . . EXPLORING RELATIONSHIPS Sa1940. . . . FECAL AND MUCOSAL PSYCHOSOCIAL FEATURES OF… (2*) BETWEEN HANDGRIP STRENGTH, MID- MICROBIOTA PROFILING IN… (2*) UPPER… (3*)|(Baxter Cada) Sa1960. . . . A SURVEY-BASED STUDY OF Sa1941. . . . STRUCTURED PATIENT GROUP IRRITABLE BOWEL… (5*) Sa2023. . . . 13C-CAFFEINE BREATH TEST EDUCATION VERSUS STRUCTURED… (2*)| FOR THE IDENTIFICATION… (4*) Sa2004. . . . HIGH METHYL DIET IMPAIRS Sa1942. . . . REAL-WORLD E.COLI OVERGROWTH,… (4*) Sa2024. . . . ASSOCIATION BETWEEN IMPLEMENTATION OF THE LOW FODMAP… MALNUTRITION, NUTRITIONAL (2*) Sa2005. . . . EXPERT CONSENSUS ON ASSESSMENT TOOLS,… (4*) MANAGING IRON DEFICIENCY… (3*)|(Vifor Sa1943. . . . IMPACT OF IRRITABLE BOWEL Pharma) Sa2025. . . . DYSREGULATION OF LIVER SYNDROME ON… (5*) MITOCHONDRIAL FUNCTION AND… Sa2006. . . . MODERATE ETHANOL (3*)|(Tsumura & Co.) Sa1944. . . . DIFFERENCES OF CONSUMPTION INHIBITS VILLUS CELL… GASTROINTESTINAL (GI) SYMPTOMS (2*) Sa2026. . . . IMPROVEMENT IN NUTRITION BETWEEN… (5*) STATUS IS ASSOCIATED… (4*) Sa2007. . . . ASPIRIN/NSAID USE GREATER Sa1945. . . . FECAL MICROBIOTA THAN 4 YEARS… (2*)| Sa2027. . . . VALIDATION OF THE MODIFIED TRANSPLANTATION IN IRRITABLE BOWEL… NUTRIC SCORE… (5*) (5*) Sa2008. . . . RISK OF METACHRONOUS SESSILE SERRATED ADENOMAS… (5*) Sa2028. . . . DIETARY FIBER IS ESSENTIAL Sa1946. . . . THE MOST BOTHERSOME TO MAINTAIN… (6*) SYMPTOM IN FUNCTIONAL… (4*) Sa2009. . . . COMBINATORIAL BLOCKADE OF DE NOVO CHOLESTEROL… (2*) Sa2029. . . . HABITUAL DIETARY INTAKE OF Sa1947. . . . RANDOMIZED, DOUBLE-BLIND, DUTCH IBD… (5*) PLACEBO-CONTROLLED TRIAL OF Sa2010. . . . LIPOPHILIC STATINS INHIBIT COLESEVELAM… (5*) YAP NUCLEAR LOCALIZATION,… (2*) Sa2030. . . . RANDOMIZED CLINICAL TRIAL TO COMPARE TWO… (5*) Sa1948. . . . NEEDLELESS Sa2011. . . . USEFULNESS OF TRACE TRANSCUTANEOUS ELECTRICAL ACETALDEHYDE/ETHANOL Sa2031. . . . HIGH PREVALENCE OF FOOD ACUSTIMULATION IMPROVES IRRITABLE… MEASUREMENTS IN… (5*) AVOIDANCE DIETS… (4*) (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Sa2032. . . . ALCOHOL CONSUMPTION AND Su1036. . . . SULFORAPHANE ALLEVIATES THE COLONIC MUCOSA-ASSOCIATED… (2*) Su1014. . . . IMMUNE PROFILING OF THE DEXTRAN SODIUM SULFATE (DSS)- HUMAN GASTRIC… (4*) INDUCED… (2*) Sa2033. . . . SHORT- AND LONG-TERM ALCOHOL INTAKE AND… (2*) Su1015. . . . WNT SIGNALING REGULATES Su1037. . . . HEPATOCARCINOGENESIS SIRT2 EXPRESSION IN… (2*) WITHOUT CIRRHOSIS IN THE ELDERLY… Sa2034. . . . INTRAPERITONEAL (4*) TREATMENT WITH KISSPEPTIN MODIFIES Su1016. . . . PROTEIN KINASE D REGULATES FEEDING… (4*) THE NUCLEAR… (2*) Su1038. . . . NOD1 DEFICIENT GASTRIC STEM CELLS FAIL… (4*) Sa2035. . . . DIETARY INTERVENTIONS Su1017. . . . ESTABLISHMENT AND RAPIDLY ALTER METABOLOMICS PROFILE… CHARACTERIZATION OF A LEAKY… Su1039. . . . HUMAN DIFFERENTIATED (6*) (3*)|(Innovate Biopharmaceuticals Inc, ENTEROID MONOLAYERS EXHIBIT Raleigh NC) EGFR/MEK-… (2*) Sa2036. . . . AN EVALUATION OF DIETARY INTAKE, MACRO… (4*)|(5) Su1018. . . . INTESTINAL BARRIER Su1040. . . . EARLY ACTIVATION OF SOX9- DYSFUNCTION ORCHESTRATES THE POSITIVE CELLS IN… (2*) Sa2037. . . . EFFECT OF CALCIUM AND ONSET… (6*)|(Primary Source: Intertiol VITAMIN D… (2*) Foundation for Ethical Research Additiol Su1041. . . . NEW DIAGNOSTIC APPROACH Source 1: Bio & Medical Technology FOR BILIARY TRACT… (2*)|(Grant-in-Aid for Sa2038. . . . LACK OF EXPERIMENTAL Development Program of the tiol Research Scientific Research (B), Japan Society for the REPRODUCIBILITY IN PRECLINICAL… (2*) Foundation funded by the Ministry of Promotion of Science) Science and ICT Additiol Source 2: Cancer Sa2039. . . . UNDERSTANDING HOW Research Institute Additiol So) Su1042. . . . HUMAN CYTOKINE DIFFERENCES IN SOCIOECONOMIC PRODUCTION BY THE INTACT… (2*) STATUS,… (5*) Su1019. . . . LARAZOTIDE PROTECTS THE INTESTINAL TIGHT JUNCTION… Su1043. . . . EXPLORING GLP2 ACTIVITY Sa2040. . . . VITAMIN B12 (3*)|(Innovate Biopharmaceuticals Inc., AND CELLULAR TARGETS… (4*) MALABSORPTION AND DEFICIENCY Raleigh, NC, USA) FOLLOWING… (5*) Su1044. . . . OPTIMIZATION OF CULTURE Su1020. . . . NAFAMOSTAT MESYLATE, A CONDITIONS FOR IMPROVED… Sa2041. . . . DIETARY ADHERENCE IN BROAD SPECTRUM SERINE… (4*) (3*)|(AbbVie) FUNCTIONAL GASTROINTESTINAL DISORDERS:… (5*) Su1021. . . . PROTEINASE 3 Su1045. . . . MINIMUM ESSENTIAL ANTINEUTROPHIL CYTOPLASMIC ORGANDOIDS CULTURE MEDIA (MEOM)… Su1006. . . . INTERACTION BETWEEN LONG ANTIBODIES IN… (5*) (2*) NONCODING RNA UC.173… (2*) Su1022. . . . INTERLEUKIN 4 RECEPTOR α Su1046. . . . CRISPR/CAS9-MEDIATED Su1007. . . . NLRP3 INFLAMMASOME- DEFICIENCY ALLEVIATES… (5*) GENOME EDITING OF MULTI-DRUG MEDIATED IL-1β ACTIVATION ENHANCES 5- RESISTANCE… (4*) FU… (4*) Su1028. . . . WHOLE-GENOME SEQUENCING OF AFRICAN AMERICANS Su1047. . . . THE CHARACTERIZATION OF Su1008. . . . MIR874-3P IS INVERSELY IDENTIFIES… (6*) THE FUNCTION OF… (2*)|(JSPS KAKENHI CORRELATED WITH ITS… (7*)|(We like to Grandts Numbers 15K10124 (KY and YIK) acknowledge the Intertiol Organization for Su1029. . . . TIO2 NANOPARTICLES and grants from the tiol Center for Global the study of Inflammatory Bowel Disease ABROGATE THE PROTECTIVE EFFECT… (2*) Health and Medicine (26-117 and 29- (IOIBD), and the tiol Institute of Diabetes 1019).) and Digestive and Kidney Diseases IBD Su1030. . . . UTILITY OF TARGETED NEXT- Genetics Consortium [NIDDK IBDGC] for GENERATION SEQUENCING PANEL… (2*) Su1048. . . . INTESTINAL EPITHELIAL their fincial support.) BARRIER ABNORMALITIES AND CHANGES… Su1031. . . . PREVALENCE OF GERMLINE (2*) Su1009. . . . LOSS OF RAB25 AGGRAVATES MUTATIONS AND VARIABLE… (2*) A HYPERTROPHIC… (2*) Su1049. . . . MULTIPLEX NANOSCALE HIGH Su1032. . . . MIST+ ISTHMUS STEM CELLS RESOLUTION FLOW CYTOMETRY… (4*) Su1010. . . . ABNORMAL ACTIVATION OF CONTRIBUTE TO… (2*) HNRNPA0 INHIBITS CANCER… (2*) Su1050. . . . COMPARISON OF FISH VERSUS Su1034. . . . REBAMIPIDE REDUCES DDPCR-BASED GENE… (4*) Su1011. . . . HUMAN LAMINA PROPRIA GASTRIC EPITHELIAL CELL APOPTOSIS… LYMPHATIC CELLS AS… (5*) (4*) Su1051. . . . CONSTRUCTION OF COLORECTAL CANCER SUBTYPES BASED… Su1012. . . . MECHANICAL STIMULI AFFECT Su1035. . . . SCREENING ANTI-FIBROTIC (5*) ENTEROTOXIGENIC E. COLI… (2*)|(Emulate AGENTS: EXPLORATION OF PROMISING… Inc.) (4*) Su1052. . . . A NOVEL MICRORNA PANEL FOR NON-INVASIVE… (5*) Su1013. . . . INCREASED BASOPHIL RECRUITMENT TO THE COLON… (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1053. . . . HIGH RISK POPULATION Su1074. . . . ASSOCIATION BETWEEN Su1115. . . . ACTIVATION OF EGFR-DNA-PK SCREENING FOR COLORECTAL… (5*) SINGLE NUCLEOTIDE POLYMORPHISMS PATHWAY BY IGFBP2… (4*) IN… (2*) Su1054. . . . PYRROLINE-5-CARBOXYLATE Su1116. . . . EOSINOPHILS ARE PRESENT IN REDUCTASE 1(PYCR1) UPREGULATION Su1096. . . . CALCIUM SIGNALING IN THE HUMAN AND… (5*) CONTRIBUTES TO… (2*) REGULATION OF… (2*) Su1117. . . . APURINIC/APYRIMIDINIC Su1055. . . . REPRIMO-LIKE: A POTENTIAL Su1097. . . . NCX1/CA/NF-KB SIGNAL ENDONUCLEASE-1 IS ASSOCIATED WITH TUMOR SUPPRESSOR AND… (2*) PATHWAY COULD BE A… (2*) ANGIOGENESIS… (1*)

Su1056. . . . A CHEMORADIOTHERAPY Su1098. . . . TUMOR-DERIVED EXOSOMES Su1118. . . . MEDICATION EFFECTS ON TREATMENT RESPONSE MRNA PROMOTE TUMOR GROWTH AND… (4*) METHYLATION-RELATED BIOLOGICAL SIGNATURE… (7*) AGING… (2*)| Su1099. . . . MYOARCHITECTURE OF THE Su1057. . . . INCREASED EXPRESSION OF SLING FIBERS OF… (2*) Su1119. . . . IS THE AGE OF DIAGNOSIS OF… THE LONG NONCODING… (2*) (5*) Su1100. . . . MUCOSAL BARRIER Su1058. . . . POTENTIAL OF URINARY DYSFUNCTION OF ATROPHIC MUCOSA… Su1120. . . . HAS ACCURACY OF CLINICAL CYSTEINE-RICH PROTEIN 61… (3*)|(the (5*) STAGING OF… (5*) Kobayashi Foundation for Cancer Research) Su1101. . . . CAN NSAID-INDUCED INJURY Su1121. . . . M1A DISEASE SHOULD BE Su1059. . . . IMMUNE CELL INFILTRATION OF GASTRIC EPITHELIAL… (2*) RECONSIDERED IN… (5*) AND TUMOUR LOCATION… (5*) Su1102. . . . CARBON MONOXIDE Su1122. . . . COMPREHENSIVE Su1060. . . . CLINICAL UTILITY OF THE RELEASED FROM ITS PHARMACOLOGICAL… MUTATIONAL ANALYSIS OF BACKGROUND QUANTITATIVE MONITORING… (2*) (4*)|(Grant from tiol Science Centre, Poland MUCOSA… (5*) (UMO-2016/23/N/NZ4/01890).) Su1061. . . . IDENTIFICATION OF A ROBUST Su1123. . . . ADDED VALUE OF MRI TO MICRORNA SIGNATURE… (2*) Su1103. . . . DOES PPI PLAY A PROTECTIVE ENDOSCOPIC… (5*) ROLE… (5*) Su1062. . . . MOLECULAR DEPENDENCIES IN Su1124. . . . LONG TERM RESULTS OF ESOPHAGEAL ADENOCARCINOMA: A… (2*) Su1104. . . . A RANDOMIZED CONTROLLED ENDOSCOPIC TREATMENT… (4*) STUDY ON THE… (5*) Su1063. . . . MIR-4715-3P MODULATES Su1125. . . . ESOPHAGEAL STENT AURKA AND INDUCES FERROPTOSIS… (2*) Su1105. . . . ESOPHAGEAL MUCOSAL PLACEMENT FOR POST-OPERATIVE IMMUNE RESPONSE TO CANDIDA… (5*) COMPLICATIONS… (5*) Su1065. . . . CANCER-DERIVED EXOSOMES ACTIVATE FIBROBLASTS THROUGH Su1106. . . . TACROLIMUS-INDUCED PAN- Su1126. . . . CLINICAL PREDICTORS OF SUPPRESSION… (5*) ESOPHAGEAL AND DUODENAL LOCALLYADVANCED ESOPHAGEAL ULCERATION: A… (5*) ADENOCARCINOMA… (5*) Su1066. . . . NOVEL METABOLOMIC PREDICTORS OF INCIDENT COLORECTAL… Su1107. . . . CLINICAL SIGNIFICANCE OF Su1127. . . . INCREASED SOX2 EXPRESSION (2*) SERUM MARKERS IN… (5*) IN THE EARLY… (2*)

Su1067. . . . GENETIC COLORECTAL CANCER Su1108. . . . COLLAGENOUS GASTRITIS: A Su1128. . . . CLINICAL EPIDEMIOLOGY OF RISK VARIANTS ASSOCIATED… (2*) RARE CAUSE OF… (5*) ESOPHAGEAL CANCER: NATIONWIDE… (7*)|(Korean College of Helicobacter and Su1068. . . . MUTATIONAL LANDSCAPE OF Su1109. . . . DEVELOPMENT OF Upper Gastrointestil Research) EARLY-ONSET COLORECTAL CANCER… (2*) NEOSQUAMOUS EPITHELIUM IN THE… (5*) Su1129. . . . PREDICTIVE SIGNIFICANCE OF Su1069. . . . THE ROLE OF RARE VARIANTS Su1110. . . . EVALUATION OF SMALL ENDOSONOGRAPHIC (EUS) STAGING… (1*) IN… (2*) BOWEL INJURY IN… (5*) Su1130. . . . OUTCOMES AFTER Su1070. . . . MORPHOLOGICAL AND Su1111. . . . GRADING OF ACUTE ESOPHAGECTOMY FOR ESOPHAGEAL MOLECULAR RISK MARKERS FOR… (5*) ESOPHAGEAL GRAFT VERSUS… (5*) CANCER… (5*)

Su1071. . . . NOVEL LONG NON-CODING Su1112. . . . ESOPHAGEAL PEMPHIGUS: THE Su1131. . . . HIGH CHOLESTEROL AND RNA MOLECULAR SUBTYPES… (4*) EXPERIENCE FROM A… (5*) HEMOGLOBIN A1C LEVELS… (4*)

Su1072. . . . HELICOBACTER PYLORI- Su1113. . . . RISK FACTORS, ENDOSCOPIC Su1132. . . . NOVEL APPLICATION OF RELATED DNA METHYLATION IN FEATURES, AND CLINICAL… (5*) IMPEDANCE-PH TECHNOLOGY SHOWS… PRIMARY… (2*) (5*) Su1114. . . . SWOLLEN STIMULANTS OF Su1073. . . . GENE NETWORK DIFFERENCES ORAL CAVITY MAY… (5*) Su1133. . . . ACID SUPPRESSION DOES NOT OF COLON CANCER… (5*) IMPROVE LARYNGOMALACIA… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1146. . . . USE OF FECAL OCCULT BLOOD Su1280. . . . EFFICACIES OF TAILORED TESTING… (2*) Su1262. . . . PREVALENCE OF THERAPY VERSUS GUIDELINE- HELICOBACTER PYLORI INFECTION IN… (5*) RECOMMENDED… (4*) Su1147. . . . BLEEDING AND THROMBOSIS RISK IN CRTICALLY… (5*) Su1263. . . . ASSESSMENT OF GASTRIC Su1281. . . . TETRACYCLINE-LEVOFLOXACIN PREMALIGNANT LESIONS BY… (2*) QUADRUPLE THERAPY ACHIEVES A Su1148. . . . RISK OF ADVANCED HIGHER… (4*) METACHRONOUS NEOPLASIA IS… (5*) Su1264. . . . HELICOBACTER PYLORI ANTIBODY PREVALENCE BY YEAR… (2*) Su1282. . . . ERADICATION RATES OF Su1149. . . . ARE PPIS ASSOCIATED WITH TRIPLE, TRIPLE WITH… (5*) DEMENTIA? -… (5*) Su1265. . . . PROSPECTIVE COMPARISON VALIDATION STUDY OF 13C-UREA… (5*) Su1283. . . . TEN-DAY CONCOMITANT, 10- Su1150. . . . RISK OF TUBERCULOSIS IN DAY SEQUENTIAL, AND 7-DAY… PATIENTS WITH… (5*) Su1266. . . . HELICOBACTER PYLORI (2*)|(Ministry of Health and Welfare, TESTING AND TREATMENT IN… Republic of Korea) Su1151. . . . EARLY VS DELAYED ERCP IN (3*)|(Otsuka Pharmaceutical Development ACUTE… (5*) and Commercialization, Inc. (Rockville, MD)) Su1284. . . . EFFICACY AND SAFETY OF VONOPRAZAN, SITAFLOXACIN… (5*) Su1152. . . . IMPACT OF NURSE OR TRAINEE Su1267. . . . MANAGEMENT OF PARTICIPATION… (5*) HELICOBACTER PYLORI INFECTION AT… Su1285. . . . SYNERGISTIC INHIBITORY (5*) EFFECTS OF NANOPARTICLE HEATING… Su1247. . . . SCREENING FOR GASTRIC (2*) INTESTINAL METAPLASIA: WHAT… (4*) Su1268. . . . HELICOBACTER PYLORI INFECTION: PRACTICE PATTERNS IN… (5*) Su1286. . . . A POTASSIUM-COMPETITIVE Su1248. . . . COMBINATION OF ACID BLOCKER-BASED REGIMEN AS… (5*) HELICOBACTER PYLORI STATUS AND… (5*) Su1269. . . . HELICOBACTER PYLORI INFECTION AND IRON DEFICIENCY… (5*) Su1287. . . . A PHASE 1, RANDOMIZED, Su1249. . . . DEMOGRAPHIC, LIFESTYLE DOUBLE-BLIND STUDY… (3*)|(Takeda AND DIETARY RISK FACTORS… (5*) Su1270. . . . CLINICAL PERFORMANCE OF Pharmaceutical Company Limited) THE H. PYLORI… (3*) Su1250. . . . FEASIBILITY OF GASTRIC Su1288. . . . FIRST LINE HELICOBACTER INTESTINAL METAPLASIA SURVEILLANCE… Su1271. . . . CHANGES IN GUT MICROBIOTA PYLORIERADICATION IN PATIENTS… (5*) (5*) AFTER HELICOBACTER… (5*) Su1289. . . . INFLUENCE OF CLOSTRIDIUM Su1251. . . . CLINICOPATHOLOGICAL Su1272. . . . THE RATIO OF PEPSINOGEN I BUTYRICUM AS PROBIOTICS… (5*) FEATURES OF SPORADIC NON-AMPULLARY TO… (4*) DUODENAL… (5*) Su1290. . . . EFFICACY AND SAFETY OF Su1273. . . . HELICOBACTER PYLORI LACTOBACILLUS REUTERI… (5*) Su1252. . . . INCIDENT DIAGNOSES OF ERADICATION CANNOT RESTORE THE… GASTRIC INTESTINAL METAPLASIA… (5*) (2*)|(This work was supported by the tiol Su1291. . . . EFFECTIVENESS OF HIGH DOSE Research Foundation of Korea (NRF) grant DUAL THERAPY… (1*) Su1253. . . . EVALUATION OF DNA AND funded by the Korea government (MSIT) RNA EXTRACTION… (4*) (2017R1C1B5075233)) Su1292. . . . TRIPLE-DRUG BLISTER- PACKAGED DRUG WITH VONOPRAZAN Su1254. . . . OLGA AND OLGIM STAGE Su1274. . . . HELICOBACTER PYLORI IMPROVES… (5*) DISTRIBUTION ACCORDING… (5*) INFECTION AMONG YOUNG PEOPLE… (5*) Su1293. . . . LONG-TERM EFFET FOR LIPID Su1255. . . . AUTOIMMUNE METAPLASTIC Su1275. . . . HELICOBACTER PYLORI IN METABOLISM BY… (5*) ATROPHIC GASTRITIS (AMAG) –… (5*) SOUTH TEXAS: ERADICATION… (5*) Su1294. . . . ERADICATION RATIO AND Su1257. . . . CHARACTERISTICS OF Su1276. . . . LONG-TERM FOLLOW UP OF ADVERSE EVENTS INCIDENCE… (1*) GASTROINTESTINAL STROMAL TUMORS ENDOSCOPIC/HISTOLOGICAL ATROPHY,… USING… (5*) (5*) Su1295. . . . SUSCEPTIBILITY-BASED THIRD LINE RESCUE THERAPY FOR… (4*) Su1258. . . . MISSED OPPORTUNITIES FOR Su1277. . . . THE MANAGEMENT OF H. SCREENING OR SURVEILLANCE… (5*) PYLORI IS… (5*) Su1296. . . . SUPERBUG OR SOMETHING ELSE: FACTORS CONTRIBUTING… (5*) Su1259. . . . THE INCIDENCE OF GASTRIC Su1278. . . . ASSOCIATION OF CANCER IN… (5*) HELICOBACTER PYLORI INFECTION AND… Su1297. . . . GENETIC AND BACTERIAL (4*) FACTORS FOR OUTCOME… (5*) Su1260. . . . LOW PREVALENCE OF HELICOBACTER PYLORI-POSITIVE PEPTIC… Su1279. . . . IMPACT OF PRIOR EXPOSURE Su1298. . . . CLARITHROMYCIN VERSUS (5*) TO MACROLIDE… (5*) METRONIDAZOLE CONTAINING FIRST-LINE VONOPRAZAN… (5*) Su1261. . . . SMOKING, HELICOBACTER PYLORI SEROLOGY, AND GASTRIC… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1299. . . . A RANDOMIZED CONTROLLED Su1320. . . . IDENTIFICATION OF NOVEL Su1438. . . . METABOLOMIC PROFILING STUDY FOR LEVOFLOXACIN-BASED… (4*) NEURONAL MARKERS IN… (2*) IDENTIFIES PHOSPHOLIPID SIGNATURE IN… (4*)|(nil) Su1300. . . . NATION-WIDE ANTIBIOTIC Su1418. . . . ROLE OF THERAPEUTIC RESISTANCE MAPPING OF HELICOBACTER… ANTICOAGULATION IN SPLANCHNIC… (5*) Su1439. . . . RISK FACTORS FOR DIABETES (2*) MELLITUS IN… (5*) Su1419. . . . ONE YEAR RISK OF OPIOID Su1301. . . . CHANGES OF GASTRIC CORPUS ADDICTION… (5*) Su1440. . . . COEXISTENCE OF ALCOHOLIC MICROBIOTA AFTER… (5*) LIVER DISEASE (ALD)… (4*) Su1420. . . . MULTI-ORGAN FAILURE IS THE Su1302. . . . PRESENTATION, CLINICAL STRONGEST DETERMINANT… (5*) Su1441. . . . ASSOCIATION OF COURSE AND OUTCOME IN… (5*) AUTOIMMUNE DISEASES IN CHILDREN… Su1421. . . . TRENDS AND TIMING OF (2*) Su1303. . . . PEDIATRIC CAPSULE CHOLECYSTECTOMY IN… (5*) ENDOSCOPY: ACHIEVING 0 CAPSULE… (5*) Su1442. . . . METABOLIC SYNDROME Su1422. . . . THE IMPACT OF OPIOID RELATED DISORDERS ARE LESS… (5*) Su1304. . . . A NOVEL HISTOLOGY INDEX ABUSE/DEPENDENCE DISORDER… (5*) FOR EVALUATION… (6*) Su1443. . . . PREVALENCE, TREND AND Su1423. . . . GASTROINTESTINAL FAILURE IS DETERMINANTS OF LEAVING… (5*) Su1305. . . . SEROTONIN ACTING VIA 5-HT3 A PREDICTOR OF… (5*) RECEPTORS MEDIATES… (2*) Su1444. . . . RISK FACTORS AND Su1424. . . . IS EARLY CT OVERUTILIZED IN NOMOGRAM FOR STEATORRHEA… (5*) Su1306. . . . A NOVEL POTENT POST- MANAGEMENT… (5*) SYNAPTIC SIGNALING PATHWAY… (2*) Su1445. . . . IS CHRONIC PANCREATITIS Su1425. . . . ANNULAR PANCREAS AND ITS WITH HIGH BMI… (5*) Su1307. . . . EZH2 REGULATES GASTRIC ASSOCIATION WITH… (5*) PACEMAKER STEM CELL… (2*) Su1446. . . . CLINICAL CHARACTERISTICS OF Su1426. . . . PATIENTS TAKING ANTI- PATIENTS WITH SYMPTOMS… (2*) Su1308. . . . FIRST IN MAN PATCH CLAMP TUMOR NECROSIS FACTOR α… (5*) RECORDINGS IN FRESHLY… (2*) Su1447. . . . CLINICAL FEATURES OF IGG4 Su1427. . . . A MULTIVARIATE MODEL FOR NEGATIVE AUTOIMMUNE… (5*) Su1309. . . . IMPACT OF GUT SURGICAL PREDICTION OF… (5*) MANIPULATION ON… (2*) Su1448. . . . PREDICTIVE VALUE OF ISLET Su1428. . . . DOES INTRACELLULAR FLUID PROCESSING PARAMETERS… (5*) Su1310. . . . BETA 2 ADRENERGIC SHIFT CONTRIBUTE TO… (4*) RECEPTOR MEDIATES THE… (2*) Su1449. . . . DO PATIENTS WITH CHRONIC Su1429. . . . NEUTROPHIL CD64 PANCREATITIS RECEIVE… (5*) Su1311. . . . OPTOGENETIC ANALYSIS OF EXPRESSION IS A NOVEL… (4*) CHOLINERGIC NERVE PATHWAYS… (2*) Su1450. . . . CHRONIC PANCREATITIS Su1430. . . . ISOLATED EXTRA-PANCREATIC ASSOCIATED WITH CYSTIC FIBROSIS… (5*) Su1312. . . . ABNORMAL BIOELECTRICAL NECROSIS IS ASSOCIATED WITH… (5*) SLOW-WAVE IN PATIENTS WITH… (2*) Su1451. . . . AMMANN PAIN TYPE AND THE Su1431. . . . NECROTIZING ACUTE NATURAL… (4*) Su1313. . . . ROLE OF ETV1 IN REGULATING PANCREATITIS: CAN MRI DIFFUSION- GASTROINTESTINAL… (2*) WEIGHTED… (5*) Su1452. . . . CHARACTERIZATION OF NUTRITIONAL STATUS THROUGH PHASE… Su1314. . . . INTERSTITIAL CELLS OF CAJAL Su1432. . . . THE CLINICAL SPECTRUM OF (5*) PLAY A… (5*) GROOVE PANCREATITIS… (5*) Su1453. . . . DIAGNOSIS AND TREATMENT Su1315. . . . EPIGENETIC CHANGES IN Su1433. . . . ACUTE PANCREATITIS IN OF AUTOIMMUNE PANCREATITIS:… (4*) GASTRIC ANTRAL SMOOTH… (5*) PATIENTS WITH HEMOPHILIA:… (5*) Su1454. . . . PANCREATIC CYSTIC LESIONS: Su1316. . . . DAIKENCHUTO, A Su1434. . . . ACUTE PANCREATITIS IN ACTIVE VERSUS PASSIVE… (7*) TRADITIONAL JAPANESE (KAMPO) PATIENTS WITH HEART… (5*) MEDICINE,… (2*) Su1455. . . . NATURAL HISTORY OF Su1435. . . . AGGRESSIVE FLUID PANCREATIC CYSTIC LESIONS… (7*) Su1317. . . . INHIBITING FATTY ACID AMIDE REPLACEMENT IN ACUTE PANCREATITIS;… HYDROLASE AMELIORATES… (4*) (5*) Su1456. . . . ASSESSMENT OF ENDOSCOPIC ULTRASOUND (EUS) AND… (5*) Su1318. . . . P2X2 RECEPTOR SIGNALING Su1436. . . . ORGAN FAILURE PERSISTING INDUCES ENTERIC GLIA… (2*) FOR MORE THAN… (5*) Su1457. . . . COMPARISON OF DOTATATE PET-CT SCAN AND… (5*) Su1319. . . . KAMPO FORMULA Su1437. . . . IDENTIFYING REDUCED DAIKENCHUTO FACILITATES MUCOSAL PANCREATIC FUNCTION AND FAT… Su1458. . . . PANCREATIC ISLET CELL HYPEREMIC… (2*) (3*)|(Abbvie, Inc) TUMORS: NATIONWIDE ANALYSIS… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1459. . . . IMAGING RESOURCE Su1585. . . . RACIAL DISPARITY IN HEALTH UTILIZATION IN ACTIVE PANCREATIC… (5*) Su1537. . . . NON-VARICEAL UPPER CARE UTILIZATION… (5*) GASTROINTESTINAL BLEEDING IN Su1460. . . . PANCREATIC MIXED ACINAR PATIENTS… (5*) Su1586. . . . RACIAL DISPARITIES IN CELL/NEUROENDOCRINE CARCINOMA: PATIENTS WITH IRRITABLE… (5*) GENOMIC… (4*) Su1538. . . . ASSOCIATION BETWEEN VARICEAL BLEED AND HELICOBACTER… Su1587. . . . NEW PATIENT REPORTED Su1519. . . . RIFAXIMIN AND LACTULOSE (5*) OUTCOME MEASURE: DIARY… (3*)|(This COMBINATION THERAPY VERSUS… study was funded by Allergan plc and (3*)|(Salix Pharmaceuticals) Su1539. . . . PENTADECAPEPTIDE BPC 157 Ironwood Pharmaceuticals.) COUNTERACTS PORTAL HYPERTENSION,… Su1520. . . . A NATIONAL ESTIMATE OF (4*) Su1588. . . . HOW COST AFFECTS COMPENSATED AND… (5*) TREATMENT CHOICE FOR… (5*) Su1571. . . . GABA IN THE GUT: Su1521. . . . COMBINATION THERAPY VS DISTRIBUITION OF… (4*) Su1589. . . . PREDICTIVE FACTORS OF MONOTHERAPY FOR EUS-GUIDED… (5*) RESPONSE TO RIFAXIMIN… (5*) Su1572. . . . ENTERIC NERVOUS SYSTEM: A Su1522. . . . PREVALENCE OF UPPER NOVEL NEURO-EPITHELIAL… (4*) Su1590. . . . STUDY ON THE EFFECTIVENESS GASTROINTESTINAL NEOPLASIA IN… (5*) OF HERBAL… (5*) Su1573. . . . CHOLINERGIC-INDUCED ANION Su1523. . . . IMPACT OF TRANSFER STATUS SECRETION IN MOUSE JEJUNAL… (2*) Su1591. . . . COMMUNICATION BETWEEN ON OUTCOMES… (5*) CLINICIANS AND PATIENTS WITH… Su1574. . . . CLOSTRIDIOIDES DIFFICILE (3*)|(Synergy Pharmaceuticals) Su1524. . . . FLASH GLUCOSE-SENSING INFECTION INDUCES INCREASED S100B… TECHNOLOGY AS A REPLACEMENT… (5*) (2*)|(CAPES/PROCAD Su1592. . . . THE INTESTINAL GAS CAPES/FUNCAP/PRONEX CAPES/PDSE QUESTIONNAIRE (IGQ): PSYCHOMETRIC… Su1525. . . . SUPRAHEPATIC INFERIOR University of Virginia/Department of (3*)|(Da funded the study) CAVAL VEIN OCCLUSION AND… (4*) Infectious Diseases) Su1593. . . . LOW FODMAPS DIET Su1526. . . . COMPLICATIONS OF PORTAL Su1575. . . . ESTROGEN INCREASES THE IMPROVES FUNCTIONAL TRIAD OBSTRUCTION AND… (4*) EXPRESSION OF BKCA… (5*) GASTROINTESTINAL… (5*)

Su1527. . . . POTENTIALLY PREVENTABLE Su1576. . . . METABOLOMIC PROFILING OF Su1594. . . . REDUCTION IN OVERALL READMISSIONS AND COMPLICATIONS IN… SUBJECTS WITH FUNCTIONAL… (2*) HOSPITALIZATIONS FOR FUNCTIONAL… (2*)|(Partly from Investigator Initiated (5*) Grants from Grifols and Valeant and from Su1577. . . . UNDERSTANDING THE ROLE NCATS NIH) OF BILE ACIDS… (2*) Su1595. . . . DIETARY EDUCATION IN FUNCTIONAL GASTROINTESTINAL Su1528. . . . ENDOSCOPIC FINDINGS IN Su1578. . . . CHRONIC INTRACOLONIC DISORDERS:… (5*) PATIENTS WITH CIRRHOSIS… (5*) ADMINISTRATION OF LINACLOTIDE INHIBITS… (2*)|(Supported by Ironwood Su1596. . . . RELATIONSHIP BETWEEN Su1529. . . . PORTAL TRIAD OBSTRUCTION Pharmaceuticals Inc, Allergan) IDEAL (BRISTOL TYPE IV)… (5*) AND REPERFUSION IN… (4*) Su1579. . . . ENTERIC NEURONAL SILENT Su1597. . . . INCREASING INPATIENT Su1530. . . . PRE-EXISTING LIVER DISEASE AND MEMORY PROPERTIES… (2*) BURDEN OF CONSTIPATION AND… (5*) INCREASES RISK OF… (5*) Su1580. . . . A LONGITUDINAL STUDY Su1598. . . . ESTIMATION OF OPIOID USE Su1531. . . . SPLENECTOMY IN RATS EXAMINING THE EFFECT… (2*) FOR THE… (3*)|(The funding for this study INDUCED PORTAL AND… (4*) was provided by Ironwood Pharmaceuticals, Su1581. . . . GPCR-CONTAINING B7-2+ Inc. Writing assistance by Complete Su1532. . . . COMPLICATIONS OF EXTRACELLULAR VESICLES FROM HealthVizion, funded by Ironwood SUPRAHEPATIC INFERIOR CAVAL VEIN… IMMUNE… (2*) Pharmaceuticals, Inc.) (4*) Su1582. . . . ANTI-INFLAMMATORY AND Su1599. . . . PANCREATITIS FOLLOWING Su1533. . . . ADMISSION SERUM UREA IS A EPITHELIAL PROTECTIVE EFFECTS OF… (3*) ELUXADOLINE USE: 1-YEAR BETTER… (5*) REASSESSMENT… (5*) Su1583. . . . MORTALITY RISK IN IRRITABLE Su1534. . . . BPC 157 GIVEN DURING BOWEL SYNDROME:… (7*) Su1600. . . . MANAGEMENT OF REPERFUSION COUNTERACTS… (4*) FUNCTIONAL ABDOMINAL PAIN IN… (5*) Su1584. . . . PSYCHOLOGICAL, PHYSICAL Su1535. . . . SAFETY AND EFFICACY OF COMORBIDITIES AND FUNCTIONAL Su1601. . . . DIAGNOSTIC ACCURACY OF COMBINED ENDOSCOPIC… (5*) IMPAIRMENT… (2*)|(Study was funded by TWO HOUR AND… (5*) NIDDK K23 103911 and Intramural Research Su1536. . . . PROGNOSTIC VALUE OF Program of the NIMH (ZIAMH002806).) Su1602. . . . NOVEL USE OF TIMED BARIUM NEUTROPHIL-TO-LYMPHOCYTE RATIO IN… ESOPHAGRAM… (5*) (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1603. . . . WHEN ANTEGRADE ENEMAS Su1642. . . . SUPERIOR PERFORMANCE OF GO RETROGRADE: SIGNIFICANCE… (5*) Su1624. . . . GENETIC ETHNICITY AFFECTS GASTROINTESTINAL ULTRASOUND OVER… RESPONSE VARIABILITY IN… (4*) (5*) Su1604. . . . A PRELIMINARY STUDY OF THE IMPACT… (5*) Su1625. . . . IN VIVO AND IN VITRO Su1643. . . . DEVELOPMENT OF VALIDATED EFFECTS… (2*)|(NIH/NIDDK) QUESTIONNAIRE EVALUATING PARENT- Su1605. . . . ALTERATIONS IN BRAIN PERCEIVED… (4*) FUNCTIONAL CONNECTIVITY IN… (2*) Su1626. . . . POST-STROKE CONSTIPATION IS ASSOCIATED WITH IMPAIRED… (5*) Su1644. . . . INTEROBSERVER ANALYSIS Su1606. . . . AUTONOMIC NERVOUS TRIAL ON COLONIC MOTOR… (4*) SYSTEM RESPONSE IN IRRITABLE… (2*) Su1627. . . . OPIOID USAGE IS SIGNIFICANTLY ASSOCIATED WITH… (5*) Su1645. . . . NALOXEGOL RESTORES Su1607. . . . SOCIAL STRAIN AND LOW CODEINE-INDUCED INHIBITION OF HIGH- SOCIAL SUPPORT… (4*) Su1628. . . . INVASIVE AND NONINVASIVE AMPLITUDE… (4*)|(No industry or VAGAL NERVE STIMULATION… (5*) commercial source funding was received for Su1608. . . . VAGUS NERVES PROVIDE A this study.) ROBUST AFFERENT… (2*) Su1629. . . . THE AGEING GUT: SYMPTOMS COMPATIBLE WITH… (4*)| Su1646. . . . THE INFLUENCE OF BRAIN Su1609. . . . NEUROMODULATION AND METASTASES ON… (3*)|(This work was COLON MOTILITY MAPPING IN… (2*) Su1630. . . . SENSORY DOMAINS, NOT supported by Salix Pharmaceuticals, STOOL FREQUENCY, PREDICT… (5*) Bridgewater, NJ, USA, which has licensed Su1610. . . . DYSREGULATION OF the rights to develop and commercialize PARKINSON’S DISEASE RELATED GENES… Su1631. . . . MACHINE LEARNING WITH Relistor® from Progenics Pharmaceuticals, (2*) PAIN MEASURES ALONE… (5*) Inc., New York, NY, USA.)

Su1611. . . . COLORECTAL DISTENSION Su1632. . . . PARKINSON’S DISEASE Su1647. . . . THE INFLUENCE OF AGE ON MODULATES THE PAG FUNCTIONAL… (2*) PATIENTS WITH CONSTIPATION: RESULTS… CENTRAL… (3*)|(This work was supported (5*) by Salix Pharmaceuticals, Bridgewater, NJ, Su1612. . . . EFFECT OF VISCERO-VISCERAL USA, which has licensed the rights to INTERACTION ON FMRI… (2*) Su1633. . . . LACTOBACILLUS RHAMNOSUS develop and commercialize Relistor® from GG SUPERNATANT IMPROVES Progenics Pharmaceuticals, Inc., New York, Su1613. . . . THE ASSOCIATION OF DEFECATION… (5*) NY, USA.) VISCERAL ADIPOSITY WITH… (2*) Su1634. . . . IRRITABLE BOWEL SYNDROME Su1648. . . . EFFICACY VARIABLES IN Su1614. . . . HYPOGLYCEMIC EFFECTS OF AND STRUCTURAL ABNORMALITIES… (5*) CANCER VERSUS NONCANCER… (3*)|(This CHRONIC VAGAL NERVE… (5*) work was supported by Salix Su1635. . . . ORAL IRON Pharmaceuticals, Bridgewater, NJ, USA, Su1615. . . . PROMOTING EFFECTS AND SUPPLEMENTATION, MICROBIOME which has licensed the rights to develop AUTONOMIC MECHANISMS OF… (5*) RELATED METHANOGENESIS… (5*) and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.) Su1616. . . . ANTI-INFLAMMATORY EFFECTS Su1636. . . . THE PLACEBO RESPONSE IN AND MECHANISMS OF SACRAL… (2*) CHRONIC IDIOPATHIC… (5*) Su1649. . . . WHY PATIENTS WITH CHRONIC CONSTIPATION OR… (5*) Su1617. . . . NEUROANATOMICAL AND Su1637. . . . THE RELATIONSHIPS AMONG CONNECTIVITY ABNORMALITIES FECAL MICROBIOTA AND… (2*)|(This study Su1650. . . . SACRAL NERVE STIMULATION IDENTIFIED IN… (4*) was supported by Dalian municipal science FOR SLOW TRANSIT… (2*) and technology plan project (NO. Su1618. . . . SEXUALLY DIMORPHIC BRAIN 2015F11GH098).) Su1651. . . . A RANDOMIZED DOUBLE- SIGNATURES IN STIMULUS… (2*) BLIND PLACEBO-CONTROLLED TRIAL ON… Su1638. . . . CSP01, A NOVEL (5*) Su1619. . . . RIKKUNSHITO IMPROVES CCK SUPERABSORBENT HYDROGEL, REDUCES… AND STRESS-INDUCED ANOREXIA… (4*) (3*)|(Gelesis Inc.) Su1652. . . . CONSTIPATION MANAGEMENT STRATEGIES: CONSUMER PREFERENCES Su1620. . . . NERVE FIBER SPROUTING AND Su1639. . . . DAIKENCHUTO (TU-100), A AND… (3*)|(Sanofi) NEURO-IMMUNE INTERACTIONS… (4*) TRADITIONAL JAPANESE HERBAL… (3*)|(Tsumura & Co.) Su1653. . . . THE STUDY ON HEALTH- Su1621. . . . AMELIORATING EFFECTS OF RELATED QUALITY OF… (5*) SACRAL NERVE STIMULATION… (2*) Su1640. . . . PERSISTENT IMPROVEMENT IN CHRONIC CONSTIPATION WITH… (5*) Su1654. . . . THE PREVALENCE OF HLA-DQ Su1622. . . . DETERMINE GINGER GENES, CELIAC… (5*) CONSTITUENT 6-SHOGAOL-INDUCED Su1641. . . . RANDOMIZED DOUBLE BLIND EFFECT ON… (5*) CONTROLLED TRIAL TO… (3*)|(Study Su1655. . . . ADMINISTRATION OF sponsored by Bustar Alimentos S.A.P.I de NEOSTIGMINE AND GLYCOPYRROLATE BY… Su1623. . . . ABNORMAL PERIPHERAL C.V) (4*) AUTONOMIC AND CENTRAL AUTONOMIC… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1657. . . . FECAL MICROBIAL MARKERS IN Su1778. . . . THE TORONTO IBD GLOBAL Su1798. . . . THE INFLUENZA VACCINATION COLORECTAL CANCER… (5*) ENDOSCOPIC REPORTING… (5*) AND PEDIATRIC INFLAMMATORY… (5*)

Su1658. . . . MACHINE LEARNING ENABLES Su1779. . . . TEXT MESSAGE-BASED Su1799. . . . INCREASING TRENDS IN DETECTION OF EARLY-STAGE… (5*) TELEMEDICINE DOES NOT IMPROVE… (2*) DIAGNOSTIC PREVALENCE AND… (3*)

Su1659. . . . POSITIVE FAECAL OCCULT Su1780. . . . INSURANCE GENEROSITY AND Su1800. . . . EFFECT OF ADDITION OF AN BLOOD TEST AFTER… (5*) INFLAMMATORY BOWEL DISEASE:… (2*) IMMUNOMODULATOR… (5*)

Su1660. . . . COLORECTAL CANCER Su1781. . . . THE ECONOMIC BURDEN OF Su1801. . . . A NOVEL SALT OF RESOLVIN SCREENING: COMPLIANCE WITH MULTI- ULCERATIVE COLITIS… (3*)|(Funded by E1… (2*)|(This work was funded in part by TARGET… (3*)|(Exact Sciences) Janssen Scientific Affairs, LLC) Thetis Pharmaceuticals.)

Su1661. . . . A FAVORABLE SURVIVAL OF Su1782. . . . REDUCTION OF OPIOID USE Su1802. . . . SLCO2A1 DEFICIENCY THE SCREENING-DETECTED… (5*) AND DEPRESSION… (5*)|(There are no EXACERBATES EXPERIMENTAL COLITIS industry or commercial sources.) VIA… (5*) Su1662. . . . TIME TO DIAGNOSIS OF EARLY- ONSET VS.… (2*) Su1783. . . . RATES OF TREATMENT Su1803. . . . TWEAK/FN14 AMELIORATES INEFFECTIVENESS AFTER INITIATING… (6*)| EXPERIMENTAL ILEITIS BY REGULATING… Su1663. . . . WATER EXCHANGE (WE) (2*) ENHANCED DETECTION OF… (2*)| Su1784. . . . REINVENTING INFLAMMATORY BOWEL DISEASE (IBD) Su1804. . . . THE COMMON IBD Su1664. . . . HIGH YIELD OF TOTAL AND CLINICAL… (5*) COMPLICATIONS IRON DEFICIENCY… (2*) RIGHT-SIDED… (4*) Su1785. . . . RECENT TRENDS IN Su1805. . . . WHEAT AMYLASE/TRYPSIN Su1665. . . . USE OF SCREENING DIAGNOSTIC PREVALENCE AND… (3*) INHIBITORS AGGRAVATE EOSINOPHILIC COLONOSCOPY IN AFRICAN… (5*) ESOPHAGITIS… (2*) Su1786. . . . REDUCTION IN COSTS OF CARE Su1666. . . . PREDICTORS OF MODIFIABLE IN… (3*)|(Project Sor is a joint venture Su1806. . . . BERBERINE REGULATES FAILURES TO SCREEN… (2*) between Blue Cross Illinois, SorMD Inc.) LYSOPHOSPHATIDYLCHOLINE TO PROTECT DSS-INDUCED… (2*)|(This work was kindly Su1667. . . . INCREASING UPTAKE OF Su1787. . . . DEVELOPMENT OF A DEEP funded by grants from tiol tural Science COLON CANCER SCREENING… (5*) LEARNING ALGORITHM… (5*) Foundation of Chi (Project No. 81560676), Logan Charitable Foundation, Hong Kong Su1668. . . . THE CORRELATION OF FIT Su1788. . . . MONITORING RESPONSE TO Baptist University Research Grant (No. LEVELS WITH… (5*)|(The first author ANTI-TNF THERAPY IN… (3*)|(AbbVie LIUYE/15-16/01-CLNC) and Shenzhen completed this research as part of an Deutschland GmbH & Co. KG) Science and Technology Innovation Commi) Newman Fellowship, which was funded by Boston Scientific.) Su1789. . . . PATIENTS WHO UNDERGO Su1807. . . . POST-OPERATIVE RECURRENCE COLECTOMY FOR PEDIATRIC… (2*) AFTER ILEO-CAECAL RESECTION FOR… Su1754. . . . OVERESTIMATION OF THE (5*)|(Lesaffre Intertiol, Lesaffre Group, PREVALENCE OF EOSINOPHILIC… (2*) Su1790. . . . INFLIXIMAB RESCUE LESS Marcq-en-Barœul, France) EFFECTIVE IN PREVENTING… (2*) Su1771. . . . SYSTEMS GENOMICS OF Su1808. . . . DOWNREGULATION OF ULCERATIVE COLITIS: COMBINING… (6*) Su1791. . . . LONGTERM OUTCOME OF RALGTPASE-ACTIVATING PROTEIN LEADS PEDIATRIC PATIENTS WITH… (5*) TO… (2*)|(Japan Society for the Promotion Su1772. . . . INFLAMMATION-DEPENDENT of Science (JSPS) Grants-in-Aid for Scientific TRANSCRIPTIONAL RE-PROGRAMMING OF Su1792. . . . ELEVATION OF PLASMA Research (KAKENHI)) THE HIF… (2*) ONCOSTATIN M IS… (2*)| Su1809. . . . A COMPARISION STUDY OF Su1773. . . . INTESTINAL ORGANOIDS Su1793. . . . TRENDS OF UTILIZATION OF SYSTEMIC VERSUS… (3*)|(Progenity Inc.) DERIVED FROM HUMAN INDUCED… (5*) TUMOR NECROSIS… (7*) Su1810. . . . COMBINATORIAL TREATMENT Su1774. . . . AN INTERPLAY OF PAK1 AND Su1794. . . . PROPOSED MODIFICATION OF WITH A HIF-HYDROXYLASE INHIBITOR… NRF2… (2*) PARIS CLASSIFICATION TO… (2*) (2*)|(Sigmoid Pharma)

Su1775. . . . ARTIFICIAL SWEETENER Su1795. . . . UTILIZATION OF ANTI-TNF Su1811. . . . NOVEL INSIGHT INTO ACESULFAMEPOTASSIUMENHANCED THERAPY (BIOLOGICS) IN… (6*) MECHANISM OF PROTECTIVE… (4*)|(tiol LYMPHOCYTE MIGRATION TO… (4*) Science Centre, Poland (grant number Su1796. . . . ROOM FOR IMPROVEMENT IN UMO-2015/19/B/NZ4/03130).) Su1776. . . . ASSOCIATION OF BIOLOGIC TRANSITION OF… (5*) PRESCRIBING FOR INFLAMMATORY… (5*) Su1812. . . . TREATMENT WITH Su1797. . . . CHILDREN WITH CROHN’S HYDROLYZED DIET SUPPLEMENTED WITH… Su1777. . . . RECEIPT OF PREVENTIVE CARE DISEASE WHO RESPOND… (5*) (3*)|(Bioiberica SAU) SERVICES AMONG… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1813. . . . THERAPEUTIC EFFICACY OF Science Foundation of Guangdong Province, BILE ACID SEQUESTRATION… (2*) Chi grant 2016A030313009; Science and Su1848. . . . CLINICAL CHARACTERISTICS Technology Innovation Commission of AND RISK FACTORS FOR… (5*) Su1814. . . . DETERMINATION OF MINIMAL Shenzhen Municipality, Chi grant EFFICACIOUS DOSES OF… JCYJ20150331142757394.) Su1849. . . . RISK OF NEW OR RECURRENT (3*)|(Karyopharm Therapeutics) CANCER… (5*) Su1832. . . . INHIBITION OF INTESTINAL Su1815. . . . GRAPE SEED EXTRACT AND EPITHELIAL CELL PYROPTOSIS… Su1850. . . . RATE OF SERIOUS INFECTION EMU OIL… (4*) (3*)|(Takeda Pharmaceutical Company Ltd) IN ELDERLY… (4*)

Su1816. . . . PROTECTION BY CCR6 Su1833. . . . ELEVATED CAP-D3 LEVELS IN Su1851. . . . ANTI-TNF INDUCED BLOCKADE IN A… (4*) INTESTINAL EPITHELIAL… (2*) LYMPHOCYTOSIS IN PATIENTS WITH… (5*)

Su1817. . . . BIOTIN SUPPLEMENTATION Su1834. . . . REDUCED AQUAPORIN 5 Su1852. . . . POST-OPERATIVE AMELIORATES MURINE COLITIS BY… (2*) EXPRESSION IN COLORECTAL… (4*) COMPLICATIONS FOLLOWING ELECTIVE SURGERY IN… (5*) Su1818. . . . PRECLINICAL EFFICACY AND Su1835. . . . VEDOLIZUMAB USE IS NOT SAFETY OF NX-13:… (5*) ASSOCIATED WITH… (3*)|(Medical writing Su1853. . . . TUBERCULOSIS INFECTION assistance was provided by Fraser Harris of UNDER ANTI-TNF THERAPY –… (5*) Su1819. . . . NEW CLASS OF ANTI- Oxford PharmaGenesis, Oxford, UK, and INFLAMMATORY THERAPEUTICS BASED… was supported by Takeda Pharmaceutical Su1854. . . . PROFILE OF PATIENTS WITH (2*)|(Inwex Ltd. is an employer of Company Ltd.) INFLAMMATORY BOWEL… (5*) Remigiusz Szczepaniak) Su1836. . . . HIGH EXPOSURE TO Su1855. . . . VEDOLIZUMAB IS NOT Su1820. . . . THE EFFECT OF PROBIOTIC INFLIXIMAB IS ASSOCIATED… (5*) ASSOCIATED WITH INCREASED… (5*) LACTOBACILLUS CASEI… (1*)|(PROGRES Q40-15 from Charles University.) Su1837. . . . HIGHER DISCONTINUATION Su1856. . . . A PILOT STUDY COMPARING RATES OF ANTI-TNF THERAPY… (2*)|(The POSTOPERATIVE OUTCOMES… (5*) Su1821. . . . TARAXACUM OFFICINALE IBDREAM registry is facilitated by Janssen, EXTRACTS AMELIORATES MURINE Pfizer, MSD, Takeda, Celgene, AbbVie, Su1857. . . . COMPARATIVE SAFETY AND EXPERIMENTAL… (2*) DrFalk, MundiPharma.) EFFECTIVENESS OF TUMOR… (5*)

Su1822. . . . NP-120 AND NP-178: Su1838. . . . COMPARATIVE RISK OF Su1858. . . . REAL-WORLD EFFECTIVENESS REPURPOSED NEUROLOGICAL DRUGS… SERIOUS INFECTIONS WITH… (2*) AND SAFETY OF VEDOLIZUMAB… (3*)|(The (3*)|(SH Pharmaceuticals (a subsidiary of study was sponsored by Takeda Breathtec Biomedical Inc.)) Su1839. . . . RISKS OF CANCERS IN Pharmaceuticals Company Ltd. Evidera was THIOPURINES USERS… (5*) funded by Takeda Pharmaceuticals Su1823. . . . TRADITIONAL CHINESE Company Ltd to conduct this study and MEDICINE-DERIVED MIR5368 ALLEVIATES Su1840. . . . HIGHER ADALIMUMAB SERUM provide medical writing assistance. The ULCERATIVE… (2*) LEVELS DO NOT… (4*) abstract was prepared by Evidera; no additiol medical writing assista) Su1824. . . . EFFECT OF ZOFENOPRIL ON Su1841. . . . FACTORS ASSOCIATED WITH ACETIC ACID-INDUCED… (2*) WEIGHT GAIN IN… (5*) Su1859. . . . REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB… (3*)|(This Su1825. . . . FIBROBLAST GROWTH FACTOR Su1842. . . . CHARACTERISTICS OF study was sponsored by Takeda 21 DEPLETION ATTENUATES… (2*) HEPATOSPLENIC T-CELL LYMPHOMA IN… Pharmaceuticals Company Ltd. Evidera was (3*)|(Janssen Scientific Affairs, LLC funded by Takeda Pharmaceuticals Su1826. . . . SMALL INTESTINAL EPITHELIAL supported this study) Company Ltd to conduct this study and MICROVILLI-ASSOCIATED DEFECTS provide medical writing assistance. The PRESENT… (2*)| Su1843. . . . SAFETY AND EFFICACY OF abstract was prepared by Evidera; no GLUCAGON-LIKE-PEPTIDE-2 ANALOGUE… additiol medical writing assist) Su1827. . . . ORGANOIDS DERIVED FROM (5*) INFLAMED AND NON… (4*) Su1860. . . . COMPARISON OF REAL- Su1844. . . . HEMOPHAGOCYTIC WORLD TREATMENT OUTCOMES WITH… Su1828. . . . MIR-124 MEDIATES THE LYMPHOHISTIOCYTOSIS IN (3*)|(This study was sponsored by Takeda IMPAIRMENT OF INTESTINAL… (2*) INFLAMMATORY BOWEL DISEASE… (5*) Pharmaceutical Company, Ltd.)

Su1829. . . . LACTOBACILLUS ACIDOPHILUS Su1845. . . . HOME INFUSION OF BIOLOGIC Su1861. . . . COMPARATIVE EFFICACY AND CAUSES AN ENHANCEMENT OF… (2*) MEDICATIONS IN… (5*) SPEED OF ONSET… (1*)

Su1830. . . . INDUCIBLE NITRIC OXIDE Su1846. . . . OUTCOMES OF PREGNANCY IN Su1862. . . . LOW-DOSE METHOTREXATE IS MEDIATED PHOSPHORYLATION IBD PATIETNS… (5*) EQUALLY EFFECTIVE AS… (5*) REGULATES… (2*) Su1847. . . . RAPID 30-MINUTE INFLIXIMAB Su1863. . . . COMPARATIVE EFFICACY OF Su1831. . . . ACTIVATION OF ADENOSINE INFUSION PROTOCOLS ARE… (1*)|(This VEDOLIZUMAB AND ADALIMUMAB… (5*) A3 RECEPTOR INHIBITS… (2*)|(tural research was supported by a Pfizer Grant.)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1864. . . . THE FRAGILITY OF LANDMARK Su1884. . . . COMBINED RNASEQ AND Su1902. . . . PHOSPHATASE SHP2 RANDOMIZED TRIALS… (5*) CYTOF ANALYSIS OF… (4*)|(CCFA CDA) EXACERBATES INTESTINAL INFLAMMATION BY… (2*) Su1865. . . . REAL-WORLD SHORT-TERM Su1885. . . . ANALYSIS OF HUMAN EFFECTIVENES OF USTEKINUMAB IN… (5*) COLONIC TISSUE AND… (2*)| Su1903. . . . EARLY MEASUREMENT OF SERUM CYTOKINES AS… (4*) Su1866. . . . INTEGRATING EFFICACY AND Su1886. . . . SACRAL NERVE STIMULATION SAFETY OF VEDOLIZUMAB… (3*)|(Takeda) INHIBITS THE MAPK/NF-KB… (5*) Su1904. . . . SELECTIN-INHIBITION BY DOUBLY GLYCOSYLATED LYSOZYME Su1867. . . . SUSTAINANILITY OF BIOLOGIC Su1887. . . . ENDOGENOUS OPIOIDS IN MUTANTS… (5*) THERAPIES IS LESS… (5*) CHRONIC COLITIS INDUCE… (6*) Su1905. . . . B2 STRICTURING BEHAVIOR Su1868. . . . COMPARATIVE EFFICACY AND Su1888. . . . ESTROGEN RECEPTOR β ASSOCIATED WITH TGF… (2*) SAFETY OF PROBIOTICS… (5*) ACTIVATION INHIBITS INFLAMMATION… (2*) Su1906. . . . MARKERS FOR SEVERE, Su1869. . . . EFFECT OF THALIDOMIDE ON REFRACTORY CROHN’S DISEASE… (4*) CLINICAL REMISSION… (5*) Su1889. . . . T HELPER 2 (TH2)-MEDIATED REGULATION OF… (2*) Su1907. . . . DIAGNOSTIC ACCURACY OF Su1870. . . . IDENTIFYING THE OPTIMAL THE SERUM-BASED MUCOSAL… (4*)|(This TREATMENT SEQUENCE WITH… (3*)|(This Su1890. . . . PREDICTED FECAL study was supported in part by a research was funded by an investigator- MICROBIOTA SIGNATURES ARE collaborative grant from Prometheus initiated grant from Janssen ASSOCIATED… (2*) Laboratories Inc, and grants to Drs. Pharmaceuticals) Sandborn and Dulai from the Litwin IBD Su1891. . . . MONOCYTE/MACROPHAGE Pioneers Program and American College of Su1871. . . . CURCUMIN USE IN PHENOTYPIC ALTERATION WITH Gastroenterology Clinical Research Award. ULCERATIVE COLITIS -… (5*) ENHANCED PRO-INFLAMMATORY… (2*) Serum assays for the)

Su1872. . . . EVALUATION OF REAL-WORLD Su1892. . . . PERIOSTIN PROMOTES Su1908. . . . A VALIDATED SERUM MAINTENANCE DOSING FOR… ENDOPLASMIC RETICULUM STRESS- HEADSPACE METABOLOME PROFILE… (4*) (3*)|(Funded by Janssen Scientific Affairs MEDIATED FIBROSIS… (6*) LLC, USA.) Su1909. . . . PREDICTING ENDOSCOPIC Su1893. . . . LYSOPHOSPHATIDYLSERINE RESPONSE IN USTEKINUMAB TREATED… Su1873. . . . REMISSION TO VEDOLIZUMAB DETERIORATES MURINE TNBS-INDUCED (4*)| IS NOT HIGHER… (5*) COLITIS… (5*) Su1910. . . . A NOVEL QUANTITATIVE Su1874. . . . SUBCUTANEOUSLY Su1894. . . . THE JAK INHIBITOR- PROTEIN EXPRESSION PROFILE… ADMINISTERED ANTI-TNFS FOR THE TOFACITINIB INHIBITS SIGNALING (2*)|(nostring Technologies participated in TREATMENT… (3*)|(Janssen Inc.) PATHWAYS… (3*)|(Pfizer provided support this research under their Technology Access for the study through an independent Program (TAP).) Su1875. . . . DEVELOPMENT OF TARGETED research grant) THERAPEUTIC ANTIBODIES FOR… Su1911. . . . IDENTIFICATION OF SERUM (3*)|(Progenity Inc.) Su1895. . . . TARGETING AMPKβ1 AS A PROTEIN BIOMARKERS FOR… (6*) NOVEL STRATEGY… (4*) Su1876. . . . INFLIXIMAB INDUCTION Su1912. . . . A SEROLOGICAL BIOMARKER REGIMES IN STEROID REFRACTORY… (5*) Su1896. . . . RECOMBINANT RNASET2 OF TYPE VIII… (3*)|(Nordic Bioscience A/S) MODULATES IFNγ SECRETION: A… (2*) Su1877. . . . IMPACT OF Su1913. . . . ANTI-MAA IMMUNOSUPPRESSIVE THERAPY ON THE… Su1897. . . . INTESTINAL IMMUNE (MALONDIALDEHYDE-ACETALDEHYDE (5*) CONDITIONING WITH HELMINTHS ADDUCTS) IMMUNOGLOBULIN ISOTYPES EMPLOY… (2*) IN… (4*) Su1878. . . . INTERLEUKIN-33 DELAYS RECOVERY OF MUCOSAL Su1898. . . . HEPATOCYTE GROWTH Su1914. . . . ASSOCIATION BETWEEN INFLAMMATION… (4*) FACTOR AND MET, NOVEL… (4*) SEROLOGICAL MARKERS AND RATE… (5*)

Su1880. . . . SECONDARY BILE ACIDS Su1899. . . . EXPRESSION PROFILES OF Su1915. . . . METABOLOMICS UNCOVERS PROTECT AGAINST INTESTINAL… (6*) HELPER T-CELL-RELATED GENES… (5*) UNIQUE DISEASE SIGNATURES IN… (2*)

Su1881. . . . THE NUCLEAR RECEPTOR LRH-1 Su1900. . . . DIFFERENCES IN Su1916. . . . ABSENCE OF PERIANAL IS A… (2*) INFLAMMATION-RELATED GENE SYMPTOMS DOES NOT… (5*) EXPRESSION IN… (3*)|(GlaxoSmithKline Su1882. . . . CYCLIC GMP-AMP SYNTHASE Investigator Initiated Grant) Su1917. . . . CLINICAL AND ENDOSCOPIC (CGAS) PLAYS A… (2*) FEATURES OF XIAP… (5*) Su1901. . . . SPECIFIC ISOFORMS OF THE Su1883. . . . COLON IL-33 IS PRIMARILY LONG NON-CODING… (4*) Su1918. . . . A 1-YEAR CROSS-SECTIONAL PRODUCED BY… (2*) INFLAMMATORY BOWEL DISEASE… (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1919. . . . MONITORING VITAMIN D Su1962. . . . DOES HIGHER SERUM METABOLISM IN INFLAMMATORY… Su1942. . . . CRYPTOSPORIDIUM PARVUM PROCALCITONIN LEVELS PREDICT… (5*) (3*)|(Immundiagnostik AG, Bensheim, INFECTION INDUCES AUTOPHAGY IN… (2*) Germany) Su1963. . . . AMINO ACID SENSING IS AN Su1943. . . . LONG-TERM EHEC INFECTION ESSENTIAL… (2*) Su1920. . . . PHENOTYPE CLASSIFYING STIMULATES MUCUS PRODUCTION… (5*) CROHN'S DISEASE INTO ILEAL… (2*) Su1964. . . . THE FOOD ADDITIVE EDTA Su1944. . . . METASTATIC ASSOCIATED INCREASES INTESTINAL… (7*) Su1921. . . . VALIDATION OF SCORING COLON CANCER 1 (MACC1)… (2*) SYSTEMS FOR DIFFERENTIATING… (5*) Su1965. . . . CROHN'S LIKE LYMPHOID Su1945. . . . DIFFERENTIAL RESPONSE OF REACTION IS ASSOCIATED… (5*) Su1922. . . . PERFORMANCE OF A NOVEL INTESTINAL EPITHELIAL CELLS… (6*) FECAL CALPROTECTIN… (3*) Su1966. . . . NOVEL EVIDENCE FOR SERUM Su1946. . . . DISRUPTION OF INTESTINAL MIR-203 LEVELS… (4*) Su1923. . . . NOVEL ASSOCIATIONS OF EPITHELIUM WITH THE… (2*) PLATELETS WITH CLINICAL… (2*) Su1967. . . . HIGH RIBOFLAVIN INTAKE Su1947. . . . HYA, A METABOLITE OF PROTECTS AGAINST SESSILE… (2*) Su1924. . . . THE USE OF ALVIMOPAN AS LINOLEIC ACID… (5*) PROPHYLAXIS… (5*) Su1968. . . . INCREASED PREVALENCE OF Su1948. . . . CHARACTERISTICS AND TYPE 2 DIABETES… (2*) Su1925. . . . NON-ADHERENCE TO INFLUENCING FACTORS OF GUT… (5*) MAINTENANCE MEDICATIONS IS Su1969. . . . PSOAS MUSCLE INDEX AFFECTS COMMON… (2*) Su1949. . . . SMALL INTESTINAL ASPIRATES THE LONG-TERM… (5*) REQUIRE SPECIFIC TREATMENT… (4*) Su1926. . . . RISK OF INFECTIONS AND Su1970. . . . THE ASSOCIATION OF LACTOSE HOSPITALISATIONS IN… (5*) Su1950. . . . RISK FACTORS FOR CENTRAL INTOLERANCE WITH… (5*) LINE-ASSOCIATED BLOODSTREAM… (5*) Su1927. . . . CONTINUING 5-ASA THERAPY Su1971. . . . ASSOCIATION BETWEEN IN MODERATE-TO-SEVERE ULCERATIVE… Su1951. . . . GLOBAL DISPARITIES AND SARCOPENIA AND GASTRIC (4*) NEW INDICATIONS IN… (5*) CARCINOGENESIS:… (5*)

Su1928. . . . TOFACITINIB IMPROVES Su1952. . . . PATIENTS’ PERSPECTIVE AND Su1972. . . . GASTRIC MICROBIOME IN CLINICAL DISEASE ACTIVITY IN… (5*) COMPLIANCE AFFECT THE… (1*) PATIENTS WITH INTESTINAL… (2*)

Su1929. . . . OUTCOMES FOLLOWING Su1953. . . . PATIENT PERCEPTIONS OF Su1973. . . . CAN INTRAGASTRIC BALLOON INTRAVENOUS STEROID USE IN… (5*) FECAL MICROBIOTA TRANSPLANTATION… THERAPY NORMALIZE THE… (5*) (5*) Su1930. . . . SAFETY AND EFFICACY OF Su1974. . . . FECAL MICROBIOTA OLORINAB, A… (3*)|(Are Pharmaceuticals, Su1954. . . . LONG-TERM EFFICACY OF TRANSPLANT IN GRAFT VERSUS… (5*) Inc.) RIFAXIMIN TO MANAGE… (1*) Su1975. . . . GERM-FREE C57BL/6 MICE ARE Su1931. . . . DOES CORTICOSTEROID Su1955. . . . CLOSTRIDIUM DIFFICILE- SUSCEPTIBLE TO… (4*) THERPAY AFFECT PROGNOSIS IN… (5*) ASSOCIATED OUTCOMES AMONG HOSPITALIZED INFLAMMATORY… (5*) Su1976. . . . IMPACTS OF ADDITIVE FOOD Su1932. . . . SAFETY OF RECOMBINANT E171 (TITANIUM… (4*) ZOSTER VACCINE (RZV-SHINGRIX)… (5*) Su1956. . . . IS DIARRHEA THE ONLY SYMPTOM OF… (5*) Su1977. . . . THE SAFETY AND EFFICACY OF Su1933. . . . ANTI-MYCOBACTERIUM FECAL… (5*) PARATUBERCULOUS THERAPY IN CROHN’S Su1957. . . . CLOSTRIDIUM DIFFICILE DISEASE:… (5*) SCREENING IN HOSPITALIZED PATIENTS… Su1978. . . . ASSOCIATION OF (5*) FUSOBACTERIUM NUCLEATUM IN Su1934. . . . SAFETY OF GRANULOCYTE COLORECTAL… (2*) AND MONOCYTE ADSORPTIVE… (3*) Su1958. . . . GEOSPATIAL DISTRIBUTION AND TRENDS IN COMMUNITY… (5*) Su1979. . . . UPREGULATED CLAUDIN-1 Su1935. . . . SAFETY AND EFFECTIVENESS EXPRESSION INDUCES GUT DYSBIOSIS… OF GRANULOCYTE AND… (3*) Su1959. . . . TRENDS IN INCIDENCE, (2*)| MORTALITY, AND COSTS… (5*) Su1936. . . . ENDOSCOPIC EVALUATION Su1980. . . . THE NETWORK FOR GASTROINTESTINAL GRAFT-VERSUS- Su1960. . . . ASSESSMENT OF CLOSTRIDIUM CONSTRUCTION AND MODULE HOST DISEASE:… (5*) DIFFICILE EPIDEMIOLOGY AMONG… ORGANIZATION… (2*) (7*)|(Merck Cada) Su1937. . . . THE MANITOBA LIVING WITH Su1981. . . . INDUCTION OF SPECIFIC IBD STUDY:… (2*) Su1961. . . . COST-EFFECTIVENESS OF CARCINOGENIC MICRO-RNAS TREATMENT REGIMENS FOR EXPRESSION… (2*) Su1941. . . . HELICOBACTER PYLORI CAGA CLOSTRIDIUM… (2*) PROTEIN NEGATIVELY REGULATES… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su1982. . . . MUCOSA-ASSOCIATED Su2003. . . . MICROENCAPSULATED MICROBIOTA IN THE UPPER GUT… (1*) SODIUM BUTYRATE SIGNIFICANTLY Su2025. . . . SHOULD A DIAGNOSIS OF MODIFIES THE… (4*) CANCER PRECLUDE… (5*) Su1983. . . . LACK OF PREVENTIVE DENTAL CARE IS… (2*) Su2004. . . . DISRUPTION OF CIRCADIAN Su2026. . . . HOME PARENTERAL RHYTHM REDUCES THERMOGENESIS… (2*) NUTRITION (HPN): INDICATIONS FOR… (5*) Su1984. . . . THE DIFFERENCE OF GUT MICROBIOME IN… (5*) Su2005. . . . AGE-RELATED Su2027. . . . PERCUTANEOUS DYSMETABOLISM IS ASSOCIATED WITH TRANSESOPHAGEAL GASTRO-TUBING AS Su1985. . . . PRELIMINARY DATA ON ORAL CHANGES… (2*) AN ALTERNATIVE… (5*) AND FECAL… (5*) Su2006. . . . FUSOBACTERIUM NUCLEATUM Su2028. . . . NATURAL HISTORY OF Su1986. . . . GUT DYSBIOSIS INDUCED MAY PROMOTE GLYCOLYSIS VIA… (2*) PERCUTANEOUS ENTERAL ABNORMAL BILE ACIDS… (5*) GASTROSTOMY… (5*) Su2008. . . . MECHANISM OF INHIBITION Su1987. . . . THE CHANGE OF THE GUT OF VILLUS CELL… (2*) Su2029. . . . USEFULLNESS OF BRANCHED- MICROBIOTA… (5*) CHAIN AMINO ACID-ENRICHED ENTERAL… Su2009. . . . NUTRITIONAL ASSESSMENT IN (5*) Su1988. . . . MUCOSA-ASSOCIATED PATIENTS UNDERGOING GASTRIC… (5*) MICROBIOTA DIVERSITY SIGNIFICANTLY Su2039. . . . USE OF PATIENT-DERIVED DIFFERS IN… (5*) Su2010. . . . MORTALITY AND OUTCOMES TUMOR XENOGRAFT MODEL… (1*) IN PATIENTS WITH… (3*)|(Study funding Su1989. . . . ASSOCIATIONS BETWEEN provided by Shire) Su2040. . . . DIVERSE TUMOR GASTROESOPHAGEAL HISTOPATHOLOGY SUSCEPTIBILITY IN COLLABORATIVE AND THE… (5*) Su2011. . . . SHORT BOWEL SYNDROME CROSS… (2*) PATIENTS WITH RESIDUAL… (2*) Su1990. . . . FUSOBACTERIUM NUCLEATUM Su2042. . . . DERIVATION OF INFECTION ASSOCIATES WITH TWO… (2*) Su2012. . . . ETIOLOGY OF AND PREDICTIVE OESOPHAGEAL ORGANOIDS TO FACTORS FOR… (5*) RECAPITULATE… (7*) Su1991. . . . DIFFERENCES IN THE GASTROESOPHAGEAL MICROBIOME AND… Su2013. . . . EFFECTS OF GLEPAGLUTIDE, A Su2043. . . . A NOVEL CANINE INTESTINAL (2*) NOVEL LONG-ACTING… (3*)|(The trial was ORGANOID MODEL… (4*) sponsored by Zealand Pharma, Denmark.) Su1992. . . . INFECTION BY PATHOGENIC E. Su2044. . . . EXOSOMES RELEASED FROM COLI INDUCES… (2*) Su2014. . . . HOME PARENTERAL PATIENT-DERIVED ORGANOIDS CONTAIN… NUTRITION PATIENTS WITH SEVERE… (5*) (2*)|(This study was supported by JSPS Su1993. . . . DIET AND OBESITY RATHER KAKENHI Grant number JP18K15803.) THAN ETHNICITY… (4*) Su2015. . . . EFFECT OF APRAGLUTIDE, A NOVEL LONG-ACTING… (3*) Su2045. . . . VASCULAR SHUT DOWN Su1994. . . . THE COMMON FOOD EFFECTS OF PHOTODYNAMIC… (5*) ADDITIVES SODIUM SULFITE… (6*) Su2016. . . . ADIPOSE-DERIVED SECRETOME (ADS) MEDIATES THE STIMULATION… (2*) Su2046. . . . MORPHOLOGIC DIFFERENCE Su1995. . . . HIGH-FAT DIET-INDUCED GUT OF PATIENTS-DERIVED IMMORTAL MICROBIOTA DYSBIOSIS PROMOTE… (2*) Su2018. . . . LONG NON-CODING RNA ESOPHAGEAL… (2*) ZFAS1 PROMOTES PROLIFERATION… (2*) Su1996. . . . ALTERED GUT MICROBIOTA Su2047. . . . FUNCTIONAL LUMEN IMAGING INDUCED BY A… (2*) Su2019. . . . INTESTINAL GROWTH IN PROBE IS USEFUL… (5*) GLUCAGON RECEPTOR KNOCKOUT… (6*) Su1997. . . . COCONUT OIL DIET AS Su2048. . . . ENDOSCOPIC RETEROGRADE ADJUVANT FOR… (2*) Su2020. . . . NUTRITIONAL CARE APPENDICOGRAPY: AN EFFECTIVE PATHWAYS OF PATIENTS WITH… DIAGNOSTIC… (5*) Su1998. . . . EARLY LIFE SOLID FOOD (3*)|(THIS RESEARCH WAS FUNDED BY INGESTION REMODELS… (5*) CALEA, FRESENIUS KABI, UK.) Su2049. . . . NONINVASIVE POINT-OF-CARE MEASUREMENT OF GUT PERMEABILTIY… Su1999. . . . THE EFFECT OF DIETARY FIBER Su2021. . . . IS HOME PARENTERAL (6*)|(Support received from MediBeacon INTAKE… (2*) NUTRITION BURDERSOME IN… (3*)|(Calea- Inc.) Fresenius Kabi) Su2000. . . . CROHN'S DISEASE PATIENTS IN Su2050. . . . NEAR INFRARED (NIR) REMISSION CONSUMING… (6*) Su2022. . . . TOLERANCE AND OUTCOME FLUORESCENCE READOUTS OF… OF NUTRITION SUPPORT… (5*) (3*)|(Abbvie) Su2001. . . . EFFECT OF A MODIFIED AMERICAN DIET… (2*) Su2023. . . . A RETROSPECTIVE STUDY ON Su2051. . . . INTRACOLIC MOLECULAR ICU ADMISSION… (5*) ULTRASOUND IMAGING FOR NON- Su2002. . . . ALTERATIONS IN THE SMALL INVASIVE… (5*) BOWEL MICROBIOTA… (4*) Su2024. . . . USE OF PREOPERATIVE TOTAL PARENTERAL NUTRITION… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Su2052. . . . ABILITY OF DWI TO Mo1117. . . . GAVAGE AS-MIR-214-3P CHARACTERIZE BOWEL… (5*) Mo1009. . . . USE OF COMMUNITY HEALTH REDUCES INFLAMMATION IN WORKERS IN… (6*) EXPERIMENTAL… (2*) Su2053. . . . MUCOSAL INTEGRITY TESTING IS A POTENTIAL… (5*) Mo1010. . . . INCREASING INCIDENCE OF Mo1118. . . . PRESERVATION OF JEJUNAL STAGE I PANCREATIC… (5*) ACTIVE INTESTINAL STEM… (2*) Su2054. . . . ASSESSMENT OF ENDOSCOPIC BAND LIGATION IN… (5*) Mo1011. . . . UTILIZING SOCIAL MEDIA TO Mo1119. . . . THE ROLE OF EXTRACELLULAR SHARE SCIENTIFIC… (4*)|(5) DNA IN… (2*) Su2055. . . . CHARACTERIZING INTESTINAL STRICTURES OF CROHN'S DISEASE… (2*) Mo1100. . . . HYPERURICEMIA Mo1120. . . . A TRIAL FOR THE AMELIORATES INTESTINAL ADMINISTRATION OF… (5*) Su2056. . . . CLINICAL SIGNIFICANCE OF INFLAMMATION ALONG WITH… (4*) ROBOT CAPSULE ENDOSCOPY… (2*) Mo1121. . . . PH-DEPENDENT G PROTEIN- Mo1101. . . . SUPERIOR MESENTERIC VEIN COUPLED RECEPTOR GPR68 (OGR1)… (2*) Su2057. . . . DIAGNOSTIC YIELD OF OCCLUSION IN RATS… (4*) VOLUMETRIC LASER ENDOMICROSCOPY… Mo1122. . . . GENE EXPRESSION PROFILING (5*) Mo1102. . . . ASPIRIN AND ISCHEMIA IN AND FLOW CYTOMETRY… (4*) THE MURINE… (4*) Su2058. . . . INTERPRETATION OF Mo1126. . . . RAPID RECURRENCE OF VOLUMETRIC LASER ENDOMICROSCOPY Mo1103. . . . RESTRICTIVE EXPRESSION OF SYMPTOMS, ENDOSCOPIC FINDINGS,… (2*) IN… (5*) METALLOENDOPEPTIDASE ADAM-LIKE DECYSIN… (2*) Mo1127. . . . MAST CELLS IN ADDITION TO Su2059. . . . NOVEL MULTI-VIEW IMAGING EOSINOPHILS… (3*)|(Allakos, Inc. This DEVICE TO IMPROVE… (2*) Mo1104. . . . THE TRANS-GOLGI NETWORK work was also funded in part by the Division PROTEIN AFTIPHILIN REGULATES… (2*) of Intramural Research, NIAID, NIH) Su2060. . . . A NEW SECOND GENERATION ENDOSCOPE FOR… (4*)|(FUJI FILM) Mo1106. . . . IMMUNOLOGIC DISSECTION Mo1128. . . . VONOPRAZAN SHOWS OF COLITIS RELATED TO… (2*) EFFICACY SIMILAR TO THAT… (5*) Su2061. . . . A MULTI-SPECTROSCOPIC APPROACH TO DISEASE DIAGNOSIS:… (4*) Mo1107. . . . IRON PREVENTS HYPOXIA- Mo1129. . . . EFFICACY OF BUDESONIDE INDUCED INFLAMMATION IN THE… (2*) ORODISPERSIBLE TABLETS FOR… (3*)|(This Su2062. . . . MEASUREMENT OF MUCOSAL study was funded by Dr. Falk Pharma MITOCHONDRIAL OXYGEN DURING… (6*) Mo1108. . . . RESCUE OF RESTITUTION GmbH, Freiburg, Germany) DEFECT IN A… (2*) Su2063. . . . COLITIS ON CT – DOES THIS… Mo1130. . . . BUDESONIDE (5*) Mo1109. . . . SEVERE WOUND ORODISPERSIBLE TABLETS CAN CONTRACTION PROMOTES BARRETT'S EFFECTIVELY INDUCE… (3*)|(This study was Mo1000. . . . IMPACT OF A CITYWIDE ESOPHAGUS… (1*) funded by Dr. Falk Pharma GmbH, Freiburg, BENCHMARKING INTERVENTION… (2*) Germany.) Mo1110. . . . ER STRESS PATHWAY Mo1001. . . . COLORECTAL CANCER RISK ACTIVATION AFTER DOXORUBICIN… (2*) Mo1131. . . . CLINICAL AND ENDOSCOPIC FACTORS ACCORDING TO… (5*) CHARACTERISTICS ACCURATELY PREDICT… Mo1111. . . . THE METFORMIN INHIBITS (2*) Mo1002. . . . THE IMPACT OF A TAILORED MDSC AND M2… (5*) INTERVENTION… (5*) Mo1132. . . . DIETARY ELIMINATION Mo1112. . . . MICRORNA-24 IS THERAPY IS EFFECTIVE FOR… (2*) Mo1003. . . . BREATH ANALYSIS CAN BE OVEREXPRESSED IN ULCERATIVE COLITIS… USED TO… (3*)|(The eNose company (2*) Mo1133. . . . HIGH PATIENT-REPORTED supplied the eNose devices free of charge.) DISEASE BURDEN FOR EOSINOPHILIC… (2*) Mo1113. . . . 3-OXO-C12:2 N-ACYL Mo1004. . . . IMPACT OF FIT CUT-OFF HOMOSERINE LACTONE, A QUORUM… (4*) Mo1134. . . . ESOPHAGEAL LICHEN VALUES ON… (5*) PLANUS: DIAGNOSTIC CRITERIA AND… (5*) Mo1114. . . . DOXORUBICIN EXPOSURE Mo1005. . . . HEARTBURN AND THE DECREASES INTESTINAL EPITHELIAL Mo1135. . . . ROLE OF REFLUX IN THE AMERICAN COLLEGE OF… (5*) BARRIER… (2*) PATHOGENESIS… (5*)

Mo1006. . . . OBSTRUCTION AND Mo1115. . . . PRO-INFLAMMATORY AND Mo1136. . . . EOSINOPHIL COUNT ON PERFORATION AS INITIAL PRESENTATION… PRO-FIBROTIC STEM CELL VARIANTS… (2*) BASELINE ENDOSCOPY PREDICTS… (5*) (6*) Mo1116. . . . MOLECULAR Mo1137. . . . QUALITY IMPROVEMENT IN Mo1007. . . . IDENTIFICATION OF RISK CHARACTERIZATION OF COLONIC MAIT THE MANAGEMENT OF… (5*) FACTORS FOR EARLY… (5*) CELLS… (4*) Mo1138. . . . A COMPREHENSIVE Mo1008. . . . SCREENING FOR HEAD AND ASSESSMENT OF EOSINOPHILIC NECK SECOND… (5*) OESOPHAGITIS… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1139. . . . CAN IGG4 BE USED AS AN… Mo1159. . . . LYMPHOCYTIC ESOPHAGITIS: Mo1259. . . . ANTEGRADE DEEP (5*) A CASE SERIES OF… (5*) ENTEROSCOPY SHOULD BE CONSIDERED… (5*) Mo1140. . . . EOSINOPHILIC OESOPHAGITIS Mo1160. . . . EATING BEHAVIOR IN IN CHILDREN AND ADULTS:… (5*) PATIENTS WITH EOSINOPHILIC… (6*) Mo1260. . . . MANAGEMENT OF ACUTE GASTROINTESTINAL BLEEDING IN… (5*) Mo1141. . . . FECAL EOSINOPHIL CATIONIC Mo1161. . . . THE ENDOSCOPIC BURDEN OF PROTEIN AS POTENTIAL… (5*) EOSINOPHILIC ESOPHAGITIS… (5*) Mo1261. . . . ENDOSCOPIC AND CLINICAL MANAGEMENT OF GASTROINTESTINAL… Mo1142. . . . ACHALASIA IS A COMMON Mo1162. . . . THE ENDOSCOPICALLY (5*) FINDING IN… (5*) NORMAL ESOPHAGUS IN EOSINOPHILIC… (2*) Mo1262. . . . ADHERENCE TO LOWER Mo1143. . . . ESOPHAGEAL MOTILITY GASTROINTESTINAL HEMORRHAGE DISORDERS IN EOSINOPHILIC Mo1163. . . . EG AND EOE PATIENT GUIDELINES… (5*) ESOPHAGITIS… (5*) BIOPSIES HAVE… (3*)|(Allakos, Inc.) Mo1263. . . . ACUTE UPPER Mo1144. . . . EOSINOPHILIC Mo1164. . . . THE UTILITY OF EPITHELIAL GASTROINTESTINAL BLEEDING: GASTROINTESTINAL DIESEASE FOLLOWING EOSINOPHILIC DERIVED… (1*) EVALUATING PHYSICIAN… (2*) INTESTINAL TRANSPLANT… (5*) Mo1165. . . . THE THIAZOLIDINEDIONES AS Mo1264. . . . HELICOBACTER PYLORI Mo1145. . . . EOSINOPHILIC ESOPHAGITIS POTENTIAL THERAPEUTIC AGENTS… (2*) INFECTION DECREASES NA,K-ATPASE IS ASSOCIATED WITH A… (5*) EXPRESSION… (2*) Mo1166. . . . DISRUPTION OF ESOPHAGEAL Mo1146. . . . CLINICAL MANIFESTATION, EPITHELIAL BARRIER FUNCTION… (5*) Mo1265. . . . DYSBIOSIS OF THE GASTRIC COURSE OF DISEASE AND… (5*) MICROBIOTA IN… (2*) Mo1167. . . . EFFECT OF VARYING TIME Mo1147. . . . ASSOCIATION OF ALLERGENIC INTERVALS ON… (4*) Mo1266. . . . SOCIO-ENVIRONMENTAL HOUSING COMPOUNENTS AND… (2*) FACTORS AND COLOMBIAN HOST GENE… Mo1168. . . . SERUM MILK-SPECIFIC IGG4 (2*) Mo1148. . . . ESOPHAGEAL LAMINA LEVELS ARE ASSOCIATED… (2*) PROPRIA FIBROSIS OCCURS IN… (4*) Mo1267. . . . ROLE OF IL-22 IN Mo1169. . . . AUTOMATED ANALYSIS OF HELICOBACTER PYLORI-INDUCED… (2*) Mo1149. . . . PREVALENCE OF EOSINOPHIL PEROXIDASE FOR… (2*) EOSINOPHILIC ESOPHAGITIS IN CROHN'S… Mo1268. . . . VITAMIN K DEFICIENCY IN (5*) Mo1249. . . . INVESTIGATING THE ROLE OF ANTIBIOTIC-TREATED, H.… (2*) INTEGRINS IN… (2*) Mo1150. . . . SUBSTANTIAL BURDEN OF Mo1269. . . . DEVELOPMENT OF PSYCHIATRIC COMORBIDITIES AND… (5*) Mo1250. . . . CONTRIBUTION OF THE NEOPLASIA IN THE ABSENCE… (2*) INTESTINAL EPITHELIUM IN… (2*) Mo1151. . . . PSYCHIATRIC COMORBIDITY Mo1270. . . . PARACRINE LOOPS BETWEEN IS ASSOCIATED WITH DEMOGRAPHIC… (5*) Mo1251. . . . NATIONAL TRENDS AND HELICOBACTER PYLORI, FIBROBLASTS… OUTCOMES OF GASTROINTESTINAL… (5*) (4*)|(This study receives funding from Mo1152. . . . VALIDATION OF A MODEL TO Jagiellonian University Medical College PREDICT… (2*) Mo1252. . . . A COMPARISON OF LOGISTIC (statutory grant).) REGRESSION AND… (5*) Mo1153. . . . BIOMARKERS OF DISEASE Mo1271. . . . THE INFLUENCE OF H. PYLORI ACTIVITY AND TREATMENT… (5*) Mo1253. . . . THE RISK OF INFECTION… (5*) GASTROINTESTINAL BLEEDIND OF… (5*) Mo1154. . . . PREVALENCE AND Mo1272. . . . SHORT-TERM EFFECTS OF CHARACTERISTICS OF EOSINOPHILIC Mo1254. . . . GASTROINTESTINAL AMBIENT FINE PARTICULATE… (4*) ESOPHAGITIS… (3*)|(This study was funded BLEEDING DURING DIRECT ORAL by Shire Human Genetic Therapies, Inc.) ANTICOAGULANT… (5*) Mo1273. . . . A SYSTEMATIC REVIEW AND META-ANALYSIS. ANALYSING… (5*) Mo1155. . . . PATTERNS OF CARE IN THE Mo1255. . . . GUIDELINE ADHERENCE AND MANAGEMENT… (5*) EFFECTS OF ASPIRIN… (5*) Mo1274. . . . NON-VITAMIN K ORAL ANTICOAGULANTS HAVE LOWER… (1*) Mo1156. . . . ENDOSCOPIC FEATURES OF Mo1256. . . . PREVALENCE AND GERD PREDICT PARTIAL… (2*) PREDICTORS OF GASTROINTESTINAL Mo1275. . . . THE EFFECT OF LOW-DOSE BLEEDING… (5*) ASPIRIN ON… (3*)|(This study was funded Mo1157. . . . THE ASSOCIATION OF by Bayer AG) EOSINOPHILIC ESOPHAGITIS AND… (5*) Mo1257. . . . RISK OF GASTROINTESTINAL BLEEDING HOSPITALIZATION IN… (5*) Mo1276. . . . NO DIFFERENCES IN GI Mo1158. . . . CLINICAL FEATURES AND BLEEDING RISK… (5*) TREATMENT OUTCOMES ACCORDING… Mo1258. . . . ONLINE SYMPTOM CHECKERS (5*) FOR GASTROINTESTINAL BLEEDING:… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Mo1277. . . . ANTIPLATELET VERSUS ANTICOAGULANT EFFECTS IN NON- Mo1297. . . . SARCOPENIA IS Mo1379. . . . NOTABLE FINDINGS FOR VARICEAL… (5*) INDEPENDENTLY ASSOCIATED WITH AN… EARLY DIAGNOSIS OF… (5*) (5*) Mo1278. . . . UPPER GASTROINTESTINAL Mo1380. . . . THE RELATIONSHOP BLEEDING IN THE PRESENCE… (5*) Mo1298. . . . DIAGNOSTIC YIELD OF BETWEEN THE PD-L1 EXPRESSION… (5*) ISOLATED DEAMIDATED GLIADIN… (5*) Mo1279. . . . PREDICTION OF DIEULAFOY’S Mo1381. . . . ANTIOXIDANTS AS POSSIBLE LESION OR PEPTIC… (2*)|(Supported by VA Mo1362. . . . PANCREATIC TRIGLYCERIDE ANTI-PROLIFERATIVE AGENTS FOR… (4*) Clinical Merit Review Grant (CLIN – 013- LIPASE (PNLIP) MEDIATED 07F) and NIH CURE: DDRC Grant (NIH- UNSATURATED… (4*) Mo1382. . . . SUCCESSFUL ESTABLISHMENT NIDDK 41301) Human Studies CORE.) OF PANCREATIC CANCER PATIENT- Mo1363. . . . GABA INHIBITED NERVE- DERIVED… (4*) Mo1280. . . . DEMAND ISCHEMIA IS ACTIVITY-MEDIATED INSULIN SECRETION: ASSOCIATED WITH INCREASED… (5*) A… (2*) Mo1383. . . . DIAGNOSTIC YIELD OF EUS- FNA FOR SOLID… (5*) Mo1281. . . . THE IMPACT OF URGENT Mo1364. . . . ECT2 IS REGULATED BY YAP UPPER ENDOSCOPY… (4*) AND… (2*) Mo1384. . . . ADULT MOUSE MODEL OF PANCREATIC CANCER… (2*) Mo1282. . . . CHARACTERISTICS OF Mo1365. . . . SENSITIVITY OF PATIENTS WITH NON-HELICOBACTER COMPUTERIZED TOMOGRAPHY DURING Mo1385. . . . IGF-1 (INSULIN LIKE GROWTH PYLORI… (4*) PRE-DIAGNOSTIC… (5*) FACTOR 1)… (2*)

Mo1283. . . . ACUTE KIDNEY INJURY IS Mo1366. . . . DETECTION AND Mo1386. . . . STATINS INHIBIT ASSOCIATED WITH… (5*) CHARACTERIZATION OF EARLY DUCT… (2*) PROLIFERATION OF PANCREATIC DUCTAL… (2*) Mo1284. . . . COMPARING OUTCOMES IN Mo1367. . . . MICRORNA-296-5P UPPER GASTROINTESTINAL BLEEDING… PROMOTES EMT PROCESS AND CELL… (2*) Mo1387. . . . STATINS INHIBIT YAP (2*) ACTIVATION IN RESPONSE… (2*) Mo1368. . . . SUCCESSFUL GROWTH OF Mo1285. . . . RECENT TRENDS IN BLEEDING RECOMBINANT CO-CULTURED Mo1388. . . . TARGETED NEXT GENERATION LOCATION AND… (5*) PANCREATIC… (5*) SEQUENCING FOR PREDICTING… (5*)

Mo1286. . . . CAN CLINICAL FACTORS AND Mo1369. . . . ROLE OF IL-18R AND IL-1R Mo1389. . . . DETECTION SYSTEM OF DEMOGRAPHICS DETERMINE… (5*) SIGNALING… (2*) CIRCULATING TUMOR DNA… (6*)|(This study was funded by The Osaka Foundation Mo1287. . . . CHARLSON COMORBIDITY Mo1370. . . . PANCREATIC CANCER for The Prevention of Cancer and Life-style INDEX, HEMOGLOBIN LEVEL AND… (5*) DETECTION BY PLASMA ASSAY… related Diseases (Public Interest (4*)|(Exact Sciences) Incorporated Foundation).) Mo1288. . . . THALIDOMIDE IS AN EFFECTIVE TREATMENT FOR… (1*) Mo1371. . . . SURVIVAL OF RESECTABLE Mo1390. . . . SYNERGISTIC EFFECT OF PANCREATIC CANCER: THE… (5*) VERTEPORFIN-PDT WITH GEMCITABINE… Mo1289. . . . INTERMITTENT DOSING OF (2*) PROTON PUMP INHIBITOR… (5*) Mo1372. . . . GENETIC SUSCEPTIBILITY TO CHRONIC INFLAMMATORY INTESTINAL… Mo1391. . . . CIRCULATING Mo1290. . . . COMPARISON OF RISK (2*) EXTRACELLULAR VESICLE LNCRNA SCORING SYSTEMS IN… (5*) LINC02280 IS… (2*) Mo1373. . . . IS THERE AN ASSOCIATION Mo1291. . . . FACTORS AFFECTING BETWEEN PREVIOUSLY-IDENTIFIED… (5*) Mo1392. . . . THE UTILITY OF HIGH REBLEEDING AND MORTALITY IN… (5*) INTENSITY FOCUSED… (5*) Mo1374. . . . 12 YEARS OF PROSPECTIVE Mo1292. . . . END- STAGE RENAL DISEASE IS PANCREATIC CANCER… (4*) Mo1393. . . . THE AUTOPHAGY-RELATED- ASSOCIATED… (5*) PROTEIN VMP1 IS SECRETED IN… (4*) Mo1375. . . . CLINICAL COURSE AND RISK Mo1293. . . . CLINICAL OUTCOMES IN FACTORS OF… (5*) Mo1394. . . . ROLE OF GENETIC PATIENTS WITH ACUTE… (5*) EVALUATION IN CHILDREN… (5*) Mo1376. . . . FAMILIAL PANCREATIC Mo1294. . . . RISK FACTORS OF POOR CANCER PATIENTS HAVE BETTER… (5*) Mo1395. . . . METABOLIC PROGNOSIS AND… (5*) REPROGRAMMING AND SUBSEQUENT Mo1377. . . . THE CLINICOPATHOLOGIC AUTOPHAGY TRIGGERED… (2*) Mo1295. . . . MANAGEMENT OF CHARACTERISTICS OF MUCINOUS CYST… ANTITHROMBOTIC THERAPY AFTER (5*) Mo1396. . . . THE EXPRESSION OF GNAS IN GASTROINTESTINAL… (6*) PANCREATIC… (2*) Mo1378. . . . AUTOPHAGY INHIBITION Mo1296. . . . PROTON PUMP INHIBITOR ENHANCES ANTIPROLIFERATIVE EFFECT Mo1397. . . . DYSFUNCTION OF RAB TREATMENT INITIATED PRIOR… (5*) OF… (5*) PROTEINS AND ENDO-LYSOSOMAL… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Mo1545. . . . CHARACTERIZATION OF Mo1398. . . . ACTIVATION OF P21- Mo1498. . . . A NOVEL APPROACH FOR THE ABDOMINAL PAIN RESPONSE TO… ACTIVATED KINASE 4 (PAK4)… (2*) GENETIC… (5*) (3*)|(Funded by Salix Pharmaceuticals.)

Mo1399. . . . HIGH LEVELS OF AMINO Mo1499. . . . DEOXYCHOLIC ACID-INDUCED Mo1546. . . . TIME TO ONSET OF ACIDS (AA)… (2*) SENESCENT HEPATIC STELLATE CELLS… TEGASEROD EFFECT… (3*)|(US WorldMeds (2*)| provided funding for this realysis.) Mo1400. . . . CALCIUM/ CALCINEURIN SIGNALING PATHWAY MEDIATES Mo1500. . . . NRF2 ACTIVATION Mo1547. . . . IMPACT OF TRANSANAL AUTOPHAGY… (2*) PROMOTES MUTANT K-RAS/P53 DRIVEN… IRRIGATION (TAI) DEVICE… (5*) (5*) Mo1401. . . . FLAGELLIN INHIBITS THIAMIN Mo1548. . . . EFFICACY, FEASIBILITY, AND UPTAKE BY PANCREATIC… (2*) Mo1501. . . . THE RISK OF DEVELOPING SAFETY OF THE… (4*) PRIMARY HEPATOCELLULAR… (5*) Mo1402. . . . PREVENTIVE AND Mo1549. . . . INFANT COLIC MIGHT THERAPEUTIC EFFECT OF TRAILPEG… (2*) Mo1502. . . . THE ASSOCIATION OF PREDISPOSE TO BEHAVIORAL… (5*) HEPATOCELLULAR CARCINOMA AND… (5*) Mo1403. . . . DNA PROFILING OF MAIN Mo1550. . . . INITIAL EXPERIENCE WITH PANCREATIC DUCT… (5*) Mo1503. . . . COMPARISON OF SELF- ABDOMINAL MASSAGE DURING… (5*) EXPANDING METAL STENTS IN… (5*) Mo1404. . . . CONCENTRATION CHANGES Mo1551. . . . LIFESTYLE, PSYCHOLOGICAL OF GEMCITABINE METABOLITES Mo1504. . . . LONG NON-CODING RNA STRESS, AND INCIDENCE OF… (2*) COMBINED… (5*) LINC00152 REGULATES CELL… (2*) Mo1552. . . . COMPLICATIONS OF ANAL Mo1405. . . . MICRO-RNA ANALYSIS OF Mo1505. . . . MALIGNANT HILAR SPHINCTER BOTULINUM TOXIN… (5*) CYST FLUID FOR… (2*) STRICTURES WITH BISMUTH IV… (5*) Mo1553. . . . COMPARISON OF ROME III Mo1406. . . . THE CORRELATIONS OF Mo1506. . . . MISCLASSIFICATION OF AND ROME… (2*) ADIPONECTIN WITH SEVERITY… (5*) KLATSKIN TUMORS: DID THE… (5*) Mo1554. . . . CHARACTERIZATION OF THE Mo1407. . . . PANCREATIC SENESCENT Mo1507. . . . INCREASED SUSCEPTIBILITY COLONIC RESPONSE TO… (5*) STROMA INFLUENCE ON PROGNOSIS… (5*) TO BET INHIBITION IN… (2*) Mo1555. . . . PROTON PUMP INHIBITORS Mo1433. . . . CHOLESTATIC JAUNDICE IN Mo1508. . . . EXTRAHEPATIC REDUCE DUODENAL NEONATES: HOW COMMON… (5*)|(The MANIFESTATIONS OF NON-ALCOHOLIC HYPERPERMEABILITY,… (5*) study requires no funding.) FATTY LIVER… (5*) Mo1556. . . . OPIOID USE DISORDER IS Mo1434. . . . CHARACTERIZATION OF Mo1509. . . . NONALCOHOLIC FATTY LIVER ASSOCIATED WITH… (5*) PEDIATRIC ENDOSCOPIC RETROGRADE DISEASE IS ASSOCIATED… (5*) CHOLANGIOPANCREATOGRAPHY… (5*) Mo1557. . . . NATIONAL ESTIMATES OF 30- Mo1510. . . . PREVALENCE AND RISK DAY READMISSIONS AMONG… (5*) Mo1491. . . . NOVEL PREOPERATIVE FACTORS FOR ADVANCED… (4*) NOMOGRAMS PREDICT MICROVASCULAR Mo1558. . . . FUNCTIONAL DYSPEPSIA AND INVASION… (5*) Mo1511. . . . ASSOCIATIONS BETWEEN DUODENAL EOSINOPHILIA ARE… (4*) WEIGHT LOSS METHOD, PATIENT… (4*) Mo1492. . . . TRANSCUTANEOUS Mo1559. . . . GENERAL POPULATION ELECTRICAL ACUSTIMULATION IMPROVES Mo1539. . . . ASSESSING THE RISK FOR PREVALENCE AND CLINICAL GASTROINTESTINAL DISTURBANCES… (5*) ACUTE ISCHEMIC… (5*) CHARACTERISTICS… (5*)

Mo1493. . . . EUS-GUIDED BILIARY Mo1540. . . . DETERMINANTS OF QUALITY Mo1560. . . . APPLYING NUTRIENT DRINK DRAINAGE IS NON-INFERIOR TO… (5*) OF LIFE IMPACT… (5*) TEST AS A… (4*)

Mo1494. . . . THE CHANGING Mo1541. . . . PLECANATIDE IMPROVED Mo1561. . . . PREVALENCE OF CYCLIC HISTOLOGICAL FACE OF GALLBLADDER… PATIENT GLOBAL RATING OF… VOMITING SYNDROME IN… (5*) (5*) (3*)|(Synergy Pharmaceuticals, Inc., New York, NY) Mo1562. . . . EARLY-LIFE ADVERSITY Mo1495. . . . ASPARTATE-β-HYDROXYLASE INDUCESD SEX-DEPENDENT GASTRIC REGULATES METABOLIC Mo1542. . . . PRIMARY BILE ACIDS IN A HYPRSENSITIVITY… (4*) REPROGRAMMING IN HEPATOCELLUAR… SINGLE… (4*) (4*) Mo1563. . . . REGONAL GASTRIC Mo1543. . . . THE EFFECT OF LOW FODMAP RETENTION DURING GASTRIC EMPTYING… Mo1496. . . . TRENDS IN CURE RATES DIET… (5*) (5*) AMONG MEDICARE… (5*) Mo1544. . . . ASSOCIATION OF CANNABIS Mo1564. . . . WHICH ANTI-NAUSEA Mo1497. . . . PREDICTIVE VALUES OF AND HEALTH CARE… (5*) THERAPIES DO PATIENTS BELIEVE… (5*) MUSCLE VOLUME AND… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Mo1565. . . . CONFOCAL LASER Mo1582. . . . TRANSCUTANEOUS VAGAL Mo1601. . . . GASTROINTESTINAL ENDOMICROSCOPY IN PATIENTS WITH… NERVE STIMULATION IMPROVES SYMPTOMS IN CHILDREN DURING (2*)|(Study supported by Michigan Institute SYMPTOMS… (4*) GASTRIC… (5*) for Clinical and Health Research (MICHR) grant number UL1TR000433) Mo1583. . . . GHRELIN AND MOTILIN Mo1602. . . . SCINTIGRAPHIC DERANGEMENTS DURING WIRELESS… METHODOLOGY USING MID-ANTRUM Mo1566. . . . CHARACTERISTICS OF THE (7*)| REGIONS OF… (5*) HOT-WATER BATHING PATTERN… (4*)| Mo1584. . . . EFFECTIVENESS OF Mo1603. . . . PREVALENCE AND INCIDENCE Mo1567. . . . IMPACT OF GENETIC LANREOTIDE IN THE TREATMENT… OF GASTROPARESIS IN… (3*)|(This study VARIATION IN GLP-1… (2*) (3*)|(This study was sponsored by Ipsen was supported by Takeda Pharmaceuticals Pharmaceuticals.) Intertiol Inc,. All authors are employees of Mo1568. . . . CORRELATION BETWEEN Takeda Pharmaceuticals Intertiol Inc,.) SLEEP DISTURBANCE IN FUNCTIONAL… (5*) Mo1585. . . . ROLE OF SEX HORMONES AND THEIR… (2*) Mo1604. . . . COMPARISON OF SYMPTOM Mo1569. . . . EXOSOMAL HSA-MIR-933 IN AND QUALITY OF… (3*)|(The parent GASTRIC JUICE AS… (2*)|(Japan Society for Mo1586. . . . OPIOID USE DISORDER IS investigation supporting this study was the Promotion of Science(JSPS) KAKENHI ASSOCIATED WITH… (5*) funded by Medtronic (grant MA501).) Grant Number JP16K09252) Mo1587. . . . PRUCALOPRIDE VERSUS Mo1605. . . . CLINICAL CHARACTERISTICS Mo1570. . . . A NOVEL COMBINED PLACEBO IN DIABETIC GASTROPARESIS:… AND GUT PHYSIOLOGY IN… (4*) NONINVASIVE MULTIPLE GASTRIC… (5*) (3*)|(Janssen Inc.) Mo1606. . . . AUTONOMIC AND ENTERIC Mo1571. . . . COMPARISON OF GASTRIC Mo1588. . . . INCREASED SYMPTOM FUNCTION PROFILING CAN… (5*) SLOW WAVES AND… (5*) SEVERITY ASSOCIATED WITH THE… (3*)|(Takeda Pharmaceuticals) Mo1607. . . . BASELINE PREDICTIVE Mo1572. . . . DELAYED GASTRIC EMPTYING FACTORS FOR FORE AND… (5*) BY WIRELESS MOTILITY… (3*)|(This study Mo1589. . . . GASTRIC RETENTION IN was supported by a grant from Medtronic.) GASTROPARESIS: RELATIONSHIP OF… (2*) Mo1608. . . . ALTERED INTESTINAL PERMEABILITY AND EFFECT OF… (5*) Mo1573. . . . 3D MRI IMAGING OF THE Mo1590. . . . BODY WEIGHT AND BODY STOMACH… (2*) WEIGHT CHANGES… (2*) Mo1609. . . . CAREGIVER BURDEN IN GASTROPARESIS: CORRELATION WITH… Mo1574. . . . GASTRIC ELECTRICAL Mo1591. . . . DOES OTHER END-ORGAN (5*) NEUROSTIMULATION COMBINED WITH DAMAGE CORRELATE WITH… (2*) PYLOROPLASTY… (5*) Mo1610. . . . CHARACTERIZING SYMPTOMS Mo1592. . . . MARIJUANA USE IN PATIENTS OF BRAIN FOGGINESS AND… (5*) Mo1575. . . . ASSESSMENT OF GASTRIC WITH SYMPTOMS… (2*) EMPTYING MOTILITY UTILIZING… (5*) Mo1611. . . . SYMPTOMS OF Mo1593. . . . DOCUMENTATION OF AVOIDANT/RESTRICTIVE FOOD INTAKE Mo1576. . . . GASTRIC EMPTYING RESULTS PYLORIC SMOOTH MUSCLE DISORDER… (5*) FROM WIRELESS MOTILITY… (5*) DYSFUNCTION… (5*) Mo1612. . . . SYMPTOM VARIABILITY Mo1577. . . . ADVANCED GASTRIC Mo1594. . . . MODELING DELAYED GASTRIC THROUGHOUT THE DAY IN… (5*) EMPTYING SCINTIGRAPHY TO EVALUATE… EMPTYING USING WNT1CRE-IDTR… (2*) (4*) Mo1613. . . . WIRELESS MOTILITY CAPSULE Mo1595. . . . THE IMPACT OF RISK EVALUATION OF REGIONAL… (5*) Mo1578. . . . SURGICAL INTERVENTIONS FACTORS ON… (5*) FOR REFRACTORY GASTROPARESIS: Mo1614. . . . COMPARISON OF GASTRIC GASTRIC… (5*) Mo1596. . . . A PILOT CHRONIC ANIMAL ACCOMMODATION MEASUREMENTS BY… STUDY OF… (2*) (5*) Mo1579. . . . CLINICAL AND GASTRIC MOTILITY FEATURES IN… (5*) Mo1597. . . . THE VIPUN BALLOON Mo1615. . . . FAT-SOLUBLE VITAMINS, B12, CATHETER REVEALS A… (4*) AND IRON DEFICIENCY… (3*)|(Progenity, Mo1580. . . . EFFECT OF DIETARY Inc) INTERVENTION ON PATIENTS… (4*) Mo1598. . . . THE DIAGNOSIS AND MANAGEMENT OF GASTROPARESIS:… (5*) Mo1616. . . . CARDIAC SAFETY AND Mo1581. . . . EVALUATION OF THE SAFETY, CLINICAL EFFICACY OF… (5*) TOLERABILITY, PHARMACOKINETIC… Mo1599. . . . COMBINED GASTRIC (3*)|(The study was funded by Theravance ELECTRICAL STIMULATION PYLOROPLASTY Mo1617. . . . DIFFERENCES IN PYLORIC Biopharma US, Inc., while medical writing IMPROVES… (5*) DISTENSIBILITY IN PATIENTS… (5*) assistance was provided by Colin Glen of Oxford PharmaGenesis, Oxford, UK and Mo1600. . . . ASSESSING PYLORUS Mo1618. . . . PER-ORAL ENDOSCOPIC supported by Takeda Pharmaceutical DISTENSION WITH IMPEDANCE PYLOROMYOTOMY FOR SEVERE Company Ltd.) PLANIMETRY… (5*) REFRACTORY… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Mo1619. . . . AN INTERNATIONAL SURVEY immunochemical tests for this study were ON THE DIAGNOSIS… (5*) provided by Eiken Chemical Company.) Mo1719. . . . ASSOCIATION BETWEEN HEPATITIS C VIRUS INFECTION… (4*) Mo1620. . . . DISTENSION-INDUCED Mo1640. . . . DIFFERENT CUT-OFF LEVELS GASTRIC SLOW WAVE DYSRHYTHMIAS OF FECAL IMMUNOCHEMICAL… (5*) Mo1720. . . . INVESTIGATION OF DEFINED… (2*) RECOMMENDED ALCOHOL INTAKES AND… Mo1641. . . . REPEAT FECAL OCCULT (5*) Mo1622. . . . WHICH COMBO WORKS BLOOD TESTS FOR… (2*) BEST? A COMPARISON… (5*) Mo1721. . . . INCREASING INCIDENCE OF Mo1642. . . . PATIENTS ARE OFTEN ADVANCED NON-CARDIA GASTRIC… (5*) Mo1623. . . . THE ROLE OF SOCIAL MEDIA UNAWARE OF ABNORMAL… (5*) ON… (5*) Mo1722. . . . ABDOMINAL OBESITY IS Mo1643. . . . CORRELATING QUANTITATIVE ASSOCIATED WITH ESOPHAGEAL… (5*) Mo1624. . . . ARE PATIENTS WITH NON- FECAL IMMUNOCHEMICAL TEST (FIT)… (5*) COLORECTAL CANCER AT… (5*) Mo1723. . . . PREDICTORS OF STAGE III/IV Mo1644. . . . INAPPROPRIATE OUTPATIENT COLORECTAL CANCER… (5*) Mo1625. . . . ETHNIC DISPARITIES AND USE OF FECAL IMMUNOCHEMICAL… (5*) BODY MASS INDEX… (5*) Mo1724. . . . METABOLIC SYNDROME IS Mo1645. . . . THE FECAL OCCULT BLOOD ASSOCIATED WITH INCREASED… (5*) Mo1626. . . . EFFECT OF DYNAMIC TEST POSITIVE… (5*) POSITION CHANGES ON… (5*) Mo1725. . . . HELICOBACTER PYLORI Mo1646. . . . ASSOCIATION BETWEEN INFECTION DOES NOT MODIFY… (2*) Mo1627. . . . COLON CANCER IN YOUNG CONCENTRATIONS OF FECAL AMERICANS… (5*) HEMOGLOBIN… (5*) Mo1726. . . . CHROMOENDOSCOPY LEADS TO A HIGHER SPIGELMAN-STAGE… (4*) Mo1628. . . . PROSPECTIVE PRE- Mo1647. . . . FACTORS ASSOCIATED WITH COLONOSCOPY BOWEL PREPARATION COMPLETION OF MAILED… (2*) Mo1727. . . . GENETIC COUNSELING AND STUDY COMPARING… (1*) GERMLINE TESTING AMONG… (5*) Mo1648. . . . IMPROVING ACCESS TO Mo1629. . . . EVALUATION OF THE COLONOSCOPY FOR UNINSURED… (1*) Mo1728. . . . GENETIC VARIANTS IN DPF3 DISSEMINATION AND IMPLEMENTATION… ARE ASSOCIATED… (5*) (2*) Mo1708. . . . COMPARISON OF PRESENTING DIAGNOSES AND Mo1729. . . . FEASIBILITY OF UTILIZING Mo1630. . . . HISTOLOGY, TOTAL NUMBER SYMPTOMS… (2*) PREMM SCORE FOR… (5*) OF POLYPS, AND… (5*) Mo1709. . . . RISK OF COLORECTAL CANCER Mo1730. . . . BUTYRATE-TREATED COLON Mo1631. . . . AGE AND GENDER INCIDENCE AND… (7*) ORGANOIDS FROM FAP SUBJECTS… (4*) DEPENDENT REDUCTIONS IN… (2*) Mo1710. . . . PREVALENCE OF COLORECTAL Mo1731. . . . CANCER RISK IN PATIENTS Mo1632. . . . INTERVAL COLORECTAL NEOPLASIA AMONG PATIENTS… (4*) AND FAMILIES… (4*) CANCER RATES IN VETERANS… (5*) Mo1711. . . . REDUCTION OF INCIDENT Mo1732. . . . GENETIC RISK SCORE TO Mo1633. . . . SCREENING AND COLORECTAL CANCER AFTER… (2*) IDENTIFY INDIVIDUALS… (4*) MANAGEMENT OF LYNCH SYNDROME… (5*) Mo1712. . . . SURVEILLANCE OF HIGH-RISK Mo1733. . . . PREVALENCE OF GERMLINE POLYPS IN THE… (5*) MUTATIONS IN PATIENTS… (5*) Mo1634. . . . NO INCREASED RISK OF COLORECTAL ADENOMAS… (5*) Mo1713. . . . SIGNIFICANCE OF FECAL Mo1734. . . . COMPARISON OF UNIVERSAL HEMOGLOBIN CONCENTRATION FOR… (5*) SCREENING YIELD IN… (5*) Mo1635. . . . REAL-LIFE EXPERIENCE WITH MORE THAN 20000… (5*) Mo1714. . . . EFFECTIVENESS OF PHONE Mo1735. . . . LOW RATES OF GENETIC PROMPT PRIOR TO… (2*) COUNSELING AND… (5*) Mo1636. . . . THE ADDITION OF OTHER FAECAL BIOMARKERS… (5*) Mo1715. . . . THE ISRAELI MULTI CENTER Mo1736. . . . MOLECULAR SWALLOW AND FORGET STUDY:… CHARACTERISTICS OF THE DEPRESSED Mo1637. . . . SCREENING AND TREATING (3*)|(Check-Cap Ltd, Isfiya, Israel) COLORECTAL… (5*) HELICOBACTER PYLORI INTEGRATED… (2*) Mo1716. . . . INCIDENCE OF Mo1737. . . . ALDH2 AND AUTOPHAGHY- Mo1638. . . . ARE NEGATIVE FECAL METACHRONOUS SESSILE SERRATED MEDIATED REDOX HOMEOSTASIS LIMIT… IMMUNOCHEMICAL TEST HEMOGLOBIN… ADENOMAS… (5*) (2*) (3*)|(Fecal immunochemical tests were provided by Eiken Chemical Company.) Mo1717. . . . TRENDS IN EARLY-ONSET Mo1738. . . . NOTCHLESS COLORECTAL CANCER INCIDENCE… (5*) HOMOLOG1(NLE1), A STEPWISELY Mo1639. . . . USE OF FECAL UPREGULATED GENE… (2*) IMMUNOCHEMICAL TESTS IN… (3*)|(Fecal Mo1718. . . . RACIAL AND GEOGRAPHIC DISPARITIES IN PANCREATIC… (7*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Mo1739. . . . MOLECULAR MARKERS, MLH1 Bowel Disease Centre of Excellence Mo1792. . . . SELF-REPORTED DIETARY AND MSI STATUS… (2*) Award”.) BEHAVIORS FOR SYMPTOM MANAGEMENT… (4*) Mo1740. . . . ALCOHOL AND COLON Mo1775. . . . PREVALENCE OF FINANCIAL CANCER: DOES TIME… (2*) CONFLICTS OF INTEREST… (5*) Mo1793. . . . DRIVERS OF HEALTHCARE COST FOR CHILDREN… (5*) Mo1741. . . . INDUCTION OF WHOLE Mo1776. . . . SUSTAINED IMPROVEMENTS GENOME DOUBLING WITH… (2*) IN FATIGUE AND QUALITY… (3*)|(AMAG Mo1794. . . . INCREASING TRENDS IN Pharmaceuticals, Inc.) DIAGNOSTIC PREVALENCE AND… (3*) Mo1742. . . . PROXIMAL VERSUS DISTAL COLON ADENOCARCINOMA WITH… (5*) Mo1777. . . . A PROSPECTIVE MULTI- Mo1795. . . . THREE YEAR OUTCOMES OF A CENTER STUDY ON THE… (4*) COHORT… (5*) Mo1743. . . . KNOCK-DOWN OF GRANULIN, A NOVEL STAT3-INTERACTING… (5*) Mo1778. . . . FEMALE GENDER ASSOCIATED Mo1796. . . . VEDOLIZUMAB EXPERIENCE WITH LESS-SEVERE CROHN’S… (5*) IN CHILDREN AND ADOLESCENTS… (5*) Mo1744. . . . NLRP6 TARGETING SUPPRESSES COLONIC TUMORIGENESIS Mo1779. . . . TRENDS IN EMERGENCY Mo1797. . . . IMPACT OF PREMEDICATION VIA… (2*) DEPARTMENT VISITS AND… AND OTHER VARIABLES… (5*) (3*)|(Sponsorship: Janssen Scientific Affairs, Mo1745. . . . PATHOLOGICAL IMPACT OF LLC) Mo1798. . . . INFLAMMATORY TRANSANAL COLORECTAL TUBE… (5*) MICROHETEROGENEITY IN UC: Mo1780. . . . GENDER BIAS IN REFERRAL IMPLICATIONS FOR… (5*) Mo1746. . . . 12-LIPOXYGENASE AND DIAGNOSIS… (2*) PROMOTES EPITHELIAL-MESENCHYMAL Mo1799. . . . UTILITY OF A SIMPLE BLOOD TRANSITION THROUGH THE… (2*) Mo1781. . . . ROLE OF G PROTEIN-COUPLED TEST… (5*)|(Testing of patient samples was RECEPTOR 15… (4*) provided by Prometheus Laboratories Inc.) Mo1764. . . . SERUM N-GLYCOMIC BIOMARKERS PREDICT TREATMENT Mo1782. . . . THE ROLE OF Mo1800. . . . A SIMPLE SCORING TOOL ESCALATION… (2*) CYCLOOXYGENASE IN COLITIS- PREDICTS EXPOSURE-RESPONSE… ASSOCIATED… (2*) (3*)|(Takeda Pharmaceuticals U.S.A., Inc.) Mo1765. . . . REAL-LIFE EXPERIENCE WITH LONG-TERM MAINTENANCE OF… (5*) Mo1783. . . . H. PYLORI-INDUCED PRDX2 Mo1801. . . . INCORPORATING FECAL PROTECTS AGAINST OXIDATIVE… (4*) CALPROTECTIN IN CLINICAL PRACTICE… Mo1766. . . . MULTIDISCIPLINARY TEAM (5*) CARE AT THE EMERGENCY… (5*) Mo1784. . . . THE ROLE OF FOXM1 IN HELICOBACTER… (2*) Mo1802. . . . TRANSMURAL HEALING Mo1767. . . . PEDIATRIC ONSET ASSESSED USING MRI IS… (5*) INFLAMMATORY BOWEL DISEASE IS… (5*) Mo1785. . . . CELLULAR SENESCENCE OF CD4+ T CELLS… (5*) Mo1803. . . . THE MODIFIED HARVEY- Mo1768. . . . ELEVATED RISK OF BRADSHAW INDEX AND PARTIAL… (5*) METACHRONOUS NEOPLASIA WITH… (5*) Mo1786. . . . AGE- AND CANCER- ASSOCIATED OPLAH METHYLATION IS… Mo1804. . . . THE ROLE OF FECAL Mo1769. . . . OPIOID USAGE AND PATIENT- (5*) CALPROTECTIN IN… (5*) REPORTED PAIN SCORES… (5*) Mo1787. . . . THE FUNCTIONAL ROLE OF Mo1805. . . . INFLAMMATORY BOWEL Mo1770. . . . ADHERENCE TO GUIDELINES VEGFR-2 IN… (5*) DISEASE PATIENTS WITH ILEAL… (5*) REMAINS POOR AMONG… (5*) Mo1788. . . . PREVALENCE AND RISK Mo1806. . . . ENDOSCOPIC POUCH Mo1771. . . . THE FACTORS ASSOCIATED FACTORS OF FIRST-EVER… (5*) ACTIVITY IN ASYMPTOMATIC PATIENTS… WITH THE LEVELS… (7*) (5*) Mo1789. . . . INFLAMMATORY REACTION Mo1772. . . . INCREASED HEALTHCARE PATTERNS AND MOLECULAR GENETICS… Mo1807. . . . MAGNETIC RESONANCE UTILIZATION BY MEDICAID PATIENTS… (5*) (5*) FINGERPRINTING (MRF) IS A… (2*)|(Siemens Health) Mo1773. . . . COST DRIVERS AND TRENDS Mo1790. . . . MUCOSAL HEALING IS IN INFLAMMATORY… (6*)|(Funding for this ACHIEVABLE WITH METHOTREXATE… (5*) Mo1808. . . . RAID-MONITOR TEST IS initiative is made possible through a grant UNAFFECTED BY GEOGRAPHICAL… (2*) from the Leo M. and Harry B. Helmsley Mo1791. . . . BIOLOGIC AND Charitable Trust and United Health Group.) IMMUNOMODULATOR WITHDRAWAL IN Mo1809. . . . DIAGNOSTIC ACCURACY OF PEDIATRIC… (2*)|(This Tobacco Formula FECAL LACTOFERRIN AND… (4*)|(Repha Mo1774. . . . HEALTHCARE UTILISATION grant is under the Commonwealth Universal GmbH biologische Arzneimittel TechLab COSTS MAY BE REDUCED… (3*)|(This work Research Enhancement (C.U.R.E) program Inc) was supported by a peer reviewed grant with the grant number SAP # 4100068710.) from the Gastroenterological Society of Mo1810. . . . FAECAL CALPROTECTIN Australia funded by Janssen: “Inflammatory CONCENTRATION IN INFLAMMATORY BOWEL… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Mo1828. . . . HISTOLOGIC DISEASE Mo1846. . . . ULCERATIVE COLITIS (UC) Mo1811. . . . RAPID POINT-OF-CARE ANTI- ACTIVITY AT SURGICAL RESECTION… (5*) PATIENTS WITH PRIMARY… (4*) DRUG ANTIBODIES MEASUREMENT CORRELATES… (2*)|(1) Mo1829. . . . DEGRADATION AND Mo1847. . . . NUTRITIONAL INDICATORS FORMATION OF TYPE III,… (5*) AND POSTOPERATIVE OUTCOMES IN… (5*) Mo1812. . . . CONSIDERATION OF SERUM IGA IN PATIENTS… (5*) Mo1830. . . . SEROLOGICAL BIOMARKERS Mo1848. . . . EXTRAINTESTINAL OF TYPE VI COLLAGEN… (3*)|(Nordic MANIFESTATIONS AND THEIR IMPACT Mo1813. . . . BOTH FECAL Bioscience A/S) ON… (3*)|(Pfizer Inc) IMMUNOCHEMICAL BLOOD TEST AND… (3*) Mo1831. . . . MMP-2 AND -8 DEGRADED Mo1849. . . . LONG-TERM OUTCOMES OF AND CITRULLINATED-VIMENTIN… STEROID-RESPONSIVE AND NON- Mo1814. . . . A COMBINED SET OF FOUR (2*)|(The assessment of VICM is done by RESPONSIVE… (5*) SERUM… (5*) and at the expense of Nordic Bioscience.) Mo1850. . . . PREOPERATIVE ANTI-TNFS Mo1815. . . . MODIFIED GLASGOW Mo1832. . . . AN INVERSE CORRELATION OF ARE ASSOCIATED WITH A… (5*) PROGNOSTIC SCORE IS USEFUL… (5*) SERUM FIBROBLAST… (4*) Mo1851. . . . THE TREATMENT OF Mo1816. . . . PREDICTION OF ENDOSCOPIC Mo1833. . . . CAPSULE ENDOSCOPY PERIANAL FISTULAS BY… (5*) ACTIVITY IN PATIENTS… (5*) IMPACT ON THERAPEUTIC DECISIONS… (5*) Mo1852. . . . INVESTIGATION OF Mo1817. . . . RESPONDER DEFINITIONS FOR CORRELATION BETWEEN POUCH WALL… THE ULCERATIVE COLITIS… Mo1834. . . . VALIDATION OF AN INTEGRAL (5*) (3*)|(Genentech, Inc.) DISEASE INDEX… (4*) Mo1853. . . . OPPORTUNISTIC INFECTIONS Mo1818. . . . TARGETED LIPIDOMIC Mo1835. . . . THE DEVELOPMENT OF A IN INFLAMMATORY BOWEL DISEASE:… (5*) ANALYSIS OF THE PLASMA… (5*) NON-INVASIVE ULTRASONOGRAPHIC… (5*) Mo1854. . . . WEEKEND DISCHARGES AND Mo1819. . . . PERFORMANCE OF NOVEL HOSPITAL READMISSIONS FOR… (5*) MYCOBACTERIAL DETECTION TEST… (5*) Mo1836. . . . CAN CROHN'S PATIENTS BE ACCURATELY PHENOTYPED… (2*) Mo1855. . . . HOSPITALIZATION Mo1820. . . . MONITORING OUTCOMES FOR INFLAMMATORY BOWEL INFLAMMATORY ACTIVITY IN CROHN’S Mo1837. . . . EFFECT OF UPADACITINIB ON DISEASE… (5*) DISEASE:… (5*) EXTRA-INTESTINAL MANIFESTATIONS… (3*)|(The authors and AbbVie scientists Mo1856. . . . BIG DATA ANALYTICS Mo1821. . . . THE UTILITY OF MONITR TEST designed the study, and alysed and IDENTIFIES ULCERATIVE COLITIS… (2*) AS… (5*) interpreted the data. AbbVie funded the research and provided writing support. All Mo1857. . . . 7ALPHA-HYDROXY-4- Mo1822. . . . ELEVATED ECTODOMAIN OF authors contributed to the development of CHOLESTEN-3-ONE FOR DIAGNOSIS AND TYPE 23 COLLAGEN… (5*)|(S. Sun, J.H. the content. The authors and AbbVie MANAGEMENT OF… (5*) Mortensen, M.L. Olesen, M.A. Karsdal and reviewed and approved the) T. Manon-Jensen are employed at Nordic Mo1858. . . . OUTCOMES OF ACUTE Bioscience A/S which is a company involved Mo1838. . . . CROHN’S DISEASE HAS AN PANCREATITIS IN INFLAMMATORY… (5*) in discovery and development of INCREASED RISK… (5*) biochemical biomarkers. M.A. Karsdal and Mo1859. . . . DOES A POSITIVE T. Manon-Jensen owns stocks at Nordic Mo1839. . . . RISK FACTORS FOR ACUTE CLOSTRIDIODES DIFFICILE RESULT… (6*) Bioscien) VENOUS THROMBOEMBOLISM… (5*) Mo1860. . . . PREGNANT WOMEN WITH Mo1823. . . . ENDOSCOPIC PATTERNS AND Mo1840. . . . INCIDENCE OF ADVERSE IBD HAVE WORSE… (5*) LOCATION OF POST-OPERATIVE… (2*) PSYCHIATRIC EFFECTS OF… (2*) Mo1861. . . . THE RISK OF ECTOPIC Mo1824. . . . HISTOLOGIC HEALING RATES Mo1841. . . . SAFETY AND EFFICACY OF PREGNANCY IN… (5*) OF MEDICAL THERAPIES… (5*)|(Statistical ENDOSCOPIC DILATION… (5*) alyses performed by Robarts Clinical Trials Mo1862. . . . NO INCREAED RATES OF Inc.) Mo1842. . . . RELATIVE HAZARD OF ADVERSE IBD-RELATED… (5*) CHRONIC KIDNEY DISEASE… (2*) Mo1825. . . . FECAL CALPROTECTIN (FCAL) Mo1863. . . . EXTRAINTESTINAL MONITORING IN ASYMPTOMATIC… (5*) Mo1843. . . . A SIGNIFICANT DECLINE IN MANIFESTATIONS AND QUALITY OF LIFE… COLECTOMY RATES… (5*) (3*)|(The authors & AbbVie scientists Mo1826. . . . HOLD THE MAYO, ARE designed the study, & alysed & interpreted ENDOSCOPISTS TAKING… (5*) Mo1844. . . . LONG-TERM FATE OF THE the data. AbbVie funded the research & EXCLUDED RECTUM… (5*) provided writing support. All authors Mo1827. . . . CUMULATIVE HISTOLOGIC contributed to the development of the INFLAMMATION PREDICTS COLORECTAL Mo1845. . . . INCREASED RISK OF content. The authors & AbbVie reviewed & NEOPLASIA… (5*) ADVANCED NEOPLASIA IN… (5*) approved the abstract; t)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Mo1864. . . . INCREASING RATES OF Immunology, Inflammation and Infectious Mo1897. . . . BIOLOGICAL THERAPIES IN INFECTIVE ENDOCARDITIS IN… (5*)|(There Diseases (I3) Discovery and Translatiol Area, CHRONIC ANTIBIOTIC-REFRACTORY are no industry or commercial sources of Roche Innovation Center Basel, Basel, POUCHITIS:… (5*) funding.) Switzerland. No specific funding was receive) Mo1898. . . . EVALUATION OF BODY MASS Mo1865. . . . PREDICTORS OF 30-DAY INDEX AND… (5*) READMISSION ASSOCIATED WITH… (5*) Mo1883. . . . CLINICAL RESPONSE TO USTEKINUMAB IN CROHN'S… (5*) Mo1899. . . . PROGNOSTIC FACTORS FOR Mo1866. . . . PREDICTORS OF 30 DAYS LONG-TERM ADALIMUMAB TREATMENT… READMISSIONS AFTER… (5*) Mo1884. . . . DIETARY WHEAT ALPHA- (5*) AMYLASE/TRYPSIN INHIBITORS INDUCE Mo1867. . . . THE IMPORTANCE OF SYSTEMIC… (2*) Mo1900. . . . TNF-α INHIBITORS AND RISK MONITORING THE POSTPARTUM… OF TYPE… (6*) (3*)|(UCB Sponsored) Mo1885. . . . CHRONIC INFLAMMATION PROMOTES INTESTINAL MACROPHAGES Mo1901. . . . ANTI-TNF DOSE Mo1868. . . . METHYLATION PATTERNS IN TO… (4*) AUGMENTATION INCIDENCE AND DYSPLASIA IN INFLAMMATORY… (7*) PERSISTENCE… (5*) Mo1886. . . . FLAGELLIN-ACTIVATED CD4 Mo1869. . . . SCREENING, PREVALENCE CELLS IN REMISSION CROHN… (2*) Mo1902. . . . MOOD AND ANXIETY AND INAPPROPRIATE IRON DISORDERS AND PERSISTANCE… SUPPLEMENTATION… (5*) Mo1887. . . . USTEKINUMAB ENDOSCOPIC (6*)|(Crohn's and Colitis Cada, CIHR) RESPONSE AT WEEK 16… (3*)|(Truvion Mo1870. . . . ABDOMINAL PAIN IN Healthcare (Preventis)) Mo1903. . . . THE RATES OF ANTI-TNF DOSE PATIENTS WITH INFLAMMATORY… (4*)|(5) AUGMENTATION… (6*)|(Crohn's and Colitis Mo1888. . . . IMPROVEMENT IN Cada) Mo1871. . . . THE ASSOCIATION BETWEEN RADIOGRAPHIC SMALL BOWEL INFLAMMATORY BOWEL DISEASE… (5*) INFLAMMATION… (5*) Mo1904. . . . CONCOMITANT STEROID THERAPY WITH ANTI-TNF THERAPY… (4*) Mo1872. . . . THE REGULATORY ROLE OF Mo1889. . . . YOUNG PATIENTS WITH POLYCOMB REPRESSIVE… (2*) INFLAMMATORY BOWEL DISEASE… (2*) Mo1905. . . . A RETROSPECTIVE STUDY TO EXAMINE THE… (3*)|(AbbVie Mo1873. . . . THE CONSTITUTIVE Mo1890. . . . USING THERAPEUTIC DRUG Pharmaceuticals S.A. (Greece)) ANDROSTANE RECEPTOR (CAR) ACTS… (2*) MONITORING TO PREDICT… (5*) Mo1906. . . . COMBINATION THERAPY OF Mo1874. . . . INCREASED NCR+ ILC3 LEVELS Mo1891. . . . POST-MARKETING SAFETY VEDOLIZUMAB AND TOFACITINIB… (5*) AFTER BIOLOGICAL… (2*) EXPERIENCE OF VEDOLIZUMAB IN… (3*)|(Medical writing assistance was Mo1907. . . . EVALUATION OF Mo1875. . . . IDENTIFICATION AND provided by Alex Kisbey of Oxford USTEKINUMAB TREATMENT PATTERNS VALIDATION OF NOVEL CROHN'S… (2*) PharmaGenesis, Oxford, UK and was AMONG… (3*)|(Funded by Janssen supported by Takeda Pharmaceutical Scientific Affairs, LLC.) Mo1876. . . . EXPRESSION OF CD69 ON Company Ltd.) PERIPHERAL LYMPHOCYTES… Mo1908. . . . NONBIOLOGIC DRUG USE (4*)|(Unrestricted research grant from Mo1892. . . . NON-MEDICAL REVERSE BEFORE AND AFTER… (3*)|(Funded by Janssen Cilag) SWITCH BETWEEN THE ORIGINATOR… Janssen Scientific Affairs, LLC, Horsham, PA, (4*)|(Fincial Support: This work was USA) Mo1877. . . . TUMOR NECROSIS FACTOR α supported by NKFIH-OTKA (Hungarian AND IL-17A… (4*) Scientific Research Fund) Research Grant Mo1909. . . . EVALUATION OF HEALTH (Grant ID: K115345). This work was CARE UTILIZATION, HOSPITALIZATION/… Mo1878. . . . LYMPHOCYTE ACTIVATION supported by the ÚNKP-18-3-I New tiol (3*)|(Funded by Janssen Scientific Affairs, GENE (LAG)-3 ON T… (3*)|(This project is Excellence Program of the Ministry of LLC.) funded by GlaxoSmithKline.) Human Capacities, Hungary.) Mo1910. . . . LONG-TERM CLINICAL Mo1879. . . . METHYLTRANSFERASE G9A AS Mo1893. . . . PERIPHERAL BLOOD EFFICACY OF USTEKINUMAB IN… (5*)|(No AN EPIGENOMIC REGULATOR… (2*) EOSINOPHILIA FUNCTIONS AS A… (2*) industry or commercial sources to report)

Mo1880. . . . ULCERATIVE COLITIS Mo1894. . . . EARLY VEDOLIZUMAB Mo1911. . . . SERUM BILE ACIDS PROFILING PATIENTS ARE CHARACTERIZED BY… (2*) TROUGH LEVELS ARE NOT… (6*) IN IBD… (5*)

Mo1881. . . . MULTIOMICS ANALYSIS OF Mo1895. . . . EFFICACY OF INTRAVENOUS Mo1912. . . . VEDOLIZUMAB IN ELDERLY IBD ENDOSCOPIC BIOPSIES… (3*)|(Interl USTEKINUMAB RE-INDUCTION IN… (5*) PATIENTS WITH INFLAMMATORY… (5*) funding by Bristol Myers Squibb) Mo1896. . . . VEDOLIZUMAB INDUCED Mo1913. . . . TWO YEAR EXPERIENCE WITH Mo1882. . . . IMMUNE CELL AND ENDOSCOPIC REMISSION IN ANTI-TNF… VEDOLIZUMAB IN… (4*) CHECKPOINT SIGNATURES IN… (3*)|(Study (5*) was performed in collaboration with Roche Mo1914. . . . USTEKINUMAB IS EFFECTIVE Pharma Research and Early Development, FOR THE TREATMENT… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1915. . . . LONG-TERM OUTCOMES OF Mo1934. . . . UNEXPLAINED CHRONIC Mo1957. . . . EEFFECT OF LYOPHILIZED INFLIXIMAB THERAPY FOR… (5*) ABDOMINAL PAIN IN 50-YEAR-OLD… (5*) STERILE FECAL FILTRATE… (6*)

Mo1916. . . . EFFECTIVENESS AND SAFETY Mo1939. . . . PERIPARTUM Mo1958. . . . TOXIN A AND B COMBINED OF USTEKINUMAB FOR… (5*) CLOSTRIDIOIDES DIFFICILE INFECTION AND WITH… (5*) ITS… (5*) Mo1917. . . . USTEKINUMAB: EARLY Mo1959. . . . A META-ANALYSIS OF THE EXPERIENCE AND MEDIUM-TERM Mo1940. . . . CLOSTRIDIUM DIFFICILE SAFETY AND… (5*) OUTCOMES… (5*) INFECTION MIMICS INTESTINAL ACUTE… (5*) Mo1960. . . . CORTICOSTEROIDS AND Mo1918. . . . CAN WE STOP ANTI-TUMOUR ADVERSE OUTCOMES IN NECROSIS FACTOR… (5*) Mo1941. . . . TREATMENT FOR REDUCING INFLAMMATORY… (5*) RECURRENCE OF C.… (5*) Mo1961. . . . INPATIENT MANAGEMENT OF Mo1919. . . . USTEKINUMAB EFFICIENCY AS SEVERE CLOSTRIDIUM INFECTION… (2*) A HIGHER-LINE THERAPY… (5*) Mo1942. . . . CLOSTRIDIUM DIFFICILE OF THE ILEAL POUCH… (5*) Mo1962. . . . MORBID OBESITY INCREASES Mo1920. . . . RESULTS OF INTERIM 30-DAY READMISSION AND… (5*) ANALYSIS OF A… (5*) Mo1943. . . . COLONOSCOPY-BASED FECAL MICROBIOTA TRANSPLANTATION IS Mo1963. . . . DOES ADDITION OF Mo1921. . . . TNF-α INHIBITORS HAVE HIGHLY… (5*) METRONIDAZOLE TO ORAL… (5*) SIMILAR EFFECTIVENESS IN… (5*) Mo1944. . . . ADHERENCE TO THE TESTING Mo1964. . . . COMPARISON OF IN-VITRO Mo1922. . . . SUPPLEMENTATION WITH GUIDELINES FOR… (5*) PHOTODYNAMIC BACTERICIDAL EFFECT… BUTYRATE PRODUCING BACTERIA (2*)|(Small Grant Exploratory Research, REDUCES… (4*) Mo1945. . . . THE INFLUENCE OF PETS ON Korea) RISK… (1*) Mo1923. . . . LONG-TERM SAFETY OF FECAL Mo1965. . . . EVIDENCE FOR CELLULAR MICROBIOTA TRANSPLANTATION… (5*) Mo1946. . . . RECONSTITUTION OF ENGRAFTMENT IN GI… (4*) PREBIOTIC-DRIVEN HOST-MICROBE Mo1924. . . . CLOSTRIDIUM BUTYRICUM SYNTROPHY IN… (4*) Mo1966. . . . INSTITUTIONAL EXPERIENCE PROMOTES LIGANDS RELEASE FROM… (5*) WITH CAPSULE FECAL MICROBIOTA… (5*) Mo1947. . . . TAXONOMIC AND Mo1925. . . . TRANSGENERATIONAL FUNCTIONAL INTESTINAL DYSBIOSIS IN… Mo1967. . . . DISPARITIES IN IMPACTS OF ORAL PROBIOTICS (7*) MANAGEMENT OF CLOSTRIDIOIDES ADMINISTRATION… (5*) DIFFICILE… (5*) Mo1948. . . . GUT MICROBIOTA Mo1926. . . . A SINGLE CENTER COMPOSITION AT DIAGNOSIS PREDICTS… Mo1968. . . . FECAL MICROBIOTA EXPERIENCE: FECAL MICROBIOTA… (5*) (2*) TRANSPLANTATION FOR TREATMENT OF… (5*) Mo1927. . . . CITROBACTER RODENTIUM Mo1949. . . . DECREASED COMPLEXITY OF INDUCES CD4+ TISSUE RESIDENT… (4*) SERUM N-GLYCAN STRUCTURES… (4*) Mo1969. . . . GASTROSTOMY TUBE PLACEMENT (GTP) AND ITS… (5*) Mo1928. . . . TOLL-LIKE RECEPTOR2- Mo1950. . . . POSITIVE ENZYME MEDIATED ACCLERATION OF INTESTINAL IMMUNOASSAY (EIA) TOXIN TESTING… Mo1970. . . . EFFICACY OF COLONOSCOPY, MUCOSAL… (2*) (4*) NASOGASTRIC TUBE, ENEMA,… (5*)

Mo1929. . . . CANDIDA ALBICANS SC5314 Mo1951. . . . FECAL MICROBIOTA Mo1971. . . . IN VITRO AND IN VIVO INHIBITS NLRP3/NLRP6 INFLAMMASOME… TRANSPLANT DECREASES MORTALITY IN… VIRULENCE… (2*)|(Nil) (2*) (5*) Mo1972. . . . AN ANALYSIS OF LONG-TERM Mo1930. . . . HARNESSING ANTI- Mo1952. . . . EFFICACY OF ORAL EFFICACY AND… (5*) INFLAMMATORY GUT BIOACTIVES TO VANCOMYCIN PROPHYLAXIS FOR… (5*) MODULATE… (4*) Mo1973. . . . PREDICTORS OF TREATMENT Mo1953. . . . GROWTH INHIBITION OF FAILURE IN FECAL… (5*) Mo1931. . . . URINE METABOLOMIC CLOSTRIDIOIDES DIFFICILE BY… (4*) SIGNATURES DIFFERENTIATE PREGNANCY Mo1974. . . . CLOSTRIDIUM FROM… (5*) Mo1954. . . . FECAL MICROBIOTA DIFFICILEMINFECTION (CDI) IS ASSOCIATED TRANSPLANTATION IS SAFE AND… (5*) WITH… (5*) Mo1932. . . . MECHANISTIC INSIGHT INTO BACTERIAL HTPG-HOST INTERACTIONS… Mo1955. . . . VE303, A LIVE Mo1975. . . . INPATIENT COSTS (2*) BIOTHERAPEUTIC PRODUCT FOR… ASSOCIATED WITH C. DIFFICILE… (5*) (3*)|(Vedanta Biosciences Inc.) Mo1933. . . . ASSOCIATION BETWEEN Mo1976. . . . RACIAL DISPARITIES IN PRENATAL ANTIBIOTICS EXPOSURE AND… Mo1956. . . . CONSTIPATION IS A CLOSTRIDIOIDES DIFFICILE MORTALITY… (5*) COMPLICATION OF ORAL… (5*) (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Mo1996. . . . ASSESSING SEVERITY AND Mo1977. . . . THE EFFECT OF ANTI- HEALTHCARE RESOURCE UTILIZATION… Mo2017. . . . ANTIMICROBIAL PEPTIDE INFLAMMATORY PROPERTIES OF… (5*) (3*)|(Takeda Pharmaceuticals Intertiol Co.) ELAFIN REVERSES OBESITY, INSULIN… (2*)

Mo1978. . . . OUTCOMES OF FECAL Mo1997. . . . ACUTE PANCREATITIS WITH Mo2018. . . . HEPATOCYTE-SPECIFIC MICROBIOTA TRANSPLANTATION FOR… CELIAC DISEASE: HAS… (5*) OVEREXPRESSION OF FADS1 ATTENUATED (5*) DIETARY… (2*) Mo1998. . . . CELIAC AUTOIMMUNITY AND Mo1979. . . . HOSPITAL - ONSET PREGNANCY OUTCOMES… (5*) Mo2019. . . . DEFINING CLINICALLY CLOSTRIDIUM DIFFICILE INFECTION… (5*) SIGNIFICANT WEIGHT REGAIN AFTER… (5*) Mo1999. . . . PREVALENCE OF CELIAC Mo1980. . . . VOLUME OF FECAL FILTRATE DISEASE (CD) IN… (5*) Mo2020. . . . CHARACTERISTICS OF A CASH- FOR FECAL… (5*) PAY GI-BASED MEDICAL… (5*) Mo2000. . . . INCIDENCE OF CELIAC Mo1981. . . . ETIOLOGIES, TRENDS AND DISEASE IS INCREASING… (6*) Mo2021. . . . NUMBER OF FOLLOW-UP SHORT-TERM OUTCOMES OF… (5*) VISITS IS INDEPENDENTLY… (5*) Mo2001. . . . EPIDEMIOLOGY OF PATIENTS Mo1982. . . . GENDER DIFFERENCES IN ADMITTED FOR CELIAC… (5*) Mo2022. . . . WEIGHT LOSS ADVICE FOR FECAL BACTERIOME AND… (4*) FATTY LIVER… (5*) Mo2002. . . . CELIAC DISEASE: ENHANCING Mo1983. . . . THE UTILITY OF IGA BASED EDUCATIONAL SUPPORT FOR… (5*) Mo2023. . . . ASSOCIATION BETWEEN SEROLOGIC… (5*) OBESITY AND RISK OF… (5*) Mo2003. . . . COMPARISON OF QUALITY OF Mo1984. . . . SYMPTOM PROFILES, GLUTEN CELIAC DISEASE… (5*) Mo2024. . . . OBESITY PROLONGS FREE DIET ADHERENCE,… (5*) HOSPITALIZATION IN CHRONIC Mo2004. . . . HOW ARE CELIAC DISEASE PANCREATITIS… (5*) Mo1985. . . . MINIMALLY-INVASIVE PATIENTS FOLLOWED… (5*) MONITORING OF INTESTINAL VILLOUS Mo2025. . . . COLORECTAL CANCER HEALTH… (3*) Mo2005. . . . ASSESSMENT OF PARENTAL SCREENING RATES ARE LOWER… (4*) GLUTEN-FREE DIET KNOWLEDGE… (6*) Mo1986. . . . LATIGLUTENASE IMPROVES Mo2026. . . . EFFECTIVENESS OF ANTI- QUALITY OF LIFE IN… (3*)|(Immunogenics Mo2006. . . . AN EDUCATIONAL APP TO OBESITY MEDICATIONS IN “REAL… (2*) LLC (dba ImmunogenX)) SUPPORT THE… (6*) Mo2027. . . . HIGH STRESS LEVEL IS Mo1987. . . . RESPONDER ANALYSIS FOR Mo2007. . . . COMPARISON OF CELIAC ASSOCIATED WITH… (5*) LATIGLUTENASE REDUCTION IN… (3*) DISEASE PATIENT SATISFACTION… (5*) Mo2028. . . . A STRUCTURED, Mo1988. . . . USE OF CLADRIBINE FOR Mo2008. . . . BLENDERIZED DIETS ARE COMPREHENSIVE LIFESTYLE ULCERATIVE JEJUNITIS… (5*) ASSOCIATED WITH IMPROVED… (5*) INTERVENTION PROGRAM… (5*)

Mo1989. . . . ASSESSMENT OF NOVEL Mo2009. . . . ASSOCIATION BETWEEN Mo2029. . . . OCTREOTIDE AMELIORATES CANDIDATE BIOMARKERS OF… (4*) COLORECTAL ADENOMA AND OBESITY-INDUCED PANCREATIC STEATOSIS NONALCOHOLIC… (2*) VIA… (5*) Mo1990. . . . ADHERENCE TO THE GLUTEN- FREE DIET AND… (3*)|(Takeda Mo2010. . . . THE IMPACT OF ADJUSTABLE Mo2030. . . . COST-EFFECTIVENESS OF Pharmaceutical Company) INTRAGASTRIC BALLOON… (2*) EARLY INITIATION AND/OR MORE… (4*)

Mo1991. . . . CO-LOCALISATION OF IGA Mo2011. . . . SMALL INTESTINAL Mo2031. . . . A FUNCTIONAL SCREENING AND IGG ANTI-TISSUE… (4*) MICROBIAL SHIFTS TOWARDS BILE- APPROACH FOR ANIT-OBESITY… (4*)| TOLERANT-ASSOCIATED-MICROBIOTA… Mo1992. . . . SOLVING THE STAIN (2*)|(NIDDK r01 21769 NIDDK r01 29867) Mo2032. . . . INTESTINAL ELECTRICAL DILEMMA: COMPUTATIONAL IMAGE… STIMULATION ALTERS HYPOTHALAMIC (4*)| Mo2012. . . . HIGH-FAT DIET REDUCES EXPRESSIONS… (2*) BROWN ADIPOSE TISSUE… (2*) Mo1993. . . . HEALTHCARE UTILIZATION Mo2041. . . . ARTIFICIAL INTELLIGENCE AND COMORBIDITIES AMONG PEOPLE… Mo2013. . . . HEPATIC AGO2 IS AUGMENTS REAL-TIME HISTOLOGY OF… (5*) INDISPENSABLE FOR NASH… (2*) (2*)

Mo1994. . . . IS THE INCREASE IN CELIAC Mo2014. . . . COMPARATIVE EFFECTS OF Mo2042. . . . CHROMOENDOSCOPY DISEASE… (5*) BAR502, A DUAL… (5*) REDUCES THE SUBSEQUENT RISK OF… (4*)

Mo1995. . . . THE POSITIVE AND NEGATIVE Mo2015. . . . THE ROLE OF SMALL Mo2043. . . . IMAGE ENHANCED RIPPLE-EFFECT OF… (4*) INTESTINAL BACTERIA… (5*) ENDOSCOPY DOES NOT IMPROVE… (5*)

Mo2016. . . . THE TGF-β/SMAD3 ADAPTOR Mo2044. . . . 0.02 VITAMIN C SOLUTION SPTBN1 AND ALDH2… (2*) SPRAY FOR… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu1006. . . . DEVELOPMENT OF AN Tu1029. . . . IMPACT OF SPECIFIC Mo2045. . . . MACHINE-LEARNING-BASED EVIDENCE-BASED STRATEGY TEACHING STRATEGIES ON… (5*) AUTOMATIC DIAGNOSTIC SYSTEM USING INCORPORATING… (4*) LINKED… (5*) Tu1030. . . . A LOOK AT HOW ENDOCUFF Tu1007. . . . PATIENT-INITIATED AFFECTS… (5*) Mo2046. . . . AUTOMATED REAL TIME ELECTRONIC MESSAGING WITH ENDOSCOPIC SCORING BASED… (5*) PHYSICIANS IS… (5*) Tu1031. . . . BEST PRACTICES IN TEACHING ENDOSCOPY: A… (5*) Mo2047. . . . AUTOMATED DETECTION OF Tu1008. . . . PROXIMAL NEOPLASIA YIELD ABDOMINAL FREE FLUID… (5*) AMONG SUBJECTS REFERRED… (2*) Tu1032. . . . DOES MENTORSHIP IMPACT TRAINEE PARTICIPATION IN… (5*) Mo2048. . . . UNSUPERVISED MACHINE Tu1009. . . . TRANSCRIPTOMIC PROFILING LEARNING BASED AUTOMATIC IDENTIFIES A NOVEL, NON-INVASIVE,… (2*) Tu1033. . . . A SNAPSHOT OF WOMEN IN DEMARCATION… (5*) GASTROENTEROLOGY… (5*) Tu1010. . . . VALIDATION OF A STOOL- Mo2049. . . . AUGMENTING DERIVED EUKARYOTIC RNA… Tu1034. . . . PROXIMAL SERRATED POLYP GASTROINTESTINAL HEALTH: A DEEP (3*)|(Geneoscopy) DETECTION RATE IS… (5*) LEARNING… (5*) Tu1011. . . . CHARACTERISTICS OF Tu1035. . . . IMPACT OF PATIENT Mo2050. . . . NOVEL COMPUTER-ASSISTED INDIVIDUALS UNDERGOING FIT FOR… (5*) EDUCATION ON SWITCH… (1*) DETECTION SYSTEM OF COLORECTAL… (3*) Tu1012. . . . LOW RATES OF Tu1036. . . . ENSURING JUDICIOUS PPI USE Mo2051. . . . AUTOMATED COMPUTER METACHRONOUS ADVANCED NEOPLASIA… THROUGH AN… (5*) DETECTION OF COLONOSCOPY (4*) COMPLETION… (5*) Tu1037. . . . ADDRESSING THE GENDER Tu1013. . . . ARE OUT-OF-POCKET COSTS DIVIDE: FEMALE GASTROENTEROLOGISTS… Mo2052. . . . APPLICATION OF MACHINE UNDER MEDICARE A… (1*) (5*) LEARNING AND ARTIFICIAL… (7*) Tu1014. . . . ABERRANT CRYPT FOCI Tu1038. . . . SOCIAL INFLUENCES ON Mo2053. . . . PRE-PROCEDURAL PREDICT RISK OF… (5*) CAREER CHOICES IN… (4*) ASSESSMENT OF THE FASTING STATE… (5*)|(The eNose Company, Zutphen, NL, Tu1015. . . . MULTI-TARGET STOOL DNA Tu1039. . . . WHY NOT BE A LEADER? provided Aeonose device for study but no TESTING: YIELD AS… (4*) CHARACTERISTICS… (5*) funding.) Tu1016. . . . COLORECTAL CANCER Tu1040. . . . EXPERIENCED ENDOSCOPY Mo2054. . . . A SEMI-SUPERVISED SCREENING: HOLES AND HOPE… (5*) TEACHERS USE TEACHING STRATEGIES… BLEEDING DETECTION METHOD IN… (3*)| (5*) Tu1017. . . . PREVALENCE OF COLONIC Mo2055. . . . A NATURAL LANGUAGE POLYPS IN END-STAGE… (5*) Tu1041. . . . ELECTRONIC CASE-BASED GI BASED TOOL IMPROVES… (5*) BLEEDING MODULE IMPROVES… (5*) Tu1018. . . . SHOULD SCREENING FOR Mo2056. . . . PERORAL ENDOSCOPIC COLORECTAL CANCER START… (5*) Tu1042. . . . INNOVATIVE INSTRUCTIONAL MYOTOMY: EFFECTS OF THE… (5*) STRATEGIES FOR INCORPORATING THE… Tu1019. . . . INCREASING PREVALENCE OF (5*) Mo2057. . . . INITIAL NORTH AMERICAN SESSILE SERRATED POLYPS… (5*) EXPERIENCE WITH ENDOSCOPIC… (4*) Tu1043. . . . GASTROENTEROLOGY Tu1020. . . . UNDERUTILISATION OF FELLOWS HAVE SIMILAR POLYP, Tu1000. . . . CHRONIC LIVER DISEASE IS RESOURCES FOR COLORECTAL CANCER… ADENOMA… (5*) ASSOCIATED WITH… (5*) (5*) Tu1044. . . . WORK-LIFE CONFLICT AND ITS Tu1001. . . . PERFORMANCE OF THE Tu1021. . . . DISTANCE OF TRAVEL TO THE HEALTH EFFECTS… (4*) VETERAN'S CHOICE PROGRAM… (5*) SITE… (5*) Tu1045. . . . TEACHING THE “FOUR- Tu1002. . . . WEEKEND ADMISSIONS FOR Tu1022. . . . QUALITY OF BOWEL POSITION METHOD” MAKES BEGINNER… ACUTE CHOLANGITIS: IMPORTANCE… (5*) PREPARATION AMONG PATIENTS… (5*) (5*)

Tu1003. . . . CHARACTERIZING LOW-VALUE Tu1023. . . . ADDITIONAL INTESTINAL Tu1046. . . . KNOWLEDGE AND PPI USE AMONG OLDER… (4*) MUCOSAL BIOPSY SAMPLING FOR… (5*) PRESCRIBING PATTERNS OF INTERNAL… (5*) Tu1004. . . . FRAGMENTED CARE IS Tu1027. . . . ESOPHAGEAL MANOMETRY PREVALENT AMONG PATIENTS… (5*) COMPETENCY PROGRAM IMPROVES Tu1047. . . . FOOD FOR THOUGHT: PERFORMANCE… (5*) GASTROENTEROLOGY FELLOW AND… (5*) Tu1005. . . . ANESTHESIA ROLE IN HOSPITALIZATION FOR PNEUMONIA… Tu1028. . . . FACTORS CONTRIBUTING TO Tu1144. . . . CELLULAR SIGNALING (3*)|(Medivators) ENTRUSTMENT DECISIONS IN… (7*) CASCADES FOR ACTIVATION OF… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu1145. . . . INDUCTION OF LIVER Tu1169. . . . SEX MODERATES THE Tu1188. . . . REFLUX PATTERN AND ROLE AUTOPHAGY AMELIORATES IMPAIRED… RELATION BETWEEN NAUSEA… (2*) OF IMPEDANCE-PH… (5*) (3*)|(Tsumura & Co.) Tu1170. . . . HOSPITAL ADMISSIONS AND Tu1189. . . . A BRIEF MANOMETRIC INDEX Tu1146. . . . SCHLAFEN 3 KNOCKOUT MICE TREATMENT COST OF… (5*) FOR COMPREHENSIVE… (5*) DISPLAY GENDER-SPECIFIC… (5*) Tu1171. . . . IS THE CONCLUSIVE EVIDENCE Tu1190. . . . POSTREFLUX SWALLOW- Tu1147. . . . NPT2B, A TYPE II SODIUM- FOR GERD… (5*) INDUCED PERISTALTIC WAVE INDEX PHOSPHATE COTRANSPORTER,… (2*) INDEPENDENTLY… (5*) Tu1172. . . . INCOMPLETE RESPONSE OF Tu1148. . . . MICROFLUIDIC ORGANOTYPIC SYMPTOMS OF GASTROESOPHAGEAL… Tu1191. . . . BASELINE IMPEDANCE ON SYSTEM FOR THE ANALYSIS… (4*) (2*) HIGH-RESOLUTION ESOPHAGEAL IMPEDANCE-MANOMETRY… (5*) Tu1149. . . . IDENTIFYING FUNCTIONAL Tu1173. . . . ESOPHAGEAL MUCOSAL PATHWAY ASSOCIATIONS BETWEEN INTEGRITY IS UNCHANGED IN… (5*) Tu1192. . . . CLINICAL UTILITY OF GENE… (2*) ADVANCED IMPEDANCE METRICS… (5*) Tu1174. . . . RECLASSIFICATION OF Tu1150. . . . INSULIN PROMOTES THE PATIENTS WITH GASTROESOPHAGEAL Tu1193. . . . IMPACT OF CHRONIC OPIATES INVASION AND MIGRATION… (2*) REFLUX… (5*) ON ESOPHAGEAL… (5*)

Tu1151. . . . HUMAN MYOFIBROBLASTS Tu1175. . . . EVALUATION OF MINIMAL Tu1194. . . . ESOPHAGOGASTRIC JUNCTION SUPPORT PROLIFERATION OF INTESTINAL… CHANGE LESION USING… (5*) DISTENSIBILITY IS NEARLY ALWAYS… (2*) (5*) Tu1176. . . . SHORTER (48-HOUR) BRAVO Tu1195. . . . 3D-PRESSURE TOPOGRAPHY Tu1152. . . . CORDYCEPIN INDUCES G2/M PH MONITORING MAY… (5*) OF THE ESOPHAGOGASTRIC JUNCTION… PHASE ARREST AND… (2*) (2*) Tu1177. . . . ESOPHAGEAL BASELINE Tu1153. . . . REGULATION OF KETOGENESIS IMPEDANCE FROM HIGH RESOLUTION… Tu1196. . . . IMPAIRED SWALLOW- BY WNT/β-CATENIN/PPARγ SIGNALING… (5*) INDUCED AXIAL ESOPHAGEAL (2*) SHORTENING/ LES… (2*) Tu1178. . . . ASSOCIATION BETWEEN Tu1154. . . . TROP2 UPREGULATION IN GASTROESOPHAGEAL JUNCTION Tu1197. . . . ENDOSCOPIC MOUSE PRE-NEOPLASTIC STOMACH… (2*) MORPHOLOGY AND… (5*) INTRASPHINCTERIC INJECTION OF BOTOX IN… (2*) Tu1155. . . . EXPRESSION OF GCRG213, Tu1179. . . . A DISTINCT PATTERN OF LINE-1 ENDONUCLEASE VARIANT,… (2*) RUMINATION SYNDROME… (4*) Tu1198. . . . INEFFECTIVE ESOPHAGEAL MOTILITY IS ASSOCIATED WITH… (5*) Tu1156. . . . EVALUATION OF SERUM TFF3 Tu1180. . . . HIGH RESOLUTION LEVELS IN… (5*) MANOMETRY (HRM) EVALUATION OF… Tu1199. . . . ENDOSCOPIC MANAGEMENT (5*) OF ESOPHAGEAL SOFT FOOD… (5*) Tu1157. . . . ANALYSIS OF GASTRIC POLYPS FROM WESTERN… (5*)|(NIL) Tu1181. . . . PROSPECTIVE STUDY OF A Tu1200. . . . UTILIZING FUNCTIONAL COHORT OF… (1*) LUMINAL IMAGING PROBE (FLIP)… (2*) Tu1158. . . . GENOME-WIDE ANALYSIS FOR GASTRIC ADENOCARCINOMA-SPECIFIC Tu1182. . . . HIGH RESOLUTION Tu1201. . . . CODEINE INDUCES MAJOR H.PYLORI… (2*) ESOPHAGEAL MANOMETRY RESULTS MOTILITY DISORDERS IN… (5*) AFFECT… (5*) Tu1159. . . . BLOOD MQTL EFFECTS ARE Tu1202. . . . KEY PARAMETERS OF CONSISTENT DURING… (6*) Tu1183. . . . MEASUREMENT OF ESOPHAGOGASTRIC JUNCTION (EGJ)… (5*) ESOPHAGEAL BASELINE IMPEDANCE: A… Tu1160. . . . GENE EXPRESSION SIGNATURE (1*) Tu1203. . . . PHARMACOLOGIC OF THE “POINT… (4*) INTERROGATION OF PATIENTS WITH Tu1184. . . . MUCOSAL IMPEDANCE ESOPHAGEAL… (4*) Tu1161. . . . A PROTOCOL FOR LIVE-FACS PREDICTS ABILITY TO DISCONTINUE… (2*) FROM CRYOPRESERVED… (2*) Tu1204. . . . MUSCLE LAYER FIBROSIS DO Tu1185. . . . PROLONGED (96 H) WIRELESS NOT REDUCE… (5*) Tu1162. . . . USING TRANSCRIPTOMICS TO AMBULATORY ESOPHAGEAL… (5*) SUBCLASSIFY ULCERATIVE COLITIS… (6*) Tu1205. . . . EOSINOPHILS EXPRESSING Tu1186. . . . E-CADHERIN AND EPIDERMAL TGF-Β1 IN THE MUSCLE… (5*) Tu1163. . . . HISTONE DESACETYLASE 2 GROWTH FACTOR (EGF)… (4*) FAVORS AIEC INVASION… (4*) Tu1206. . . . DYSPHAGIA IS A COMMON Tu1187. . . . SYMPTOM RECOGNITION CONSEQUENCE OF… (5*) Tu1164. . . . SHARED GENETIC MUTATIONS DURING AMBULATORY PH-IMPEDANCE ARE FOUND IN… (2*) MONITORING:… (5*) Tu1207. . . . THE CHICAGO CLASSIFICATION FREQUENTLY IDENTIFIES MANOMETRIC… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1208. . . . NORMAL PARAMETERS OF Tu1229. . . . IMPAIRED ESOPHAGOGASTRIC Tu1248. . . . THE EFFICACY OF FLUOXETINE DISTENSION-INDUCED CONTRACTILITY JUNCTION RECESSIVE RELAXATION PLAYS… FOR TREATMENT… (5*) ASSESSED… (2*) (5*) Tu1249. . . . AUTOLOGOUS Tu1209. . . . CLINICAL, MANOMETRIC AND Tu1230. . . . CLINICAL OUTCOME AFTER HAEMATOPOETIC STEM CELL TRANSPLANT PSYCHOLOGICAL PROFILE OF… (5*) SINGLE HYDRAULUC ESOFLIP… (1*) (HSCT)… (5*)

Tu1210. . . . ESOPHAGEAL PATHOLOGY IS Tu1231. . . . DIFFERENCES IN Tu1250. . . . TOTAL DAILY OPIOID DOSE IS THE LIKELY ETIOLOGY… (5*) TRANSABDOMINAL ULTRASONOGRAPHIC ASSOCIATED… (2*) PARAMETERS AMONG… (4*) Tu1211. . . . ESOPHAGOGASTRIC JUNCTION Tu1251. . . . EFFECT OF ACUTE MEASURES FOLLOWING PER ORAL… (2*) Tu1232. . . . DISTAL ESOPHAGEAL ESOPHAGEAL ACID EXPOSURE… (2*) DYSMOTILITY AND BOLUS CLEARANCE… Tu1212. . . . HIGH PREVALENCE OF (5*) Tu1252. . . . TOPOGRAPHICAL PLOTS OF DYSPHAGIA AND ASSOCIATED… (2*) ESOPHAGEAL DISTENSION AND… (2*) Tu1233. . . . RAPID DRINKING CHALLENGE Tu1213. . . . ACUTE ADMINISTRATION OF MAY HELP DISTINGUISH… (2*) Tu1253. . . . VASCULAR PRESSURE BANDS CODEINE HAS NO… (5*) ON HIGH RESOLUTION… (5*) Tu1234. . . . CROSS-SECTIONAL IMAGING IN Tu1214. . . . FUNCTIONAL LUMEN IMAGING PATIENTS WITH ESOPHAGOGASTRIC… (4*) Tu1254. . . . ASSOCIATION BETWEEN PROBE TOPOGRAPHY (FLIP)… (5*) MEDICATION USE AND GERD… (5*) Tu1235. . . . CLINICAL UTILITY OF HIGH- Tu1215. . . . COMPARISON OF SAFETY OF RESOLUTION ESOPHAGEAL MANOMETRY… Tu1255. . . . THE EFFICACY OF TOPICAL TREATMENT OPTIONS… (5*) (5*) LIDOCAINE IN… (5*)

Tu1216. . . . RAPID SEQUENCE CT SCAN Tu1236. . . . PATHOPHYSIOLOGICAL Tu1256. . . . DEEP LEARNING FOR IMAGING TO… (2*) MECHANISMS ASSOCIATED WITH ESOPHAGEAL MANOMETRY –… (5*) SUPRAGASTRIC BELCHING.… (5*) Tu1217. . . . COEXISTING ABNORMAL Tu1257. . . . ESOPHAGEAL ESOPHAGEAL BODY MOTILITY PREDICTS… Tu1237. . . . ESOPHAGEAL ACID HISTOPATHOLOGIC PATTERNS IN PATIENTS (5*) SENSITIVITY IN PATIENTS WITH… (4*) UNDERGOING… (5*)

Tu1218. . . . ABERRANT STRIATED MUSCLE Tu1238. . . . THE TRANSITION ZONE AND Tu1258. . . . MAST CELL INFILTRATION CONTRACTILITY IN SYMPTOMATIC… (2*) DYSPHAGIA: A… (2*) ASSOCIATED WITH LOSS… (2*)|(declared.)

Tu1219. . . . MONTE CARLO SIMULATION Tu1239. . . . ESOPHAGEAL Tu1259. . . . YIELD OF ENDOSCOPIC CONFIRMS AGE-RELATED GROUP… (2*) HYPERVIGILANCE AND VISCERAL ANXIETY ULTRASOUND AND COMPUTED… (5*) ARE… (2*) Tu1220. . . . ACID EXPOSURE AND Tu1260. . . . UPRIGHT AND SUPINE DYSMOTILITY IN SYMPTOMATIC… (5*) Tu1240. . . . ASSESSMENT OF ESOPHAGEL INTEGRATED RESIDUAL PRESSURE… (5*) BOLUS TRANSIT AND… (5*) Tu1221. . . . LOW CLINICAL RELEVANCE OF Tu1261. . . . PHARYNGEAL CERVICAL INLET… (5*) Tu1241. . . . EFFECTS OF STRENGTH PRESSURIZATION SEEN ON PHARYNGEAL TRAINING ON DEGLUTITIVE… (2*) SCREENING… (5*) Tu1222. . . . ESOPHAGEAL DYSMOTILITY OF ASIAN PEOPLE WITH… (5*) Tu1242. . . . DEGLUTITIVE STRIATED Tu1262. . . . THE EFFECT OF AGING ON MUSCLE ENSEMBLE CONTRACTILITY ESOPHAGO-UES… (2*) Tu1223. . . . EFFECTIVENESS OF N- INDICES:… (2*) ACETYLCYSTEINE ON THE TREATMENT… Tu1263. . . . VARIATION OF BASAL UES (5*) Tu1243. . . . SUSTAINED ESOPHAGEAL PRESSURE WITHIN… (2*) CONTRACTIONS ON FUNCTION LUMINAL… Tu1224. . . . DEPRESSION OF HYDROGEN (5*) Tu1264. . . . INTER-OBSERVER AGREEMENT SULFIDE SYNTHESIS ENZYMES… (5*) FOR ANALYSIS OF FUNCTIONAL… (5*) Tu1244. . . . SWALLOWING AGAINST Tu1225. . . . HYPERCONTRACTILE MOTILITY LARYNGEAL RESTRICTION (SALR) Tu1265. . . . COMPARING REAL-TIME VS DISORDERS OF THE ESOPHAGUS:… (5*) EXERCISE… (2*) POST-PROCESSING DATA IN… (5*)

Tu1226. . . . FACTORS ASSOCIATED WITH Tu1245. . . . INITIAL GAINS BY Tu1266. . . . PROSPECTIVE EVALUATION OF SPASTIC ESOPHAGEAL DISORDERS… (5*) SWALLOWING AGAINST LARYNGEAL… (2*) THE CLINICAL RESPONSE… (5*)

Tu1227. . . . EFFICACY OF PER-ORAL Tu1246. . . . HIGH RESIDUAL UPPER Tu1267. . . . RELATIONSHIP BETWEEN ENDOSCOPIC MYOTOMY FOR… (5*) ESOPHAGEAL SPHINCTER PRESSURE… (5*) UPPER ESOPHAGEAL PRESSURES AND… (5*) Tu1228. . . . ACHALASIA QUALITY OF LIFE Tu1247. . . . ASSOCIATION OF NON- SCORE AND… (5*) DYSPHAGIA SYMPTOMS AND UPPER… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu1268. . . . INCOMPLETE ESOPHAGEAL Tu1288. . . . THE PREVALENCE OF BOLUS CLEARANCE IS ASSOCIATED… (5*) DISACCHARIDASE DEFICIENCY IN… (5*) Tu1320. . . . PROGNOSIS OF GASTRIC DYSPLASIA AFTER COMPLETE… (5*) Tu1269. . . . INCOMPLETE BOLUS Tu1289. . . . PILL ESOPHAGRAM CAN CLEARANCE CONTRIBUTES TO SEVERITY… IDENTIFY PEDIATRIC PATIENTS… (5*) Tu1321. . . . STRATIFICATION OF CT (5*) SURVEILLANCE BASED ON… (5*) Tu1290. . . . RELATIONSHIPS BETWEEN Tu1270. . . . CONTROL OF ESOPHAGEAL CLINICAL CHARACTERISTICS, TREATMENT, Tu1323. . . . IMPLICATION OF MOLECULAR SECONDARY PERISTALSIS BY… (4*) AND… (5*) SUBTYPE OF GASTRIC… (1*)

Tu1271. . . . APPLICATION OF A NOVEL LEG Tu1291. . . . VARIATIONS IN PRACTICE Tu1324. . . . IMPACT OF AGE ON STAGE- ELEVATION… (4*) PATTERNS IN THE… (2*) SPECIFIC MORTALITY… (2*)

Tu1272. . . . IMPACT OF GABA-B AGONIST Tu1292. . . . ABNORMAL 24-HOUR PH- Tu1325. . . . COMPARISON OF GASTRIC BACLOFEN ON… (4*) IMPEDANCE TESTING IS NOT… (4*)| CANCER PATIENTS BEFORE… (5*)

Tu1273. . . . ELEVATION OF BASAL EGJ Tu1305. . . . ASSOCIATION OF PHENOTYPES Tu1326. . . . HIGH PREVALENCE OF PRESSURE IS… (5*) OF LOW MUCOSAL… (5*) DISTANT METASTASIS AND… (4*)

Tu1274. . . . IMPACT OF PATIENT POSITION Tu1306. . . . PREVALENCE OF Tu1327. . . . RISK FACTORS OF EARLY AND ON ESOPHAGEAL… (5*) CANNABINOID USE DISORDER HAS… (5*) ADVANCED… (1*)

Tu1275. . . . HEMATOLOGICAL INDICES IN Tu1307. . . . PHYSICAL ACTIVITY AND ITS Tu1328. . . . OUTCOMES OF GI POLYPS ACHALASIA PATIENTS AND… (4*) IMPACT ON… (5*) RESECTED USING… (5*)

Tu1276. . . . DIAGNOSTIC ACCURACY OF AN Tu1308. . . . POOR SLEEP QUALITY AND Tu1329. . . . OUTCOMES IN PATIENTS ESOPHAGEAL SWEEP… (5*) DYSPEPSIA:ITS NOT… (5*) UNDERGOING GASTRECTOMY FOR… (5*)

Tu1277. . . . ESOPHAGOGASTRIC JUNCTION Tu1309. . . . EFFECT OF RIKKUNSHITO ON Tu1330. . . . FACTORS ASSOCIATED WITH OUTFLOW OBSTRUCTION: GASTROINTESTINAL MOTILITY… DEGREE OF DUODENAL… (4*) DETERMINATION OF… (4*) (3*)|(TSUMURA & CO. (Japan) provided study medication for this trial.) Tu1331. . . . EMERGENCY PRESENTATIONS Tu1278. . . . UTILITY OF ESOPHAGEAL DUAL FOR GASTROSTOMY COMPLICATIONS IN… PH SENSORS-IMPEDANCE… (1*) Tu1310. . . . EFFICACY AND SAFETY OF (5*) SOYO-SAN FOR… (2*)|(This study was Tu1279. . . . CORRELATION OF NOVEL supported by grants from the Korea Tu1415. . . . MANAGEMENT OF ACUTE INFLAMMATORY-NUTRITIONAL Evaluation Institute of Industrial Technology PANCREATITIS IN CHILDREN:… (5*) BIOMARKERS WITH… (5*) (No.10060251, The project of 'Development of the diagnostic device for functiol Tu1416. . . . PROLONGED Tu1280. . . . PERFORMING MORE THAN dyspepsia based on Korean-Western HYPERAMYLASEMIA IN PATIENTS WITH TEN SWALLOWS DURING… (5*) medicine fusion abdomil diagnosis').) ACUTE… (5*)

Tu1281. . . . UPPER ESOPHAGEAL Tu1311. . . . ENDOSCOPIC GASTRIC Tu1417. . . . ACUTE PANCREATITIS IN SPHINCTER IS HYPOTENSIVE IN… (5*) FUNCTION TEST: THE RELATIONSHIP… (4*) PATIENTS WITH CYSTIC… (5*)

Tu1282. . . . CLINICAL CHARACTERISTICS Tu1312. . . . CAMOSTAT MESILATE, Tu1418. . . . THE EPIDEMIOLOGY OF ACUTE AND TREATMENT RESPONSE OF… (5*) PANCRELIPASE AND RABEPRAZOLE PANCREATITIS IN… (5*) COMBINATION… (1*) Tu1283. . . . ESOPHAGOGASTRIC JUNCTION Tu1419. . . . SAFETY AND EFFICACY OF AN OUTFLOW OBSTRUCTION ASSOCIATED Tu1313. . . . EATING AND PSYCHIATRIC ED… (5*) WITH… (5*) DISORDERS ARE INDEPENDENT… (5*) Tu1420. . . . SAME ADMISSION Tu1284. . . . SWALLOW-TO-SWALLOW Tu1314. . . . CLASSIFYING FUNCTIONAL CHOLECYSTECTOMY FOR MODERATE TO… VARIATION IN ESOPHAGEAL MOTOR DYSPEPSIA USING A NOVEL… (5*) (5*) PATTERNS… (5*) Tu1315. . . . ACYLATED GHRELIN LEVELS Tu1421. . . . MORE ABOUT NPO IN ACUTE Tu1285. . . . MANOMETRIC WERE ASSOCIATED WITH… (1*) PANCREATITIS… (5*) CHARACTERISTICS OF UPPER ESOPHAGEAL SPHINCTER… (2*) Tu1316. . . . DOES MEASUREMENT OF Tu1422. . . . DEVELOPMENT AND SYMPTOMS DURING A… (5*) VALIDATION OF RISK PREDICTION… (2*) Tu1286. . . . DURATION OF SYMPTOMS AND MANOMETRIC PARAMETERS… (5*) Tu1318. . . . TOOSENDANIN EXERTS Tu1423. . . . ROLE OF INFLAMMATORY ANTITUMOR ACTIVITY IN GASTRIC… (2*) MARKERS IN STEP-UP… (5*) Tu1287. . . . ESOPHAGEAL MOTILITY AND ANTI-REFLUX BARRIER FUNCTION… (5*) Tu1319. . . . PREDICTIVE FACTORS OF Tu1424. . . . MARKED SERUM LIPASE LYMPH NODE METASTASIS… (5*) ELEVATIONS ARE ASSOCIATED… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu1445. . . . COMPARISON OF ONSITE, Tu1425. . . . ARE OPIATE NAIVE PATIENTS GLUCOMETER-MEASURED, CYST FLUID… Tu1535. . . . SEX, RACE AND INSURANCE WITH ACUTE… (5*) (5*) DISPARITIES IN… (5*)

Tu1426. . . . ADMITTING ACUTE Tu1446. . . . CLINICOPATHOLOGICAL Tu1536. . . . ASSESSING THE SURVIVAL PANCREATITIS PATIENTS WHO REQUIRE… FEATURES OF PANCREATIC DUCTAL OUTCOME RELATIONSHIP BETWEEN… (5*) (5*) ADENOCARCINOMA… (5*) Tu1537. . . . DEMOGRAPHICS FOR DO-NOT Tu1427. . . . ACUTE PANCREATITIS AND Tu1447. . . . EFFICACY OF LUMEN- RESUSCITATE STATUS AND… (5*) BMI: MORTALITY RATES… (5*) APPOSING METAL STENT INSERTION… (5*) Tu1538. . . . ETIOLOGY OF CIRRHOSIS Tu1428. . . . GASTROINTESTINAL Tu1448. . . . ALCOHOL-INDUCED CHANGING TRENDS OVER… (5*) FISTULISATION IN WALLED OFF EXPERIMENTAL PANCREATITIS: PANCREATIC… (5*) THERAPEUTIC BENEFITS BY… (2*) Tu1539. . . . PREVALENCE OF LIVER DISEASE IN PATIENTS… (5*) Tu1429. . . . LEFT VENTRICULAR ASSIST Tu1449. . . . PIRFENIDONE AMELIORATES DEVICE (LVAD), HEART… (5*) WELL-ESTABLISHED CHRONIC Tu1540. . . . HEPATOBILIARY-SPECIFIC PANCREATITIS IN… (2*) DELETION OF POLYMERIC Tu1430. . . . THE PREVALENCE OF VITAMIN IMMUNOGLOBULIN RECEPTOR… (6*) D DEFICIENCY,… (5*) Tu1450. . . . COMBINATION OF HEPARANASE INHIBITORS AND ASPIRIN… Tu1541. . . . VALIDATION OF NON- Tu1431. . . . FACTORS PREDICTING FAILURE (5*) INVASIVE BIOMARKERS OF LIVER… (2*) OF PERCUTANEOUS DRAINAGE… (5*)|(Nil) Tu1451. . . . CLINICAL CHARACTERISTICS Tu1542. . . . THE EFFECT OF LOW-ENERGY Tu1432. . . . COMPARISON OF OUTCOME AND OUTCOMES OF IMMUNE… (5*) EXTRACORPOREAL SHOCK… (5*) IN ACUTE PANCREATITIS… (5*) Tu1452. . . . EPITHELIAL PROLIFERATION OF Tu1543. . . . REVERSAL OF IMMUNE Tu1433. . . . RISK FACTORS AND INCIDENCE THE INTRAPANCREATIC DUCTS… (4*) EXHAUSTION FOLLOWING SVR… (3*)|(The FOR 30-DAY… (5*) Bristol-Myers Squibb Virology Fellows Tu1453. . . . TEDUGLUTIDE AMERIORATES Research Program for 2015-2017, (EA).) Tu1434. . . . TRENDS IN EARLY VS LATE EXTRA-PANCREATIC INFLAMMATION BY MORTALITY… (5*) REDUCTION… (2*)|(Shire Pharmaceuticals) Tu1544. . . . ACCURACY OF NON-INVASIVE TESTS TO DETECT… (5*) Tu1435. . . . MATRIX Tu1454. . . . USEFULNESS OF METALLOPROTEINASES AND THEIR TISSUE TRANSABDOMINAL SHEAR WAVE Tu1545. . . . SHEAR WAVE ELASTOGRAPHY INHIBITORS… (4*) ELASTOGRAPHY… (5*) USE FOR SCREENING… (5*)

Tu1436. . . . OBESITY BUT NOT NAFLD IS Tu1455. . . . CARBOXYL ESTER LIPASE DOES Tu1546. . . . GPBAR1 IS A MODULATOR OF A… (5*) NOT MEDIATE… (2*) LIVER… (5*)

Tu1437. . . . DEPLETION OF GRAM- Tu1456. . . . MORPHINE TREATMENT IN Tu1547. . . . GAUCHER DISEASE POSITIVE BACTERIA IN THE… (2*) ACUTE PANCREATITIS AFFECTS… (2*) PRESENTING AS NEONATAL CHOLESTASIS… (5*) Tu1438. . . . ACCURACY OF ENDOSCOPIC Tu1457. . . . ELEVATED BODY MASS INDEX ULTRASOUND TO ASSESS… (5*) INCREASES RISK… (5*) Tu1548. . . . STATIN-ASSOCIATED AUTOIMMUNE MYOPATHY: AN UNUSUAL Tu1439. . . . GROWTH FACTOR RECEPTOR Tu1458. . . . IMPACT OF PATIENT’S WEIGHT CAUSE… (5*) SIGNALING IN MEN1… (4*) ON PERFORMING… (5*) Tu1549. . . . SKYROCKETING LIVER Tu1440. . . . PREOPERATIVE C-REACTIVE Tu1459. . . . A PAIN IN THE GUT: A… (5*) ENZYMES: A REMARKABLE CASE… (5*) PROTEIN/ALBUMIN RATIO PREDICTS CANCERIZATION… (5*) Tu1473. . . . THERAPEUTIC EFFICACY OF Tu1550. . . . INFLAMMATION, ARTERIAL CHEMORADIOTHERAPY WITH STIFFNESS AND DIRECTLY-ACTING Tu1441. . . . ANALYSIS OF PANCREAS CYST MIRIPLATIN… (2*) ANTIVIRALS… (4*) GROWTH RATES… (7*) Tu1474. . . . UTILITY OF ENDOSCOPIC Tu1551. . . . HEPATITIS C PATIENTS WITH Tu1442. . . . ASSOCIATION OF DIABETES ULTRASOUND IN THE… (5*) ADVANCED AGE,… (5*) MELLITUS FOR LONG… (5*) Tu1475. . . . SYSTEMIC INFLAMMATORY Tu1552. . . . PREVALENCE OF HEPATITIS E Tu1443. . . . PERFORMANCE RESPONSE MARKERS AS PROGNOSTIC… VIRUS INFECTION… (4*)|(5) CHARACTERISTICS OF DNA ANALYSIS IN… (5*) (5*) Tu1553. . . . HEPATITIS B VIRUS PATIENTS Tu1476. . . . AFATINIB COMBINED WITH WITH MEDICAID… (3*)|(Research funding: Tu1444. . . . THE RELATIONSHIP BETWEEN GEMCITABINE/CISPLATIN IN Gilead Sciences) OBSERVATION INTERVAL AND… (5*) CHEMOTHERAPY… (3*)|(Boehringer Ingelheim)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu1554. . . . HEPATITIS B REACTIVATION IN Tu1610. . . . RESILIENCE IN IRRITABLE Tu1631. . . . CHARACTERIZATION OF INDIVIDUALS WITH… (5*) BOWEL SYNDROME IS… (2*) SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE… (4*) Tu1555. . . . RISKY ALCOHOL Tu1611. . . . PSYCHOLOGICAL FLEXIBILITY CONSUMPTION IS COMMON AMONG… AS AN IMPORTANT FEATURE… (2*) Tu1632. . . . ASSOCIATION BETWEEN (5*) BOWEL MOVEMENTS AND Tu1612. . . . CENTRALIZED SENSITIVITY DIVERTICULITIS… (2*)|(R01 DK101495, K24 Tu1593. . . . VIRULENCE PHENOTYPES OF PHENOTYPE AS A PREDICTOR… (2*) DK 098311 and UM1 CA186107 from the ATYPICAL ENTEROPATHOGENIC tiol Institutes of Health) ESCHERICHIA… (5*) Tu1613. . . . GLOBAL IBS SYMPTOM IMPROVEMENT IN COGNITIVE- Tu1633. . . . HIGH PROPORTION OF Tu1594. . . . TETHERED CAPSULE OCT BEHAVIORAL… (2*) DIFFUSE TYPE GASTRIC… (5*) IMAGING OF THE… (6*)| Tu1614. . . . VIRTUAL REALITY Tu1634. . . . THE PREVALENCE OF Tu1595. . . . INFLAMMATORY POTENTIAL MINDFULNESS THERAPY REDUCES PAIN… CARCINOID TUMORS OF… (5*) OF DIET, CIRCULATING INFLAMMATORY… (4*) (2*) Tu1635. . . . EPIDEMIOLOGY AND Tu1615. . . . IS IT ARFID, A MANAGEMENT OF ACHALASIA IN… (5*) Tu1596. . . . MULTIPLEX GASTROINTESTINAL DISORDER… (5*) GASTROINTESTINAL PATHOGEN PCR Tu1636. . . . THE USE OF WEB FORUMS TESTING IN… (5*) Tu1616. . . . INTEGRATED INFLAMMATORY DATA… (3*)|(Da Nutricia Research) BOWEL DISEASE- BEHAVIORAL MEDICINE… Tu1597. . . . THE ROLE OF ANTIBIOTICS IN (5*) Tu1637. . . . CARDIAC RISK OF ACUTE… (5*) PROKINETICS: A POPULATION-BASED,… Tu1617. . . . PREDICTING SUCCESSFUL (5*) Tu1598. . . . EXAMINING THE UTILITY OF OUTCOMES OF ANORECTAL GASTROINTESTINAL PATHOGEN… (5*) BIOFEEDBACK… (5*) Tu1638. . . . CHANGING TRENDS IN US HOSPITALIZATIONS WITH… (5*) Tu1599. . . . AQUAPORIN-5 EXPRESSION IS Tu1618. . . . PATIENTS WITH FUNCTIONAL REDUCED IN LYMPHOCYTIC… (4*) GASTROINTESTINAL DISORDERS (FGIDS)… Tu1639. . . . QUANTIFYING RISK FACTORS (2*) FOR ISCHEMIC COLITIS:… (5*) Tu1600. . . . AIR OR CARBON DIOXIDE INSUFFLATION IN… (5*) Tu1619. . . . SELF-PERCEIVED STRESS IS Tu1640. . . . A LEFT-TO-RIGHT SHIFT ASSOCIATED WITH CHEST… (5*) REEVALUATION OF COLORECTAL… (5*) Tu1601. . . . DIARRHEA IN TUBE-FED HOSPITALIZED PATIENTS: FEEDING… (4*) Tu1620. . . . WHAT IS COGNITIVE Tu1641. . . . ANALYSIS OF UC COLECTOMY IN/FLEXIBILITY IN IRRITABLE… (4*) RATES IN… (5*) Tu1602. . . . MEASUREMENT OF STRESS AND ANXIETY AND… (7*) Tu1621. . . . ATTENTIONAL BIAS IN Tu1642. . . . VALIDATION OF THE BRISTOL PEDIATRIC INFLAMMATORY BOWEL… (4*) STOOL CHART… (2*) Tu1603. . . . GASTROINTESTINAL COMPLICATIONS IN PATIENTS WITH Tu1623. . . . EPIDEMIOLOGY OF CYCLIC Tu1643. . . . RISING INCIDENCE OF SMALL CLOCAL… (5*) VOMITING SYNDROME: ANALYSIS… INTESTINAL CANCER… (5*) (3*)|(Takeda Pharmaceuticals) Tu1604. . . . EFFICACY AND SAFETY OF Tu1644. . . . GASTRIC CANCER SCREENING ANAL SPHINCTER… (5*) Tu1624. . . . SEASONAL VARIATIONS IN THE AT 2 U.S.… (5*) INCIDENCE AND… (5*) Tu1605. . . . CHRONIC INTESTINAL PSEUDO- Tu1645. . . . KILLING TWO BIRDS WITH ONE OBSTRUCTION IN CHILDREN: Tu1625. . . . INCIDENCE AND RISK FACTORS STONE:… (5*) EPIDEMIOLOGY… (5*) OF DIVERTICULITIS… (5*) Tu1646. . . . VARIATION IN RURAL Tu1606. . . . PREVALENCE OF CHILD ABUSE Tu1626. . . . NATIONAL TRENDS, COLORECTAL CANCER SCREENING… (6*) IN CHILDREN… (5*) OUTCOMES AND PREDICTORS OF… (5*) Tu1647. . . . STATE-LEVEL HEALTH Tu1607. . . . SOMATIC AND PSYCHOSOCIAL Tu1627. . . . BUDD CHIARI SYNDROME: A INSURANCE STATUS IS ASSOCIATED… (5*) FACTORS ASSOCIATED WITH… (2*) STUDY FROM… (5*) Tu1648. . . . LOW YIELD OF ENDOSCOPIC Tu1608. . . . LONG-TERM FOLLOW-UP OF Tu1628. . . . SHOULD ORIGINAL RESEARCH SURVEILLANCE FOR… (5*) GUT-DIRECTED HYPNOTERAPY SELF- BE SHARED ON… (5*) EXERCISES… (5*) Tu1649. . . . GALLBLADDER POLYP IS Tu1629. . . . INCREASING BODY MASS ASSOCIATED WITH PROXIMAL… (5*) Tu1609. . . . HOW OFTEN DO INDEX, MALE GENDER,… (5*) GASTROENTEROLOGIST'S SCREEN FOR… Tu1650. . . . ACCURACY OF ELECTRONIC (5*) Tu1630. . . . HEPATOCELLULAR CARCIOMA HEALTH RECORD BILLING… (2*) INCIDENCE IS DECREASING AMONG… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu1651. . . . TELEPHONE COUNSELING Tu1671. . . . SMALL BOWEL NEOPLASIA study was conducted with unrestricted INTERVENTION IMPROVES UPTAKE OF… DETECTION IN LYNCH… (5*) funding from Celgene Corporation.) (4*) Tu1672. . . . PREVALENCE OF GENE Tu1708. . . . EARLY CHILDHOOD Tu1652. . . . COLORECTAL CANCER MUTATIONS IN PATIENTS… (4*) INFLAMMATORY BOWEL DISEASE IS… (2*) SCREENING AND PATIENT NAVIGATION:… (2*) Tu1673. . . . SINGLE-GENE VS. MULTI-GENE Tu1710. . . . USTEKINUMAB TO TREAT PANEL TESTING IN… (5*) PEDIATRIC PATIENTS WITH… (2*) Tu1653. . . . ACCURACY OF INITIAL RECOMMENDED COLONOSCOPY Tu1691. . . . PLATINUM BASED THERAPY IN Tu1711. . . . EXTENDED TREATMENT WITH SURVEILLANCE… (2*) PATIENTS WITH… (5*) MIRIKIZUMAB IN PATIENTS… (3*)|(Eli Lilly and Company) Tu1654. . . . THE EFFECT OF GENDER AND Tu1692. . . . CLINICAL CHARACTERISTICS OF RACE… (5*) TAXANE-BASED CHEMOTHERAPY-INDUCED Tu1712. . . . REDUCTION IN COLITIS… (5*) INFLAMMATORY BIOMARKERS IN A… Tu1655. . . . THE LONG TERM IMPACT OF (3*)|(Eli Lilly and Company) ROUX-EN-Y… (5*) Tu1693. . . . POTENTIATION OF CALCIUM- ACTIVATED CHLORIDE SECRETION AND… Tu1713. . . . EFFICACY AND SAFETY OF 2 Tu1656. . . . GASTRIC CANCER AND (4*) OR… (3*)|(Takeda) GEOGRAPHICAL/ETHNIC SHIFTS IN… (5*) Tu1694. . . . CLINICAL FEATURES OF Tu1714. . . . IMPACT OF UPADACITINIB ON Tu1657. . . . REGIONAL AND RACIAL RITUXIMAB-INDUCED GASTROINTESTINAL THE GENERAL… (3*)|(AbbVie funded the DISPARITIES IN GASTRIC… (4*) TOXICITIES… (5*) study, contributed to its design, and was involved in the collection, alysis, and Tu1658. . . . MECKEL’S DIVERTICULUM- A Tu1695. . . . ANTI-ANGIOGENESIS CANCER interpretation of the data, and in the NIDUS FOR ILEAL… (4*) THERAPY-RELATED GASTROINTESTINAL writing, review, and approval of the INJURY CAN… (5*) publication. Medical writing support was Tu1659. . . . ENDOMETRIAL POLYPS ARE provided by Maria Hovenden, PhD, Compl) MORE LIKELY TO… (2*) Tu1696. . . . NEUTROPENIC COLITIS - CLINICAL FEATURES, TREATMENT… (5*) Tu1715. . . . A NOVEL FORMULATION OF Tu1660. . . . INCREASING INPATIENT CT-P13 (INFLIXIMAB… (3*) ADMISSIONS, COSTS, AND MORTALITY… Tu1697. . . . COMPARISON OF RISK (5*) FACTORS BETWEEN INTESTINAL… (5*) Tu1716. . . . HIGHLY BIOAVAILABLE CURCUMIN (THERACURMIN®) FOR Tu1661. . . . PREVALENCE, IN-HOSPITAL Tu1698. . . . FLUOROPYRIMIDINE-INDUCED CROHN’S… (5*) OUTCOMES AND RESOURCE UTILIZATION… INTESTINAL MUCOSAL INJURY IS (5*) ASSOCIATED… (1*) Tu1717. . . . TOFACITINIB FOR THE TREATMENT OF ULCERATIVE… (3*)|(Pfizer Tu1662. . . . THE EPIDEMIOLOGY OF Tu1699. . . . BIFIDOBACTERIUM ANIMALIS Inc) GASTRIC CANCER IN… (5*) SUBSPECIES LACTIS ENGINEERED TO… (5*) Tu1718. . . . IMMUNOGENICITY OF Tu1663. . . . ANATOMICAL DISTRIBUTION Tu1700. . . . ANTI-INFLAMMATORY AND USTEKINUMAB IN PATIENTS WITH… OF GASTRIC CANCER IN… (5*) ANTI-OXIDATIVE EFFECTS OF 17-β… (5*) (3*)|(This study was funded by Janssen Research & Development, LLC) Tu1664. . . . DOES THE GEOGRAPHIC Tu1701. . . . EFFECTS OF 17β-ESTRADIOL DISTRIBUTION OF THE… (5*) ON COLORECTAL CANCER… (5*) Tu1719. . . . CLINICAL REMISSION BY LEGACY VERSUS FDA… (3*)|(This study was Tu1665. . . . TRISOMY 21 DOES NOT Tu1702. . . . ELEVATED O-GLCNACYLATION funded by Janssen Research & INCREASE THE… (5*) INCREASES FOXM1 PROTEIN VIA… (4*) Development, LLC)

Tu1666. . . . ANALYSIS OF THE Tu1703. . . . CYSTATHIONINE-GAMMA- Tu1720. . . . EFFICACY OF TOFACITINIB ASSOCIATION BETWEEN POVERTY… (5*) LYASE EXPRESSING BONE MARROW- MAINTENANCE THERAPY FOR… (3*)|(Pfizer DERIVED CELLS INHIBIT… (2*) Inc) Tu1667. . . . RACIAL/ETHNIC DISPARITIES IN GASTRIC CANCER INCIDENCE,… (5*) Tu1704. . . . THE PREVELANCE OF PRIMARY Tu1721. . . . MAINTENANCE OF EFFICACY MALIGNANT NEOPLASM… (5*) FOLLOWING TOFACITINIB DOSE… Tu1668. . . . WHAT IS THE PREVALENCE OF (3*)|(Pfizer Inc) SERRATED… (2*) Tu1705. . . . COLONOSCOPY IS INDICATED AFTER AN EPISODE… (5*) Tu1722. . . . DARVADSTROCEL TREATMENT Tu1669. . . . CHROMOENDOSCOPY LEADS OUTCOMES IN CROHN'S DISEASE… TO A HIGHER INSIGHT-STAGE… (4*) Tu1706. . . . EARLY ENDOSCOPIC (3*)|(Takeda Pharmaceutical Company) EVALUATION ASSOCIATED WITH Tu1670. . . . EXOGENOUS AND SHORTER… (5*) Tu1723. . . . IDENTIFICATION OF RISK ENDOGENOUS ASSOCIATED FACTORS TO… FACTORS ASSOCIATED WITH… (3*)|(This (5*) Tu1707. . . . PATIENT REPORTED study was funded by Janssen Research & MEASURES OF HEALTH STATUS… (3*)|(This Development, LLC)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) was funded by Janssen Research & Tu1724. . . . ASSOCIATION OF Development, LLC) Tu1748. . . . ORAL CURCUMIN IS NOT USTEKINUMAB SERUM CONCENTRATIONS MORE EFFECTIVE… (2*) AND… (3*)|(Janssen Research & Tu1736. . . . MOLECULAR RESPONSE TO Development, LLC funded this study.) USTEKINUMAB IN MODERATE-TO- Tu1749. . . . PHARMACOKINETICS AND SEVERE… (3*)|(This study was funded by EXPOSURE-RESPONSE RELATIONSHIPS OF Tu1725. . . . CHARACTERIZATION OF Janssen Research & Development, LLC) INTRAVENOUSLY… (3*)|(This study was PATIENTS WITH DELAYED RESPONSE… funded by Janssen Research & (3*)|(This study was funded by Janssen Tu1737. . . . EFFICACY OF THE ANTI- Development, LLC) Research & Development, LLC) MUCOSAL ADDRESSIN CELL… (3*)|(The TURANDOT II study was funded by Pfizer Tu1750. . . . NOVEL RIFAMYCIN SV MULTI- Tu1726. . . . THE IMPACT OF EARLY and Shire. These alyses were funded by MATRIX FORMULATION FOR… DISEASE CONTROL… (3*)|(Takeda) Shire. Medical writing support was provided (3*)|(Clinical study was funded by Dr. Falk by PharmaGenesis London and funded by Pharma GmbH.) Tu1727. . . . RAPIDITY OF SYMPTOMATIC Shire.) AND INFLAMMATORY BIOMARKER… Tu1751. . . . THE EFFECT OF REMOTE (3*)|(The authors and AbbVie scientists Tu1738. . . . BIOMARKER AND ISCHEMIC CONDITIONING… (3*)|(Novo designed the study, and alysed and PHARMACOKINETIC DATA FROM THE… Nordisk Foundation) interpreted the data. AbbVie funded the (3*)|(The TURANDOT II study was funded research and provided writing support. All by Pfizer and Shire. These alyses were Tu1752. . . . ANALYSIS OF HEMATOLOGICAL authors contributed to the development of funded by Shire. Medical writing support CHANGES IN TOFACITINIB-TREATED… the content. The authors and AbbVie was provided by PharmaGenesis London (3*)|(Pfizer Inc) reviewed and approved the) and funded by Shire.) Tu1753. . . . ANALYSIS OF THE IMPACT OF Tu1728. . . . LONG-TERM EFFICACY AND Tu1739. . . . EFFICACY AND SAFETY OF BODY… (3*)|(Pfizer Inc) PHARMACODYNAMICS OF THE… (3*)|(The USTEKINUMAB THROUGH… (3*)|(This OPERA II study was funded by Pfizer. These study was funded by Janssen Research & Tu1754. . . . SAFETY AND TOLERABILITY OF alyses were funded by Pfizer and Shire. Development, LLC) BT-11, A… (3*)|(Study was funded by Medical writing support was provided by Landos Biopharma, Inc.) Emma Saxon PhD of PharmaGenesis London Tu1740. . . . SUSTAINED REMISSION IN and funded by Shire.) PATIENTS WITH MODERATE… (3*)|(The Tu1755. . . . EFFICACY OF COMBINATION study was funded by Janssen Research & THERAPY OF FECAL… (2*) Tu1729. . . . LONG-TERM EFFICACY OF Development, LLC) TOFACITINIB IN PATIENTS… (3*)|(Pfizer Tu1756. . . . THE TREATMENT NAIVE Inc) Tu1741. . . . A NOVEL ORAL FORMULATION RECTAL TRANSCRIPTOME IDENTIFIES… (2*) OF BUDESONIDE… (3*)|(Dr. Falk Pharma Tu1730. . . . IMPROVEMENT IN PATIENT- GmbH) Tu1757. . . . FUNCTIONAL REGULATORY REPORTED INFLAMMATORY BOWEL ANNOTATION OF FINE-MAPPED IBD… (2*) DISEASE… (3*)|(Pfizer Inc) Tu1742. . . . LONG-TERM IMMUNOGENICITY OF INTRAVENOUS Tu1758. . . . INFLAMMATORY BOWEL Tu1731. . . . EARLY HISTOLOGIC VEDOLIZUMAB IN… (3*)|(Takeda) DISEASE TRANSCRIPTOMES REVEAL IMPROVEMENT DEMONSTRATED WITH REDUCED… (4*) ORAL… (3*)|(This study is sponsored by Tu1743. . . . IV IRON TREATMENT OF IRON Celgene Corporation.) DEFICIENCY… (3*)|(AMAG Pharmaceuticals, Tu1759. . . . NEW METHYLATION Inc.) BIOMARKER PANEL OF INFLAMMATORY… Tu1732. . . . CHANGES IN SIMPLIFIED (5*) ENDOSCOPIC SCORE FOR… (3*)|(AbbVie Tu1744. . . . TARGETED RELEASE ORAL funded the study, contributed to its design, CYCLOSPORINE (ST-0529) AS… (3*) Tu1760. . . . ALTERATIONS IN EXPRESSION and was involved in the collection, alysis, QUANTITATIVE TRAIT LOCI… (2*) and interpretation of the data, and in the Tu1745. . . . CORRELATION OF FECAL writing, review, and approval of the CALPROTECTIN AND C-REACTIVE… Tu1761. . . . POLYGENIC RISK SCORES ARE publication. Medical writing support was (3*)|(Are Pharmaceuticals, Inc.) ASSOCIATED WITH… (2*) provided by Maria Hovenden, PhD, Compl) Tu1746. . . . A PHASE 3 STUDY OF Tu1762. . . . GENETIC BACKGROUND OF Tu1733. . . . CLINICAL REMISSION VEDOLIZUMAB… (3*)|(Takeda THIOPURINE-INDUCED PANCREATITIS IN… DEMONSTRATED WITH ORAL OZANIMOD… Pharmaceutical Company, Ltd.) (2*) (3*)|(This study is sponsored by Celgene Corporation.) Tu1747. . . . EFFECT OF TELEMEDICINE FOR Tu1763. . . . SYSTEMIC AND TISSUE INFLAMMATORY BOWEL… (2*)|(This MODULATION OF IL-23… (3*)|(Boehringer Tu1734. . . . EFFECT OF VEDOLIZUMAB ON research was supported by the Agency for Ingelheim and AbbVie funded the study and SURGICAL RATES… (3*)|(Takeda Healthcare Research and Quality research. AbbVie provided medical writing Pharmaceuticals U.S.A., Inc.) (1R01HS018975-01A1) and the University of support. All authors contributed to the Maryland General Clinical Research Centers development of the content. The authors Tu1735. . . . EFFECTS OF USTEKINUMAB Program. Zaid Bilgrami was supported by and AbbVie reviewed and approved the INDUCTION THERAPY ON… (3*)|(This study the Program for Research Initiated by abstract. The authors maintained control Students and) ov)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu1781. . . . SEASONAL VARIATION OF Tu1764. . . . INHIBITION OF MYELOID FECAL MICROBIOTA IN… (1*) Tu1799. . . . A NATIONAL, RETROSPECTIVE, DIFFERENTIATION 1 SPECIFICALLY… (2*) OBSERVATIONAL STUDY ON… (3*)|(Ferring Tu1782. . . . COMPOSITIONAL CHANGES IN Pharmaceuticals) Tu1765. . . . HISTONE 3 LYSINE 27 THE GUT MICROBIOTA… (2*) ACETYLATION PROFILING… (2*) Tu1800. . . . A PROSPECTIVE MULTICENTER Tu1783. . . . IN VITRO EFFECTS OF XYLO- OBSERVATIONAL COHORT STUDY… Tu1766. . . . DYSREGULATED LNCRNAS IN OLIGOSACCHARIDE ON… (2*) (3*)|(This study is supported by Ferring INFLAMMATORY BOWEL DISEASE… (2*) Pharmaceuticals.) Tu1784. . . . ABNORMALITIES IN THE FECAL Tu1767. . . . MULTI-ALLELES MICROBIOME OF… (4*) Tu1801. . . . PRESCRIBING PATTERNS AND POLYMORPHISMS PREDICT PRIMARY NON- LONG-TERM CONTINUATION RATES… (5*) RESPONSE TO… (5*) Tu1785. . . . EB8018 IS ABLE TO DECREASE TNFα… (3*)|(ENTEROME S.A.) Tu1802. . . . PERCEIVED QUALITY OF CARE Tu1768. . . . IDENTIFYING MOLECULAR IS ASSOCIATED… (1*)|(The study was FEATURES CONTRIBUTING TO DISEASE… Tu1786|BSQS5. . . . CHARACTERIZATION supported by the McGill CAS Research (4*) OF THE FISTULA-ASSOCIATED Support Program, the Kimberly Sue McGall MICROBIOME IN… (4*)|(The Tobacco Award in IBD Research and the Nesbitt- Tu1769. . . . DNA METHYLATION Formula grant is under the Commonwealth McMaster Award and the WI230654 Pfizer SIGNATURES IN CROHN’S DISEASE- Universal Research Enhancement (C.U.R.E) unrestricted research grant.) RELATED… (2*) program with the grant number SAP # 4100068710.) Tu1803. . . . IDENTIFICATION OF PATIENTS Tu1770. . . . TLR7 AGONIST INDUCED WITH INFLAMMATORY BOWEL… (6*) DERMATITIS EXACERBATED COLITIS… Tu1787. . . . POTENTIAL PROTECTIVE (2*)|(This work is supported by the Yakult EFFECT OF PD-1 INHIBITOR… (5*) Tu1804. . . . EFFECTIVENESS OF A REMOTE bio science foundation. Author was the PATIENT MONITORING… (3*)|(Abbvie employee of Takeda pharm. Co-author was Tu1788. . . . COMPLETE ENGRAFTMENT OF Cada) the employee of Miyarisan, Tabe THE HUMAN GUT… (2*) mitsubishi, Ezaki pharm.) Tu1805. . . . REGIONAL IBD SURVEILLANCE Tu1789. . . . TREATMENT RESPONSE TO ENDOSCOPY NORTH WEST… (6*) Tu1771. . . . PRENATAL MATERNAL STRESS USTEKINUMAB AND VEDOLIZUMAB… (5*) INDUCES GUT DYSBIOSIS… (5*) Tu1806. . . . KNOWLEDGE AND ATTITUDES Tu1790. . . . BACTERIA DERIVED TOWARDS PREGNANCY IN… (5*) Tu1772. . . . ‘INDIGO NATURALIS’ TRYPTAMINE PRODUCTION ALTERS HOST… AMELIORATES ULCERATIVE COLITIS VIA… (2*) Tu1807. . . . THE COMPARISON OF (5*) DISEASE-RELATED KNOWLEDGE OF… (5*) Tu1791. . . . INSIGHTS INTO ALTERATION Tu1773. . . . CHARACTERISTICS AND OF GUT MICROBIOTA… (4*) Tu1808. . . . SIGNIFICANT REDUCTION OF PATHOGENIC ROLE OF ADHERENT- ADMISSION TIME AT… (5*) INVASIVE… (2*) Tu1792. . . . GUT MICROBIOME DIVERSITY IN ACUTE SEVERE… (2*) Tu1809. . . . INFREQUENT COUNSELING BY Tu1774. . . . MICROBIOME PHYSICIANS ON IBD… (5*) FUNCTIONALGENOMICS REVEALS NOVEL Tu1793. . . . EUKARYOTIC MICROBIAL BACTERIAL STRAINS… (3*)|(Biomica Ltd. DYSBIOSIS IN TREATMENT-NAÏVE Tu1810. . . . FRAGILITY INDEX OF Rehovot, Israel, www.biomicamed.com) PATIENTS… (6*)|(This work was supported RANDOMIZED CONTROLLED TRIALS… (5*) by the Leo M. and Harry B. Helmsley Tu1775. . . . THE NOD2 ASSOCIATION WITH Charitable Trust) Tu1811. . . . THE CONCERT INITIATIVE: CD-ASSOCIATED SEROLOGICAL… (2*) IMPROVING COMMUNITY CARE… Tu1794. . . . ADHERENT-INVASIVE (3*)|(Financial support for this study is Tu1776. . . . CLOSTRIDIUM DIFFICILE ESCHERICHIA COLI COLONIZATION being provided by AbbVie; AbbVie DIAGNOSIS BY TOXIN ENZYME… (5*) PROMOTES INTESTINAL… (2*) participated in the design of the study and approval of the abstract; all authors Tu1777. . . . THE GUT MICROBIOME Tu1795. . . . CHANGES IN SMALL contributed to the development of the MODULATES COLORECTAL INTESTINAL MICROBIOME DURING… (4*) abstract and maintained control over the fil TUMORIGENESIS… (2*)| content.) Tu1796. . . . MANAGEMENT OF Tu1778. . . . THE GUT MICROBIAL PROFILE INFLAMMATORY BOWEL DISEASE Tu1812. . . . USE OF ADVANCED PRACTICE OF PRECLINICAL… (4*) PATIENTS… (2*)|(Promoting Access and NURSING TO… (5*) Care through Centers of Excellence (PACE) Tu1779. . . . CINNAMON EXTRACT Network, Crohn's and Colitis Cada.) Tu1813. . . . WHAT ARE THE MOST AMELIORATES EXPERIMENTAL COLITIS CHALLENGING ASPECTS… (5*) VIA… (4*) Tu1797. . . . HERPES ZOSTER VIRUS IN INFLAMMATORY BOWEL… (5*) Tu1814. . . . INFLAMMATORY BOWEL Tu1780. . . . DIETARY WHEAT AMYLASE DISEASE, THE EMERGENCY TRYPSIN INHIBITORS MODIFY… (2*) Tu1798. . . . LOW MOLECULAR WEIGHT DEPARTMENT,… (5*) HEPARIN (LMWH) COMPARED… (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu1815. . . . CONCENTRATION OF Tu1832. . . . ASSOCIATION OF Tu1850. . . . ADHERENT-INVASIVE INFLIXIMAB IN THE NON-INFLAMED… VEDOLIZUMAB LEVELS WITH CLINICAL… ESCHERICHIA COLI IN INFLAMMATORY (2*)|(This study was partly supported by (5*) BOWEL… (2*) AMED (Japan Agency for MedicalResearch and Development) (J160705148).) Tu1833. . . . WEEK 2 ADALIMUMAB LEVEL Tu1851. . . . STUDY ON THE PREDICTS SHORT-TERM… (5*) INFLAMMATORY MECHANISMS OF… (2*) Tu1816. . . . COMBINATION OF BIOMARKERS REFLECTING TYPE IV… (5*) Tu1834. . . . A PROTOCOL FOR SAFE Tu1852. . . . METFORMIN AMELIORATED REINTRODUCTION OF… (5*) INFLAMMATORY BOWEL DISEASE BY… (2*) Tu1817. . . . INCREASING SUBCUTANEOUS FAT AND WEIGHT ARE… (2*) Tu1835. . . . ASSOCIATION BETWEEN Tu1853. . . . FAECALIBACTERIUM VEDOLIZUMAB TROUGH CONCENTRATION PRAUSNITZII PRODUCES BUTYRATE TO Tu1818. . . . ULTRA-PROACTIVE AND… (5*) DECREASE… (2*) THERAPEUTIC DRUG MONITORING INCORPORATING INFLIXIMAB… Tu1836. . . . INFLIXIMAB TROUGH LEVELS Tu1854. . . . ASSOCIATION BETWEEN QPCR (5*)|(Mundipharma) ARE NOT PREDICTIVE… (2*) ASSAYS TARGETING FIMS/FIMH… (3*)|(Enterome was the sponsor of the Tu1819. . . . SERUM MARKER PANEL FOR Tu1837. . . . DEVELOPING A NOVEL study) DETECTION OF… (3*)|(Kepler Diagnostics, MEDICATION ADHERENCE INDEX… (5*) Inc. purchased all alyzed ELISA kits) Tu1855. . . . MICROBIOTA EXPOSURE IN Tu1838. . . . DOES SWITCHING BETWEEN 5- EARLY LIFE IMPACTS… (2*) Tu1820. . . . PROACTIVE INFLIXIMAB DRUG AMINOSALICYLATES AFFECT THIOPURINE… MONITORING IS SUPERIOR… (5*) (5*) Tu1856. . . . THE SIDEROPHORE YERSINIABACTIN POTENTIATES Tu1821. . . . PHARMACOKINETIC AND Tu1839. . . . IMPACT OF USTEKINUMAB INFLAMMATORY BOWEL… (4*) PHARMACODYNAMIC EVALUATION OF TDM ON CLINICAL… (3*) RADIOLOGICAL… (5*) Tu1857. . . . NEONATAL Tu1840. . . . LOW DRUG LEVELS DURING SUPPLEMENTATION WITH A Tu1822. . . . IFX SERUM LEVELS AT TROUGH INFLIXIMAB MAINTENANCE… (5*) LACTOBACILLUS RHAMNOSUS… (2*) DO… (5*) Tu1841. . . . COMPARATIVE ANALYSIS OF Tu1858. . . . SEGMENTED FILAMENTOUS Tu1823. . . . THERAPEUTIC DRUG BLOOD AND MUCOSAL… (4*) BACTERIA INDUCE ALTERNATIVE TH17… MONITORING-BASED OPTIMIZATION (2*) SHOULD BE… (5*) Tu1842. . . . NOVEL POPULATION SUBSETS OF TCRΒHI TH17,… (5*) Tu1859. . . . ALTERING DIETARY Tu1824. . . . TROUGH LEVELS OF FERMENTABLE CARBOHYDRATE (FODMAP) INFLIXIMAB BETTER CORRELATE… (5*) Tu1843. . . . ACETYLCHOLINE SECRETING T- CONTENT… (2*) CELLS CONTRIBUTE TO INNATE… Tu1825. . . . USTEKINUMAB THERAPEUTIC (3*)|(Galvani Bioelectronics unrestricted Tu1860. . . . THE OCCURRENCE OF UPPER DRUG MONITORING IN CROHN’S… (5*) research grant) GASTROINTESTINAL DISEASE… (5*)

Tu1826. . . . EVALUATION OF PREDICTORS Tu1844. . . . DETERMINING PREDICTORS OF Tu1861. . . . UNIDENTIFIED COCCOID OF DURABLE CLINICAL… (5*) GASTROINTESTINAL DISEASE IN… (5*) BACTERIA (UCB) ARE ASSOCIATED… (5*)

Tu1827. . . . MAINTENANCE LEVELS OF Tu1845. . . . IDENTIFICATION OF A UNIQUE Tu1862. . . . HISTAMINE IS IMPORTANT VEDOLIZUMAB DO NOT… POPULATION OF… (4*)|(This work was FOR MACROPHAGES ACTIVITIES… (2*) (4*)|(Prometheus Laboratories) supported by the Gatorade Trust through funds distributed by the University of Tu1863. . . . DIFFERENCES AMONG Tu1828. . . . ENHANCING UTILIZATION OF Florida, Department of Medicine.) LUMINAL AND MUCOSAL MICROBIOTA… THERAPEUTIC DRUG MONITORING… (2*)| (4*) Tu1846. . . . HIGHER TNFα AND MIP-1β Tu1829. . . . COMPARISON OF SERUM EXPRESSION IN… (4*) Tu1867. . . . LNCRNAS TARGETED BY CONCENTRATIONS OF USTEKINUMAB… ENTERIC BACTERIAL INFECTION… (2*) (5*) Tu1847. . . . UREASE-POSITIVE PROTEOBACTERIA IN CROHN'S DISEASE Tu1868. . . . THERAPEUTIC FECAL Tu1830. . . . INFLIXIMAB AND IDENTIFIED… (6*) MICROBIOTA TRANSPLANTATION ADALIMUMAB CONCENTRATIONS MAY CONTROLS INTESTINAL… (6*) VARY… (3*)|(This study was funded by Tu1848. . . . ESCHERICHIA COLI Inform Diagnostics.) SIDEROPHORE PRODUCTION INDUCES Tu1869. . . . CHARACTERIZATION OF INTESTINAL… (2*) CROHN'S DISEASE MUCOSA-ASSOCIATED Tu1831. . . . USE OF DRUG-TOLERANT MICROBIOTA… (6*) ASSAYS IN INFLAMMATORY… Tu1849. . . . ROSEBURIA INTESTINALIS (3*)|(Prometheus Laboratories (who FLAGELLIN ALLEVIATES EXPERIMENTAL Tu1870. . . . ENDOBARRIER® performed the drug/antibody assays)) COLITIS… (2*) IMPLANTATION IS ASSOCIATED WITH MARKED… (2*)|(NIDDK rO1 21769 NIDDK rO1 29867)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu1888. . . . THE UTILITY OF MULTIPLEX GI Tu1907. . . . LIVER FIBROSIS STAGE AT Tu1871. . . . THE ASSOCIATION BETWEEN PCR… (5*) BASELINE PREDICTS… (2*) ANTIBIOTICS EXPOSURE DURING… (4*) Tu1889. . . . THE PROTECTIVE Tu1908. . . . EFFICACY OF Tu1872. . . . THE HUMAN INTESTINAL ANTIMICROBIAL ACTIVITY OF VSL#3… (5*) PHARMACOTHERAPY IN THE TREATMENT… PROTEOME IN CHILDREN… (7*) (5*) Tu1890. . . . GASTRIC MICROBIOTA IN Tu1873. . . . BOWEL CLEANSING MAY HELICOBACTER PYLORI-NEGATIVE AND… Tu1909. . . . ROUX-EN-Y GASTRIC BYPASS AFFECT DIAGNOSTIC YIELD… (5*) (2*)| IMPROVES ESOPHAGEAL SYMPTOMS… (5*)

Tu1874. . . . DETECTION OF ENTERIC Tu1891. . . . AUTOMATED MOLECULAR Tu1910. . . . ESOPHAGITIS AFTER INFECTIONS IN THE… (5*) DETECTION OF HELICOBACTER PYLORI… BARIATRIC SURGERY: LARGE CROSS- (3*)|(This study was funded by SECTIONAL… (4*) Tu1875. . . . CHRONIC ANTIBIOTIC USE AND AutoGenomics inc.) SUBSEQUENT DEVELOPMENT… (2*) Tu1911. . . . BARIATRIC SURGERY IS Tu1892. . . . COMPARISON OF HIGH AND ASSOCIATED WITH REDUCED… (5*) Tu1876. . . . FECAL MICROBIOTA LOW MOLECULAR… (2*)|(Small Grant TRANSPLANTATION FOR IMMUNE Exploratory Research, korea) Tu1912. . . . WEIGHT LOSS AND METABOLIC CHECKPOINT… (4*) IMPROVEMENTS ONE… (2*)|(GI Dymics Tu1893. . . . SPANISH SPECIALYST CARE provided training for the clinical staff.) Tu1877. . . . FECAL MICROBIOTA SURVEY ON THE… (3*)|(Laboratorios Casen TRANSPLANTATION (FMT) FOR IRRITABLE… Recordati, Spain.) Tu1913. . . . ‘TO DELAY OR NOT TO (5*) DELAY:… (5*) Tu1894. . . . COLONIC MUCOSAL Tu1878. . . . FECAL MICROBIOTA MICROBIOME IS ASSOCIATED WITH… (4*) Tu1914. . . . BODY COMPOSITION AS TRANSPLANTATION (FMT) IN IRRITABLE… FOLLOW UP OF… (5*) (5*) Tu1895. . . . COLONIC MUCOSAL MICROBIOME CORRELATES WITH Tu1915. . . . FEASIBILITY OF SERUM Tu1879. . . . RAPID AND DURABLE DIETARY… (2*) LIPIDOMICS AND FECAL… (2*) ENGRAFTMENT OF DONOR… (4*)|(the funding source from Gut Microbiome Tu1896. . . . ASTAXANTHIN ATTENUATED Tu1916. . . . ASSESSMENT OF NOVEL Research Center provided by the Faculty of INTESTINAL HYPERMOTILITY INDUCED BY… PLICATION TECHNIQUE IN… (5*) Medicine, The Chinese University of Hong (2*) Kong) Tu1917. . . . IMPACTS OF LIRAGLUTIDE USE Tu1897. . . . ENTERIC METHANE OR IN WEIGHT… (5*) Tu1880. . . . DURABLE FREEDOM FROM HYDROGEN PRODUCTION IN… (2*) CLOSTRIDIUM DIFFICILE INFECTION… Tu1918. . . . SEVERE NUTRITIONAL (3*)|(This alysis was funded by Rebiotix Tu1898. . . . A COMPARISON OF PATIENTS COMPLICATIONS AFTER BARIATRIC Inc., Roseville, MN, USA.) WITH UNEXPLAINED… (2*) SURGERY… (4*)

Tu1881. . . . ECONOMIC EVALUATION OF A Tu1899. . . . MICROBIAL FECALIZATION OF Tu1919. . . . COMPLIANCE WITH EARLY FECAL MICROBIOTA… (4*) THE SMALL INTESTINE… (2*)|(NIDDK r01 POST-OPERATIVE FOLLOW-UP REDUCES… 21769 NIDDK r01 29867) (4*) Tu1882. . . . FECAL VIRUS-LIKE PARTICLES REDUCE BACTERIAL DENSITY… (6*) Tu1900. . . . DOSE RESPONSE FOR ARGON Tu1920. . . . CHANGES IN QUALITY OF LIFE, PLASMA COAGULATION… (5*) BODY… (5*) Tu1883. . . . SELECTIVE MICROBIOTA TRANSPLANTATION INDUCES RADIATION Tu1901. . . . LOW FREQUENCY VAGAL Tu2026. . . . MIR-23B-3P PROMOTES PROCTITIS… (1*)| NERVE STIMULATION USING… (2*) CARCINOGENICITY THROUGH PETN/PI3K/AKT PATHWAY… (2*) Tu1884. . . . PRE-TREAT WITH Tu1902. . . . PROSPECTIVE STUDY FAECALIBACTERIUM PRAUSNITZII PREVENT INVESTIGATING CHANGES IN GASTRIC… Tu2027. . . . GREATER LINE-1 THE… (2*) (2*) HYPOMETHYLATION IN TUBULAR ADENOMAS… (4*) Tu1885. . . . PROTECTIVE EFFECT OF SMT Tu1903. . . . A COMPARISON OF GASTRIC (SELECTIVE MICROBIOTA… (2*) PLICATION ALONE… (5*) Tu2028. . . . IDENTIFICATION OF 5- FLUOROURACIL (5-FU) RESISTANCE- Tu1886. . . . COMMENSAL DERIVED Tu1904. . . . BARIATRIC SURGERY IS RELATED MICRORNA… (4*)|(5) BIOPRODUCTS CONTRIBUTE TO ASSOCIATED WITH INCREASED… (5*) MODULATE… (2*) Tu2029. . . . ESOPHAGEAL Tu1905. . . . CHANGES IN METABOLIC AND ADENOCARCINOMA WITH INTESTINAL Tu1887. . . . PATIENTS WITH INFLAMMATORY BIOMARKERS… (5*) METAPLASIA PHENOTYPE… (5*) APPENDECTOMY HAVE SIGNIFICANTLY LESS… (4*) Tu1906. . . . 30 DAY READMISSION AFTER Tu2030. . . . NOVEL CIRCULAR RNA NF1 ROUX-EN Y… (5*) ACTS AS… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.) Tu2031. . . . ITGBL1 PROMOTES Tu2052. . . . POTENTIAL NOVEL EPITHELIAL-MESENCHYMAL TRANSITION SEROLOGICAL MICRO-RNA MARKERS OF… VIA THE… (4*) (4*)

Tu2032. . . . ADDITION OF PRESERVATIVE Tu2053. . . . INFLAMMATORY BOWEL BUFFER IMPROVES DNA… (4*)|(Exact DISEASE IN CYSTIC FIBROSIS:… (5*) Sciences The Champions for Hope Foundation Florida Pancreatic Cancer Tu2054. . . . ACUTE PANCREATITIS IN Coalition) PATIENTS WITH DOWN… (4*)|(5)

Tu2033. . . . QUANTITATION OF Tu2055. . . . CHARACTERIZATION OF METHYLATION LOAD OF TUMOR… (2*) GASTROINTESTINAL SYMPTOMS IN FABRY… (3*)|(Sanofi Genzyme) Tu2034. . . . FACTORS ASSOCIATED WITH PATHOLOGICAL COMPLETE RESPONSE… Tu2056. . . . THE IMPACT OF METABOLIC (4*) SYNDROME (MS)… (5*)

Tu2035. . . . NEUROTENSIN PROMOTES EPITHELIAL-MESENCHYMAL TRANSFORMATION VIA ERK… (2*)

Tu2036. . . . A PATIENT SELF-MADE ONE STEP QUICK… (5*)

Tu2037. . . . NOVEL GENOMIC ANALYSIS OF CENTRAL AMERICA… (2*)

Tu2038. . . . LAPAROSCOPY-ASSISTED VERSUS ENTEROSCOPY-ASSISTED ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY… (5*)

Tu2039. . . . GASTRIC PERORAL ENDOSCOPIC PYLOROMYOTOMY (G- POEM) FOR… (5*)

Tu2040. . . . PROSPECTIVE ASSESSMENT OF THE USE OF… (5*)

Tu2041. . . . THE OUTCOME OF ENDOSCOPIC MUCOSAL RESECTION… (5*)

Tu2042. . . . INVESTIGATION OF POLYETHYLENE GLYCOL RECOVERY RATE… (5*)

Tu2043. . . . EFFICACY AND SAFETY OF PERCUTANEOUS RENDEZ-VOUS… (5*)

Tu2044. . . . SMALL BOWEL PREPARATION PRIOR TO VIDEO… (5*)

Tu2045. . . . EFFICACY AND SAFETY OF NOVEL, DISPOSABLE… (5*)

Tu2046. . . . CHOLEDOCHOSCOPE WITH STENT PLACEMENT FOR TREATMENT… (5*)

Tu2047. . . . A TRANSNASAL IMAGING TUBE FOR UNSEDATED… (4*)

Tu2051. . . . CANDIDATE AND EXPLORATORY GENETIC ASSOCIATION STUDY… (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)